

For personal reference only. No part of this PDF may be reproduced or transmitted in any form or by any means without the written permission from GIDEON Informatics, Inc.

COVID-19 in United States

Country note

2020 - The first case of COVID-19 in the United States was reported in Washington State on January 19 - imported from China. [\[1\]](#)

2020 - The first case of human-to-human transmission from an imported case was reported in Chicago on January 30. [\[2\]](#)

Reports

- 2020 to 2021 - Analyses of Public Health response to the COVID-19 outbreak [\[3\]](#) [\[4\]](#)
- 2020 - Demographic and clinical characteristics of 3,471 patients hospitalized for COVID-19 as of May 20 [\[5\]](#)
- 2020 - Status reports on COVID-19 epidemic in the United States [\[6\]](#) [\[7\]](#)
- 2020 (publication year) - Review of Coronavirus screening process for arriving travelers [\[8\]](#)
- 2020 (publication year) - A projection of hospital utilization during the COVID-19 outbreak [\[9\]](#)
- 2020 - Active monitoring of persons exposed to patients with COVID-19 in the United States [\[10\]](#)
- 2020 - Observations regarding an outbreak of COVID-19 in Washington State [\[11\]](#)
- 2020 - Observations regarding an outbreak of COVID-19 in California - 43 health-care workers exposed to a single index patient [\[12\]](#)
- 2020 - Observations regarding an outbreak of COVID-19 (90 cases) at a prison in Kansas. [\[13\]](#)
- 2020 - A comprehensive update on incidence and case-surveillance to May 30 [\[14\]](#)
- 2020 - Spatiotemporal characteristics of 1,386,050 cases of COVID-19 reported in the United States [\[15\]](#)
- 2020 - Burden of thrombotic events among 120,515 patients with COVID-19 [\[16\]](#)
- 2020 - Clinical characteristics and outcomes among 74,148 patients hospitalized with COVID-19 - impact of diabetic vs. non-diabetic hyperglycemia [\[17\]](#)
- 2020 - Clinical characteristics and outcomes among 66,646 inpatients with COVID-19 - impact of comorbidities and gender [\[18\]](#)
- 2020 - Clinical characteristics and predictors for severity among 174,568 adults with COVID-19 [\[19\]](#)
- 2020 to 2021 - Underlying medical conditions and severe illness among 540,667 inpatients with COVID-19 [\[20\]](#)
- 2020 - Clinical characteristics and outcomes among 64,781 patients with COVID-19 [\[21\]](#)
- 2020 - Demographic and clinical characteristics of 51,606 COVID-19 deaths among nursing home residents [\[22\]](#)
- 2020 - Risk factors for hospitalization, and mortality among 137,119 nursing home residents with COVID-19 [\[23\]](#)
- 2020 - Clinical characteristics and outcomes among 16,530 patients with COVID-19 - impact of co-morbid chronic liver disease [\[24\]](#)
- 2020 - Mortality and adverse outcomes among 14,287 cancer patients with COVID-19 [\[25\]](#)
- 2020 - Clinical characteristics and outcomes among 13,422 patients with COVID-19 [\[26\]](#)
- 2020 - Clinical characteristics and outcomes among 13,310 inpatients with COVID-19 - impact of deep venous thrombosis and pulmonary embolism [\[27\]](#)
- 2020 - Clinical characteristics and outcomes among 11,721 hospitalized patients with COVID-19 [\[28\]](#)
- 2020 - Clinical characteristics and outcomes among 10,222 patients with COVID-19 - impact of co-morbid respiratory infections [\[29\]](#)
- 2020 - Clinical characteristics and outcomes among 6,721 hospitalized patients with COVID-19 [\[30\]](#)
- 2020 - Analysis of in-hospital mortality rates among 38,517 adults with COVID-19 [\[31\]](#)
- 2020 - Characteristics of 83,000 fatal cases of COVID-19 reported to May 18 [\[32\]](#)
- 2020 - Analyses of race, ethnicity and age trends among fatal cases of COVID-19 [\[33\]](#) [\[34\]](#)
- 2020 - Clinical characteristics among 25,952 Veterans Affairs enrollees hospitalized for COVID-19 - impact of body mass index [\[35\]](#)
- 2020 - Clinical trends among 116,743 adults hospitalized with COVID-19 [\[36\]](#)
- 2020 - Analysis of late conditions diagnosed among 74,446 patients with COVID-19, during one-to-four months' follow-up

[37]

- 2020 - Demographic and clinical characteristics of 53,048 Military Health Service beneficiaries with COVID-19 [38]
- 2020 - Demographic and clinical characteristics of 14,259 Veterans with COVID-19 (1,703 fatal) [39]
- 2020 - Demographic and clinical characteristics of 43,267 Veterans with COVID-19 (8,240 hospitalized; 1,081 fatal) [40]
- 2020 - Demographic and clinical characteristics of 621 Veterans hospitalized for COVID-19 [41]
- 2020 - Analysis of hospitalization rates for children with COVID-19 in 14 states [42]
- 2020 - Demographic characteristics and prognostic indicators among 20,714 pediatric patients with COVID-19
- 2020 to 2021 - Clinical characteristics and outcomes among 643,025 patients with COVID-19 - impact of comorbid hidradenitis suppurativa [43]
- 9 [44]
- 2020 to 2021 - Analysis of co-morbid diseases among 43,465 children with COVID-19 [45]
- 2020 to 2021 - Outcomes among 124,699 obese patients hospitalized with COVID-19 [46]

Additional incidence data

- 2020 - 4,226 cases of COVID-19 were reported as of March 16. 508 of the patients were hospitalized, of whom 44 died of the infection. [47]
- 2020 - 122,653 cases of COVID-19 were reported as of March 28 - 37.8% with underlying health conditions and other known risk factors. [48]
- 2020 - An estimated 906,849 patients were hospitalized with COVID-19 as of November 18: 20.5% attributable to comorbid diabetes mellitus, 30.2% obesity, 26.2% hypertension and 11.7% heart failure. [49]
- 2020 - 395,926 cases of COVID-19 (12,757 fatal) were reported as of April 7 for statistics for individual states. [12]
- 2020 - 459,165 cases of COVID-19 (16,570 fatal) were reported as of April 9 - including 9,282 health-care personnel. [51]
- 2020 - An estimated 14.3% of the United States population had been infected by SARS-CoV-2 as of mid-November [52]
- 2020 - 10,131 individuals receiving care in the US Department of Veterans Affairs had tested positive for COVID-19 as of June 22 [53] ; 16,317 as of July 22. [54]
- 2020 - 1,761,503 cases (103,700 fatal) were reported as of May 30. [14]
- 2020 - During March 1 to March 30, 1,482 patients were hospitalized for COVID-19 among 14 states (4.6 per 100,000 population) - including 89.3% with underlying conditions. [56]
- 2020 - 2,572 cases (3 fatal) of COVID-19 in children were identified during February 12 to April 2. [57]
- 2020 - An estimated 176,190 children in the United States had acquired COVID-19 as of April 6 - including 74 admitted to Pulmonary Intensive Care Units. [58]
- 2020 - 277,285 children with confirmed COVID-19 had been reported as of September 19. [59]
- 2020 - 186 children with COVID-19 and multisystem inflammatory syndrome were reported during March 15 to May 20. [60]
- 2020 - 570 children with COVID-19 and multisystem inflammatory syndrome were reported to July 29. [61]
- 2020 - 1,080 children with COVID-19 and multisystem inflammatory syndrome were reported to October 10. [62]
- 2020 - The rate of multisystem inflammatory syndrome was estimated at 5.1 per 1,000,000 person-months (316 per 1,000,000 COVID-19 patients) [63]
- 2020 to 2021 - 4,470 cases of COVID-19 and multisystem inflammatory syndrome in children were confirmed during February 2020 to July 2021. [64]
- 2020 - As of May 2, 13,831 / 5,048 confirmed / probable fatal cases of COVID-19 had been reported in New York City. [65]
- 2020 - 3,064 pregnant or postpartum women were hospitalized for COVID-19 in New York City during a four-week-period. [66]
- 2020 - 100,570 health-care workers with COVID-19 (641 fatal) were reported to July 16: 79% female, 57% ages 16 to 44 years, 92% not hospitalized and 56% without co-morbid diseases. [67] [68]
- 2020 - Nearly 5,500 health-care workers with COVID-19 (0.7% fatal) were reported in Los Angeles, California to May 31. (9.6% of all cases). [69]
- 2020 - 9,282 health-care personnel (HCP) acquired COVID-19 during February 12 to April 9, accounting for 19% of total cases. 27 of the HCP cases were fatal.
- 2020 - 91 resident physicians with COVID-19 were identified in New York City during March 2 to April 12. [70]
- 2020 - 218 cancer patients with COVID-19 (28% fatal) were reported in New York City during March 18 to April 8 [71]
- 2020 - COVID-19 was identified in 4,913 (3% of total) workers in meat and poultry processing facilities from 19 states. [72]
- As of May 31, COVID-19 had been identified in over 16,000 meat and poultry workers, resulting in 86 deaths. [73]

- 2020 to 2021 - During March 1, 2020 to March 31, 2021 COVID-19 affected an estimated 729,293 persons working in agriculture (13,406 fatal). [\[74\]](#)
- 2020 - During April 22 to 28, 4,983 cases of COVID-19 (88 fatal) were diagnosed in incarcerated or detained persons, and 2,778 cases (15 fatal) among staff personnel at correctional and detention facilities.

COVID-19 and endemic diseases

- 2020 - Two fatal cases of hantavirus pulmonary infection were mis-diagnosed as COVID-19 [\[75\]](#)
- 2020 to 2021 - Several cases of pulmonary aspergillosis complicating COVID-19 were reported. [\[76\]](#) [\[77\]](#) [\[78\]](#) [\[79\]](#) [\[80\]](#) 186 such cases were reported among 17 countries during March 1 to August 31, 2020. [\[81\]](#)
- 2020 - Sporadic cases of coccidioidomycosis-COVID-19 co-infection have been reported in the United States. [\[82\]](#) [\[83\]](#)
- 2021 (publication year) - Analysis of risk for coccidioidomycosis and COVID-19 co-infection in the United States [\[84\]](#)
- 2021 - Ten cases of mucormycosis (6 fatal) were reported among COVID-19 patients at six hospital in Arkansas during July to September. [\[85\]](#)

Notable outbreaks


Years	Region	Cases	Deaths	Notes
2020	New York - New York City	36	0	Two outbreaks (16 and 20 cases) were reported at construction sites [86]
2020	North Carolina	670		670 cases reported among students, faculty and staff members [87]
2020	California - San Francisco	21		Outbreak involved 21 residents and staff [88]
2020	Multiple locations	12	0	Outbreak involving 12 family members in 4 states traced to a 13 year-old index patient [89]
2020	Washington - Seattle	57	15	[90]
2020 - 2022	Nationwide	59730384	836882	Case count to January 10, 2022. Includes 20,531,569 cases (360,248 fatal) in 2020. [1] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125]
2020	Florida	13		Outbreak associated with a recreational hockey game [126]
2020		20		Outbreak among major-league baseball players and staff [127]
2020	Wisconsin	118		Outbreak among high school-aged boys, counselors, and staff members from 21 states and territories and from two foreign countries [128]
2020	Washington - Seattle	43		COVID-19 was identified in 35 residents and 8 staff members of three homeless shelters [129]
2020		79		An outbreak associated with high school wrestling tournaments involved 31 wrestlers and 41 contacts [130]
2020	Indiana	371		Outbreak involved primarily undergraduate students living off-campus [131]
2020	Arkansas	35	3	[132]
2020	California - Los Angeles	27	1	COVID-19 was identified in 19 residents and 8 staff members [133]

2020		21	0	Outbreak among tourists aboard a cruise ship off the coast of California [134]
2020		5002	21	[73]
2020	Texas - Austin	64		Outbreak among college students in Texas following a spring-break trip to Mexico [136]
2020		1271		Outbreak aboard an aircraft carrier. Approximately 1,000 cases [137] [138] [139]
2020	Multiple locations	4913	20	Cases count to April 27. Outbreaks were reported in 115 meat and poultry processing facilities in 19 states. [72] [141] [142]
2020	Illinois - Chicago	210		Outbreak among residents and staff at homeless center [143]
2020	Washington	73		[144]
2020	Hawaii	21		Outbreak among patrons of fitness facilities [145]
2020	Illinois - Chicago	55	0	Outbreak among patrons of an exercise facility [146]
2020	Florida	91		Outbreak among temporary agricultural workers [147]
2020	Minnesota	23	0	Outbreak included five employees and 18 members at a fitness center. [148]
2020	Illinois - Chicago	172	27	Outbreak in a nursing home with predominantly Black residents [149]
2020	Texas - Galveston	24		[150]
2020	Georgia	260		Outbreak among attendees and staff at an overnight camp [151] [152]
2020	California - San Francisco	111		Outbreak among residents and staff [153]
2020	Alaska	399		Outbreaks (399 cases involving 5 seafood processing plants) [154]
2020	Ohio	30	1	Outbreak in an Amish community [155]
2020	Maine	177	7	Outbreak linked to a wedding reception - initially 27 cases, with additional secondary and tertiary spread [156]
2020	Pennsylvania - Philadelphia	19		Outbreak among adolescents at an inpatient behavioral health facility [157]
2020	Utah	1456	11	Outbreak involved 1,368 prisoners and 88 staff members [158]
2020	Illinois - Chicago	907	9	Outbreak among prisoners and staff [159]
2020	Minnesota	86	1	Outbreak (51 primary cases and 35 secondary cases) associated with a ten-day motorcycle rally. [160]
2020	Illinois - Chicago	17		Outbreak among University soccer teams. [161]
2020	Maine	32	13	[162]

2020	Idaho	382	0	Outbreaks involved five correctional facilities in Idaho [163]
2020	Washington	170		[164]
2021	Texas	172	1	Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant infection [165]
2021	Louisiana	321		28 outbreaks (total 321 cases) were reported among summer camps in Louisiana [166]
2021	Massachusetts	1128	0	1,098 individuals from seven states acquired COVID-19 at public events in Provincetown, Massachusetts. 30 secondary cases were later reported. [167]
2021	California	571	0	[168]
2021	Wisconsin	19		Outbreaks (5 cases and 14 secondary cases) associated with an ice-fishing shack [169]
2021		47		Outbreak associated with a gymnastics facility. [170]
2021	Massachusetts	469	0	Outbreaks associated with multiple summer events and large public gatherings in a town in Barnstable County, Massachusetts [171]
2021	Illinois - Chicago	158		Outbreak among university students following spring break. [172]
2021	California	12		Outbreak among students, associated with an infected teacher [173]
2021	Illinois	180	0	Outbreaks involved a Youth Camp and a Men's Conference [174]
2021	Kentucky	46	1	Outbreak involved 26 residents (18 vaccinated) and 20 health-care personnel (4 vaccinated) [175]


United States. COVID-19, cases

2019	2020	2021
0	20531569	33096890



United States. COVID-19, cumulative cases

2019	2020	2021	2022
0	20531569	53628459	59730384




Individual years:

2022 - Reported cases as of January 10, 2022.


United States. COVID-19, deaths

2019	2020	2021
0	360248	462274



United States. COVID-19, cumulative deaths

2019	2020	2021	2022
0	360248	822522	836882



Individual years:

2022 - Reported cases as of January 10, 2022.

Prevalence surveys

Years	Region	Study group	%	Notes
2020			1.23	Survey of environmental surfaces at food production facilities [176]
2020 - 2021	Massachusetts - Boston	neonates	0	SARS-CoV-2 was not detected in infant urine or feces after maternal infection during pregnancy [177]
2020 - 2021	Multiple locations	children	14	Survey of children seeking medical care through a large pediatric healthcare system [178]
2020	Pennsylvania - Philadelphia	children	0.58	0.68% of children undergoing routine screening prior to orthopedic surgery [179]
2020 - 2021	New York - New York City	children	13	Survey of children with a history of allergic disorders [180]
2020	Multiple locations	children	3.2	Survey of children in a large regional Health System [181]
2020	Nationwide	children	3.96	National survey of pediatric patients (defined as below age 25 years) [182]

2020	New York - New York City	children	6.3	Survey of pediatric surgical patients [183]
2020	New York - New York City	prisoners	58	[184]
2020	Illinois	prisoners	9.7 - 12.3	12.3% of inmates and 9.3% of prison staff [185]
2020	Multiple locations	prisoners	47.4	47.4% of prisoners tested following identification of at least one case of COVID-19 (16 prisons and jails) [186]
2020 - 2021	New York - New York City	students	0.83	Survey of students in re-opened private schools [187]
2020	Texas	animals	15.3 - 47.1	15.3% of dogs and 47.1% of cats from households of patients with COVID-19 infection [188]
2020	Alaska	travelers	0.8	Survey of travelers arriving to airports in Alaska [189]
2020	Multiple locations	homeless	16 - 66	16% to 66% of residents and staff of homeless shelters [190]
2020	Rhode Island	homeless	11.7	11.7% of residents in homeless shelters [191]
2020	Washington	homeless	1.4 - 2.9	[192]
2020	Illinois - Chicago	homeless	15 - 30	30% of residents and 15% of staff at homeless shelters [193]
2020	Georgia - Atlanta	homeless	0.5 - 2.1	Survey of homeless people and associated service staff [194]
2021	Multiple locations	deer	35.8	Survey of free-ranging white-tailed deer (<i>Odocoileus virginianus</i>) [195] [196]
2020	New York - Long Island	transplant recipients	5	Survey of pediatric kidney transplant recipients [197]
2020 - 2021	California	transplant recipients	21	Survey of pediatric heart transplant recipients [198]
2020	California	patients - cancer	8	Survey of breast cancer survivors [199]
2020	Nationwide	patients - cancer	7.8	Survey of veterans with cancer [200]
2020	Washington	patients - cancer	0.8	Survey of pre-operative cancer patients [201]
2020	New York - New York City	patients - cancer	3.75	Survey of cancer patients for asymptomatic COVID-19 [202]
2020 - 2021	California	patients - cancer	1.6	Survey of asymptomatic cancer patients receiving chemotherapy [203]
2020	New York - Long Island	infants	67	Survey of febrile infants presenting to an Emergency Department [204]

2020	North Carolina	patients	0.61 - 0.65	Results of a preoperative screening program for surgical patients [205]
2020	Massachusetts - Boston	patients	3.6	3.6% of asymptomatic pre-operative patients [206]
2020	Iowa - Iowa City	patients	1.1	Infection was identified in 1.1% of patients admitted to hospital without symptoms suggestive of COVID-19 [207]
2020	California - Los Angeles	patients	5.3	5.3% of patients with mild influenza-like illness presenting to an Emergency Department [208]
2020	Wisconsin	patients	0.52	0.52% of asymptomatic hospital patients [209]
2020	California - Santa Clara	patients	11	11% of non-influenza respiratory illness in outpatients attending urgent care centers. [210]
2020	Kentucky - Louisville	patients	0.8 - 6.2	Routine screening program of all patients admitted to a hospital [211]
2020	Florida	patients	1.2	Survey of pre-operative patients [212]
2020	California - Los Angeles	patients	0.13	Asymptomatic infection was identified in 0.13% of pre-operative / pre-procedure patients [213]
2020	Multiple locations	patients	21.8	Survey of patients visiting emergency departments in the Maryland/Washington DC region during the initial COVID-19 surge [214]
2020	Wisconsin - Milwaukee	patients	1.4	1.4% of children tested prior to performance of in-hospital procedures [215]
2020	Ohio	adults	0.9	Statewide survey conducted in July 2020 [216]
2020		military recruits	9	Survey of US Marine recruits [217]
2020		military recruits	3.3	[218]
2020	Nationwide	patients - dialysis	5.5	[219]
2020	California	health care workers	1.84	[220]
2020	Louisiana - New Orleans	health care workers	1.9 - 8	8.0% of hospital employees; 1.8% of surgeons involved in treating patients with COVID-19 [221]
2020	California - San Francisco	health care workers	0.2	Survey of asymptomatic health-care workers [222]
2020	New Jersey	health care workers	5	5.0% of health-care workers tested at the onset of the COVID-19 outbreak were found to be infected. [223]
2020	Massachusetts	health care workers	2.94	Survey of workers in a health-care system [224]
2020	California - Los Angeles	health care workers	1.5	[225]
2020	Minnesota	health care workers	0.52	[226]

2020	Minnesota	health care workers	7	Survey of high-risk health-care personnel [227]
2020	New York - New York City	health care workers	1.7	Survey of active-duty military personnel deployed to a COVID-19 field hospital [228]
2020	Ohio - Cleveland	health care workers	9	[229]
2020	Nationwide	health care workers	4.5	Survey of health-care workers in the Veterans Health Administration [230]
2020	New Jersey	health care workers	0.3	[231]
2020	Washington - Seattle	health care workers	5.3	Survey of symptomatic health-care workers. [232]
2021*	Texas - Dallas	health care workers	4.2	Survey of asymptomatic hospital health-care workers [233]
2020	Ohio	military facility	0.5	Survey of asymptomatic adults working at an Air Force base and surrounding areas [234]
2020	California	various	40.7	Asymptomatic infection was identified in 40.7% of residents and staff members of long-term care facilities in Pasadena, California. [235]
2020	Nationwide	general population	1.7	1.7% of individuals with COVID-19-like symptoms [236]
2020	Illinois	general population	2.1	Survey of individuals in Peoria, Illinois [237]
2020 - 2021	California	general population	19.6	Analysis of data from sentinel outpatient testing sites in California. [238]
2020	Rhode Island	general population	1.5	Statewide prevalence survey [239]
2020	Indiana	general population	1.74	[240]
2020	Illinois - Chicago	general population	11.1	Survey of community-based tests among economically-marginalized populations [241]
2020 - 2021	Massachusetts - Worcester	general population	1.5 - 13.4	1.5% in August 2020; 13.4% in January 2021. [242]
2020	Nationwide	military veterans	15.4	Survey of Veterans ages 54 to 75 years [243]
2020	Nationwide	military veterans	6.4	6.4% of individuals receiving care in the US Department of Veterans Affairs [54]
2020	Maryland	religious community	18.5	Survey of Latino members of a religious community [245]
2020	Illinois - Chicago	pregnant women	11.1	Survey of parturient women [246]

2020	New York - Long Island	pregnant women	19.9	Survey of pregnant women at delivery [247]
2020	New York	pregnant women	17.1	17.1% of pregnant women at term - most were asymptomatic [248]
2020	Illinois - Chicago	pregnant women	7.9	[249]
2020	Pennsylvania - Philadelphia	pregnant women	2.5	Survey of asymptomatic pregnant women [250]
2020	New York - New York City	pregnant women	37	SARS-CoV-2 infection was found in 37% of pregnant women undergoing routine screening [251]
2020	Illinois - Chicago	patient contacts	33	33% of the partners of SARS-CoV-2 positive women at delivery [252]
2020	Connecticut	patient contacts	31	SARS-CoV-2 infection was identified in 31% of household contacts of infected patients [253]
2020	Massachusetts	environmental	8.3	Survey of high-touch surfaces in a community setting [254]
2021	Pennsylvania	environmental	0	Survey of air and various surfaces in the environments of elementary, middle and high schools [255]
2020	Connecticut - New Haven	patients - psychiatric	5.9	Survey of inpatients from Psychiatry Units [256]
2020	California	patients - psychiatric	2.2	Survey of patients presenting to a psychiatric emergency room [257]
2020	Nationwide	patients - psychiatric	9.86 - 11.17	9.86% of patients with schizophrenia, 9.86% with mood disorder and 11.17% with anxiety disorder. [258]
2020	New York - New York City	patients - psychiatric	9.8	Survey of patients referred for psychiatric admission [259]
2020	Multiple locations	family members	33 - 42	33% / 42% of household contacts (partners / children) of COVID-19 patients [260]
2020	New York	family members	57	COVID-19 infection was identified in 57% of patient households [261]
2020	Multiple locations	patients - diabetes	4.2	COVID-19 was identified in 4.2% of patients hospitalized with diabetic ketoacidosis [262]
2020	Minnesota - Rochester	risk groups	0	Survey of first-responders in Rochester, Minnesota [263]
2020	Florida	high-risk population	8.6	8.6% of first-responders [264]
2020	Multiple locations	nursing home	0.4 - 12	12% / 0.4% of individuals in nursing homes where COVID-19 had / had not been reported previously [265]
2020	California	screening program	17	17.0% of tests performed in Alameda County, California were positive; 72.8% of Indigenous Maya persons [266]
2020	Illinois - Chicago	patients - dental	2.3	Survey of asymptomatic pediatric dental patients [267]

2020	Massachusetts - Boston	long-term care facility	37.5	[268]
2020	Washington - Seattle	long-term care facility	3.2 - 3.8	3.2% of staff members and 3.8% of residents in an assisted living community for older adults [269]
2020	North Carolina - Durham	students - university	0.12	0.12% of students from asymptomatic students were positive [270]
2020	Pennsylvania - Philadelphia	patients - orthopedic	0.5	Survey of asymptomatic patients undergoing elective orthopedic surgery [271]
2020	Pennsylvania - Philadelphia	patients - orthopedic	0.21	Survey of patients scheduled for total joint arthroplasty [272]
2020 - 2021	California - Los Angeles	patients - orthopedic	0.47	Survey of preoperative patients screen for spinal surgery [273]
2020	Illinois - Chicago	patients - HIV / AIDS	7.2	[274]
2020	California - San Francisco	patients - HIV / AIDS	4.5	[275]
2020	Illinois - Chicago	patients - HIV / AIDS	10.6	[276]
2020	Multiple locations	patients - HIV / AIDS	11.2	11.2% / 6.1% of symptomatic HIV-positive / HIV-negative negative individuals [277]
2020	California	patients - inflammatory bowel disease	3	COVID-19 was identified in 3% of patients with inflammatory bowel disease [278]

* indicates publication year (not necessarily year of survey)

Seroprevalence surveys

IgG unless otherwise specified

Years	Region	Study group	%	Notes
2020	California	farmers	22.1	Survey of farmworkers in Salinas Valley, California [279]
2020	Washington - Seattle	children	0.9	0.9% of children visiting a hospital were found to be seropositive [280]
2020	Virginia	children	8.5	[281]
2020	Pennsylvania - Pittsburgh	children	0.6	Survey of immune-compromised children [282]
2020 - 2021	New York - New York City	children	52	Survey of children with a history of allergic disorders [180]
2020	Washington, DC	children	9.46	[284]
2020	Mississippi	children	16.3	Survey of individuals below age 18 years [285]

2020	Vermont	schoolchildren	4.7	Survey of students and teachers in a school district [286]
2020	Multiple locations	animals	0.17	Survey of dogs and cats from 48 states [287]
2020	Washington, DC	workers	3.2	Survey of workers at a Government office site [288]
2020	Multiple locations	workers	7.21	Serosurvey of a space exploration technology group [289]
2021	Texas	deer	37	Survey of white-tailed deer [290]
2021	Ohio	deer	36	Survey of white-tailed deer [291]
2020	New York - New York City	transplant recipients	15.9	Survey of heart transplant recipients [292]
2020	New York - Long Island	transplant recipients	18	Survey of pediatric kidney transplant recipients [197]
2020	Pennsylvania - Philadelphia	patients - cancer	1.6	[294]
2020	New York - New York City	patients - cancer	6.2	Survey of childhood-cancer survivors [295]
2020	Pennsylvania	patients - cancer	1.6	[296]
2020	Multiple locations	patients	6.03 - 9.79	6.03% / 9.79% of trauma patients ages 45-to-69 / 18-to-44. [297]
2020	Virginia	patients	2.4	Statewide survey of adult outpatients [298]
2020 - 2021	Missouri - St. Louis	patients	4.52 - 21.16	Seroprevalence among patients visiting a hospital increased from 5.52% / 4.52% in January 2020, to 21.16% / 19.03% in January 2021 (children / adults) [299]
2020	California - Orange County	patients	9.4	Survey of outpatients and individuals visiting an Emergency Department [300]
2020	North Dakota	employees	14.6	Survey of pharmacy personnel [301]
2020	Ohio	adults	1.3	Statewide survey conducted in July 2020 [216]
2020	Nationwide	adults	4.6	Survey of adults who had not previously been diagnosed with COVID-19 [303]
2020	California - Orange County	adults	11.5	Adjusted estimated seroprevalence among adults' at drive-in testing sites [304]
2020	Nationwide	adults	6.6	Serosurvey of adults, conducted during September 2020. [305]
2020	Connecticut	adults	4	[306]
2020	California	adults	4.6	[307]
2020	New York -	adults	24.3	[308]

	New York City			
2020	Washington - Seattle	adults	1.2	Seroprevalence was 1.2% as of late marc-early April [309]
2020		military recruits	3.8	[218]
2020	Nationwide	patients - dialysis	8	Nationwide survey of patients receiving hemodialysis. [311]
2020	Nationwide	patients - dialysis	5.8	[312]
2020	Nationwide	patients - dialysis	8.3	Survey of patients on hemodilaysis [313]
2020	Minnesota - Minneapolis	patients - dialysis	9.5	[314]
2021	Nationwide	patients - dialysis	18.9	As of January, 2021 the estimated seroprevalence among hemodialysis patients in the United States was 18.9%. [315]
2020	Georgia - Atlanta	health care workers	4.1	Survey of Pediatric health-care workers [316]
2020	Midwest Region	health care workers	0.29 - 14.89	0.29% of rural health-care workers in Minnesota and South Dakota during May 13 to July 13, 1.92% during August 18 to September 25, and 14.89% during October 16 to December 22 [317]
2020	Wisconsin - Milwaukee	health care workers	7	Survey of workers in an echocardiography and stress laboratory. [318]
2020	Massachusetts - Boston	health care workers	11.3	11.3% of workers at a community health-care system (medium estimate seroprevalence) [319]
2020	New York - New York City	health care workers	35.4	[320]
2020	Kentucky	health care workers	1.55	Survey of health-care workers at a tertiary medical center. [321]
2020	Multiple locations	health care workers	4.9	4.9% of workers in a VA Healthcare System [322]
2020	California - San Francisco	health care workers	2.9	Survey of Emergency Department workers [323]
2020	Florida	health care workers	4.1	Survey of health-care workers and first responders [324]
2020	Kentucky - Louisville	health care workers	1.4 - 2.3	Seroprevalence increased from 1.4% in May, to 2.3% in July [325]
2020	California - San Francisco	health care workers	0.9	Survey of asymptomatic health-care workers [222]
2020	New York - New York City	health care workers	19.4	19.4% of asymptomatic health care workers in contact with COVID-19 patients [327]
2020	Massachusetts - Boston	health care workers	5.5	Survey of health-care workers at an academic medical center [328]

2020	Multiple locations	health care workers	0.6	Survey of health-care workers in a multi-state academic medical center [329]
2020	New York - New York City	health care workers	29	[330]
2020	New York	health care workers	2	Survey of healthcare workers in a rural hospital system [331]
2020	Georgia - Atlanta	health care workers	6.5	Survey of health-care personnel in four hospitals [332]
2020	Indiana - Indianapolis	health care workers	1.6	Survey of workers in a health-care system [333]
2020	Michigan	health care workers	8.8	[334]
2020	Washington - Seattle	health care workers	0.9	Survey of workers in a Pediatric Hospital [335]
2020	Rhode Island	health care workers	4.6	Survey of health-care personnel in hospitals and nursing homes [336]
2020	California - Los Angeles	health care workers	4.1	[337]
2020	California - Orange County	health care workers	0.35	Survey of asymptomatic Pediatric health care workers [338]
2020	Multiple locations	health care workers	1.8	Evidence for current or past SARS-CoV-2 infection was found in 1.8% of health care personnel without previously diagnosed COVID-19 [339]
2020	California - Los Angeles	health care workers	3.5	[225]
2020	Multiple locations	health care workers	6	Survey of health-care workers in a multistate hospital network [341]
2020	Georgia - Atlanta	health care workers	3.8	[342]
2020	Minnesota	health care workers	0.63	[226]
2020	Virginia	health care workers	1.15 - 4.8	1.15% of asymptomatic health-care workers in April, 2020 - increasing to 4.8% in November [344]
2020	Tennessee - Nashville	health care workers	7.6	[345]
2020	New York - New York City	health care workers	30.2	[346]
2020	Pennsylvania - Philadelphia	health care workers	5.3	Survey of employees at a Children's Hospital [347]
2020	Multiple locations	health care workers	4.4	[348]

2020	Illinois - Chicago	health care workers	4.8	[349]
2020	New York	health care workers	16.9	[350]
2020	California	health care workers	1.3	Survey of asymptomatic health care workers at a medical center [351]
2020	Connecticut	health care workers	6.3	[352]
2020	Florida	health care workers	2.7	Survey of healthcare workers in a surgical environment [353]
2020	California - San Diego	health care workers	0.98	[354]
2020	Rhode Island - Providence	health care workers	2.9	Survey of Internal Medicine residents [355]
2020	New York - New York City	health care workers	13.7	13.7% of employees of a Health Care system [356]
2020	Virginia - Richmond	health care workers	1.4	Survey of health-care workers at a medical facility [357]
2020	New Jersey	health care workers	5.2	[358]
2020	California	health care workers	1.13	[359]
2020	California - San Diego	health care workers	2.2	[360]
2020	New Jersey	health care workers	9.6	[231]
2021*	New York	health care workers	15.4	Survey of workers at a Community Health Center [362]
2021*	Texas - Dallas	health care workers	11.7	Survey of asymptomatic hospital health-care workers [233]
2020	Midwest Region	staff members	2.9	Survey of staff members in a public school system [364]
2020	Indiana	staff members	1.7	Survey of staff members in a public school system [365]
2020	Ohio	military facility	3.09	Survey of asymptomatic adults working at an Air Force base and surrounding areas [234]
2020	Minnesota	cats	8	8% of pet cats (anti-nucleocapsid antibody) [367]
2020	California - Santa Clara	firefighters	2.54	[368]
2020	California - Orange County	firefighters	5.3	[369]

2020	Louisiana - New Orleans	various	7.99	Survey of health-care workers and patients of a large health maintenance provider [370]
2020	Minnesota - Minneapolis	various	2.96 - 4.46	2.96% / 4.46% of health-care workers / outpatients [371]
2020	Pennsylvania	various	5.5 - 31.2	5.5% of individuals in a University community during August 7 to October 2, increasing to 81% by December 9; 31.2% of University students during October 26 to November 23 [372]
2020	Arizona	various	8	Survey of community members and healthcare workers from the Kingman, Arizona area. [373]
2020	California - San Francisco	various	0.1 - 0.26	0.26% of hospitalized patients admitted for non-respiratory indications and 0.1% of blood donors [374]
2020	Massachusetts	various	3.4 - 4.6	Survey of students, faculty, librarians and staff members at a university [375]
2020	California - Los Angeles	various	25 - 42	42% of residents and 25% of staff at a skilled nursing facility [376]
2020	California - San Francisco	various	0.1 - 0.26	0.1% of blood donors and 0.26% of patients hospitalized with non-respiratory diseases [377]
2020	Florida	various	8.9	8.9% of firefighters / paramedics [378]
2020	Missouri - St. Louis	general population	1.71 - 3.11	1.71% / 3.11% of children / adults [379]
2020	California - Santa Clara	general population	1.5	[380]
2020	Arizona	general population	11.5	Serosurvey in Maricopa County, Arizona [381]
2020	Texas - Houston	general population	14	Estimated seroprevalence in September 2020 [382]
2020	Idaho	general population	22.7	22.7% of individuals in Blaine County, Idaho - a ski resort-community with high rates of COVID-19 [383]
2020	New Jersey	general population	9	Survey of individuals in Essex County, New Jersey [384]
2020	North Carolina	general population	0.8	Serosurvey of asymptomatic individuals [385]
2020	Colorado - Denver	general population	8	[386]
2020	Multiple locations	general population	1 - 6.9	Seroprevalence in ten geographic sites; range 1.0% in San Francisco, California to 6.9% in New York City [387]
2020 - 2021	California - San Diego	general population	36.3	Survey of individuals in Tijuana, Mexico and San Diego, United States [388]
2020	Rhode Island	general	2.1	Statewide prevalence survey [239]

		population		
2020	Louisiana - Baton Rouge	general population	3.6	[390]
2020	Georgia	general population	2.7	Survey of two Georgia counties [391]
2020	Indiana	general population	1.09	[240]
2020 - 2021	Pennsylvania	general population	5.5 - 24.7	5.5% of individuals in Allegheny County in Fall, 2020; 24.7% in February 2021. [393]
2020	New York - New York City	general population	23.6	Survey conducted during May 13 to July 21 [394]
2020	Nationwide	general population	0 - 23.3	As of September, 2020 seroprevalence among various jurisdictions varied from 0.0% to 23.3% [395]
2020	Massachusetts	general population	31.5	Survey of asymptomatic individuals in Chelsea, Massachusetts [396]
2020	Multiple locations	religious community	30	Survey of Orthodox Jews in multiple communities [397]
2020	Pennsylvania - Philadelphia	pregnant women	6.2	[398]
2020	Florida - Palm Beach	pregnant women	26.4	Survey of Obstetric Clinic patients [399]
2020	New York - New York City	pregnant women	16.4	[400]
2019 - 2020	Multiple locations	blood donors	0 - 1	Antibody toward SARS-CoV-2 was identified in 1.4% of blood donations archived prior to the known introduction of COVID-19 into the United States. [401]
2020	New York - New York City	blood donors	10.9 - 12.1	10.9% and 12.1% of blood donors (eg, two assays used) [402]
2020 - 2021	Nationwide	blood donors	3.5 - 20.2	3.5% in July 2020, increasing to 20.2% in May 2021 [403]
2020	Nationwide	blood donors	4.22	[404]
2020	Rhode Island	blood donors	0.6	[405]
2020	Ohio - Cincinnati	blood donors	8.4	[406]
2020	New York - New York City	patient contacts	22.5	Survey of first-responders and Public Safety personnel. [407]
2020	Michigan - Detroit	patient contacts	6.9	Survey of healthcare, first response, and public safety personnel [408]

2020	Arizona	patient contacts	1.5	Survey of first-responders [409]
2020	California	patient contacts	0.93 - 5.31	0.93% / 2.58% of health-care workers during May to June / July to August; and 5.31% / 4.35% of first-responders [410]
2020	Maryland	deaths	10	Survey of all decedents undergoing forensic postmortem examination [411]
2020	California - San Francisco	risk groups	0.25	Survey of firefighters and paramedics [412]
2020	Texas	risk groups	0.73	0.73% of first-responders in Lubbock, Texas [413]
2020	Michigan - Detroit	risk groups	16.2	Survey of first-responders and health-care personnel [414]
2020	Colorado	risk groups	4	Survey of first-responders in Arapahoe County, Colorado [415]
2020	Minnesota - Rochester	risk groups	1.2	Survey of first-responders in Rochester, Minnesota [263]
2020	California - Los Angeles	students - university	4	[417]
2020	California - San Francisco	patients - HIV / AIDS	3.7	Seroprevalence was 3.7% among people with HIV compared with 7.4% among people without HIV [418]
2020	Nationwide	health care workers (Literature Review)	12.4	12.4% of health-care workers (pooled seroprevalence (meta-analysis) [419]
2020	New York	patients - rheumatological	13	Survey of pediatric patients with rheumatic disease [420]

* indicates publication year (not necessarily year of survey)

Animal infection

- 2020 - SARS-CoV-2 infection was reported among domestic cats [\[188\]](#) [\[422\]](#)[\[423\]](#) [\[424\]](#) [\[425\]](#) and dogs [\[188\]](#) [\[427\]](#) [\[428\]](#) [\[429\]](#) [\[430\]](#) ; wild deer (*Odocoileus virginianus*) in Iowa [\[431\]](#) ; and captive lions, tigers [\[432\]](#) [\[433\]](#) [\[434\]](#) , and snow leopards (*Panthera unica*). [\[435\]](#) [\[436\]](#)
- 2020 - SARS-CoV infection was reported among farmed mink [\[437\]](#) [\[438\]](#) [\[439\]](#) and wild (escaped) mink in Utah. [\[440\]](#) [\[441\]](#)
- 2021 - SARS-CoV-2 infection was reported in captive snow leopards [\[442\]](#) [\[443\]](#) [\[444\]](#) [\[445\]](#) ; captive gorillas [\[446\]](#) [\[447\]](#) [\[448\]](#) , a captive coatimundi [\[449\]](#) , a captive Canada lynx (*Lynx canadensis*) [\[450\]](#) , captive Malayan tigers [\[451\]](#) , a captive binturong and a captive fishing cat [\[452\]](#) Seropositive deer (*Odocoileus virginianus*) were identified in multiple states. [\[453\]](#) [\[195\]](#) [\[291\]](#)
- 2021 - SARS-CoV-2 variant B.1.1.7 was detected in a dog and a cat in Texas. [\[456\]](#)
- 2021 - SARS-CoV-2 infection was reported in small-clawed otters (*Aonyx cinereus*) in a Georgia aquarium. [\[457\]](#)

CASE SERIES *

Clinical characteristics

- 2020 - Clinical characteristics and outcomes of 19,584 patients with COVID-19 - impact of race and ethnicity [\[458\]](#)
- 2020 to 2021 - Clinical characteristics and risk factors among 16,182 patients with COVID-19 [\[459\]](#)
- 2020 to 2021 - Clinical characteristics of 13,170 HIV-positive patients with COVID-19 [\[460\]](#)
- 2020 - Clinical characteristics and outcomes of 12,601 cases of COVID-19 - impact of acute encephalopathy [\[461\]](#)
- 2020 - Clinical characteristics and outcomes of 12,548 hypertensive patients with COVID-19 [\[462\]](#)

- 2020 - Clinical characteristics of 10,861 cases of COVID-19 - impact of body mass index on outcomes [\[463\]](#)
- 2020 - Clinical characteristics of 9,991 cases of COVID-19 - impact of smoking [\[464\]](#)
- 2020 - Clinical characteristics and risk factors for severe disease among 9,928 patients with COVID-19 [\[465\]](#)
- 2020 - Clinical characteristics of 9,928 cases of COVID-19 - impact of advance patient age [\[466\]](#)
- 2020 - Clinical characteristics and risk factors for hospitalization and critical illness among 8,673 patients with COVID-19 [\[467\]](#)
- 2020 - Clinical characteristics and outcomes among 8,540 rheumatic disease patients with COVID-19 [\[468\]](#)
- 2020 - Clinical characteristics and risk factors for acute ischemic stroke in 8,163 patients with COVID-19 [\[469\]](#)
- 2020 - Clinical characteristics and outcomes among 7,995 patients with COVID-19 [\[470\]](#)
- 2020 - Clinical characteristics of 7,606 cases of COVID-19 - impact of Body Mass Index and patient age [\[471\]](#)
- 2020 - Clinical characteristics of 7,348 cases of COVID-19 - impact of co-morbid psychiatric disorders [\[472\]](#)
- 2020 - Clinical characteristics and outcomes among 7,032 cases of COVID-19 - impact of co-morbidities and blood biomarkers [\[473\]](#)
- 2020 - Clinical characteristics and risk factors for mortality in 6,760 patients with COVID-19 [\[474\]](#)
- 2020 - Initial chief complaint in 6,524 patients with COVID-19 [\[475\]](#)
- 2020 - Risk factors for mortality among 6,493 patients hospitalized with COVID-19 [\[476\]](#)
- 2020 - Clinical characteristics of 5,999 patients hospitalized with COVID-19 - impact of race and ethnicity [\[477\]](#)
- 2020 - Clinical characteristics and outcomes of 5,700 cases (553 fatal) of COVID-19 treated in New York City hospitals [\[478\]](#)
- 2020 - Clinical characteristics of 5,416 cases of COVID-19 - risk factors for hospitalization [\[479\]](#)
- 2020 - Clinical characteristics and outcomes among 5,256 nursing home residents with COVID-19 [\[480\]](#)
- 2020 - Clinical characteristics of 4,902 patients with COVID-19 - impact of asthma and eosinophilia [\[481\]](#)
- 2020 - Clinical and demographic characteristics of 4,895 patients with COVID-19 [\[482\]](#)
- 2021 (publication year) - Clinical characteristics and mortality among 4,798 adults with COVID-19 - impact of gender [\[483\]](#)
- 2020 - Clinical characteristics and prognostic factors among 4,783 elderly patients hospitalized with COVID-19 [\[484\]](#)
- 2020 - Clinical and epidemiological characteristics of 4,666 patients with COVID-19 and co-morbid autoimmune diseases [\[485\]](#)
- 2020 - Clinical characteristics of 4,446 patients with COVID-19 - impact of co-morbid chronic obstructive lung disease on mortality [\[486\]](#)
- 2020 - Clinical characteristics of 4,413 diabetic patients with COVID-19 - risk factors for mortality [\[487\]](#)
- 2020 - Clinical characteristics and outcomes among 4,407 critically-ill patients hospitalized with of COVID-19 - impact of patient gender [\[488\]](#)
- 2020 - Clinical characteristics and risk factors for hospitalization and mortality among 4,322 patients with COVID-19 [\[489\]](#)
- 2020 - Clinical characteristics and mortality among 4,277 hypertensive patients with COVID-19 [\[490\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 4,109 critically-ill patients with COVID-19 [\[491\]](#)
- 2020 - Clinical characteristics of 4,062 cases of COVID-19 - analysis of risk factors for severe disease and death [\[492\]](#)
- 2020 - Clinical characteristics and outcomes of 3,678 patients hospitalized with COVID-19 - impact of race [\[493\]](#)
- 2020 - Clinical characteristics of 3,641 hospitalized cases of COVID-19 - comparison with influenza patients [\[494\]](#)
- 2020 to 2021 - Clinical characteristics of 3,597 athletes following recovery from COVID-19 [\[495\]](#)
- 2020 - Clinical characteristics of 3,248 patients with COVID-19 - impact of prior stroke [\[496\]](#)
- 2020 to 2021 - Analysis of 3,229 patients with COVID-19 and gastrointestinal manifestations - follow-up at three and six months [\[497\]](#)
- 2020 - Clinical characteristics of 2,904 patients hospitalized with COVID-19 [\[498\]](#)
- 2020 - Clinical characteristics of 2,842 patients with COVID-19 - comparison of healthcare workers with non-healthcare workers [\[499\]](#)
- 2020 - Clinical characteristics of 2,804 cases of COVID-19, including 1,084 with gastrointestinal symptoms [\[500\]](#)
- 2020 - Clinical characteristics and outcomes among 2,626 patients hospitalized with of COVID-19 - impact of patient gender [\[501\]](#)
- 2020 - Clinical characteristics and outcomes of 2,511 patients hospitalized with COVID-19 - analysis of laboratory findings [\[502\]](#)
- 2020 - Clinical characteristics and risk factors for Intensive Care admission among 2,491 patients with COVID-19 [\[503\]](#)
- 2020 - Clinical characteristics of 2,379 cases of COVID-19 in patients with systemic autoimmune rheumatic diseases [\[504\]](#)
- 2021 (publication year) - Clinical characteristics of 2,366 cases of COVID-19 - impact of diabetic ketoacidosis [\[505\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 2,215 patients with COVID-19 treated in Intensive

Care Units [\[506\]](#)

- 2020 - Clinical characteristics and risk factors for mortality among 2,212 patients with COVID-19 [\[507\]](#)
- 2020 - Clinical characteristics of 2,199 patients hospitalized with COVID-19 [\[508\]](#)
- 2020 - Clinical characteristics of 2,086 patients with ischemic stroke and COVID-19 [\[509\]](#)
- 2020 - Gastrointestinal manifestations among 1,992 patients hospitalized with COVID-19, in the United States and Canada [\[510\]](#)
- 2020 - Clinical characteristics of 1,871 patients with COVID-19 - impact of preexisting respiratory disease [\[511\]](#)
- 2020 - Clinical characteristics and risk factors for severity among 1,853 young adults with COVID-19 [\[512\]](#)
- 2020 - Clinical characteristics and outcomes among 1,742 patients with COVID-19 [\[513\]](#)
- 2020 - Clinical characteristics and markers for severity among 1,697 patients with COVID-19 [\[514\]](#)
- 2020 - Clinical and epidemiological characteristics of 1,692 patients with COVID-19 [\[515\]](#)
- 2020 - Clinical characteristics of 1,641 cases of COVID-19 - impact of red blood cell distribution width [\[516\]](#)
- 2020 - Clinical characteristics of 1,595 patients hospitalized with COVID-19 - impact of pneumothorax [\[517\]](#)
- 2020 - Clinical characteristics of 1,565 cases of COVID-19 - impact of healthcare-associated infections [\[518\]](#)
- 2020 - Clinical characteristics of 1,577 patients hospitalized with COVID-19 [\[519\]](#)
- 2020 - Clinical characteristics and outcomes among 1,491 hospitalized patients with COVID-19 - comparison with patients having other forms of viral pneumonia [\[520\]](#)
- 2020 - Clinical characteristics and outcomes among 1,480 patients hospitalized with COVID-19 [\[521\]](#)
- 2020 - Clinical characteristics of 1,449 patients with COVID-19 - impact of cardiovascular comorbidities [\[522\]](#)
- 2020 - Clinical characteristics of 1,409 COVID-19 patients following discharge from hospital [\[523\]](#)
- 2021 (publication year) - Clinical characteristics of 1,398 patients with COVID-19 - impact of secondary bacterial infections [\[524\]](#)
- 2020 - Clinical characteristics and risk factors for mortality in 1,375 patients hospitalized with COVID-19 [\[525\]](#)
- 2020 - Clinical characteristics of 1,344 COVID-19 patients following discharge from hospital [\[526\]](#)
- 2020 - Clinical and epidemiological characteristics of 1,325 patients with COVID-19 [\[527\]](#)
- 2020 to 2021 - Clinical characteristics and outcomes among 1,325 patients hospitalized with COVID-19 - impact of race [\[528\]](#)
- 2020 - Clinical and epidemiological characteristics of 1,305 patients with COVID-19 - impact of advanced age [\[529\]](#)
- 2020 - Clinical characteristics of 1,299 cases of COVID-19 hospitalized through a health-care system [\[530\]](#)
- 2020 - Clinical characteristics of 1,298 patients with COVID-19 - impact of asthma [\[531\]](#)
- 2020 - Clinical characteristics of 1,252 outpatients with COVID-19 [\[532\]](#)
- 2020 - Clinical and epidemiological characteristics of 1,209 Emergency Department patients with COVID-19 [\[533\]](#)
- 2020 - Clinical characteristics of 1,206 patients hospitalized with of COVID-19 - impact of gastrointestinal bleeding [\[534\]](#)
- 2020 - Clinical characteristics of 1,173 cases of COVID-19 - impact of smoking [\[535\]](#)
- 2020 - Analysis of co-morbidities among 1,169 patients with COVID-19 [\[536\]](#)
- 2020 - Clinical and epidemiological characteristics of 1,150 patients with COVID-19 [\[537\]](#)
- 2020 - Clinical and epidemiological characteristics of 1,150 patients with COVID-19 [\[537\]](#)
- 2020 - Clinical characteristics of 1,126 diabetic patients with COVID-19 - risk factors for mortality [\[539\]](#)
- 2020 - Clinical characteristics of 1,059 cases of COVID-19 - assessment of gastrointestinal and hepatic findings [\[540\]](#)
- 2020 - Clinical characteristics and risk factors for mechanical ventilation and mortality in 1,042 patients hospitalized for COVID-19 [\[541\]](#)
- 2020 - Clinical characteristics of 1,016 patients with COVID-19 - impact of co-infections [\[542\]](#)
- 2020 - Clinical characteristics of 1,000 patients with COVID-19 [\[543\]](#)
- 2020 - Clinical characteristics of 1,000 patients with COVID-19 [\[544\]](#)
- 2020 - Clinical characteristics and risk factors for severity and hospitalization among 994 Emergency Department patients with COVID-19 [\[545\]](#)
- 2020 - Clinical characteristics of 981 patients presenting to an Emergency Department with COVID-19 - factors associated with clinical severity [\[546\]](#)
- 2020 - Clinical characteristics of 981 patients with COVID-19 - risk factors for severe disease and mortality [\[547\]](#)
- 2020 to 2021 - Clinical characteristics of 963 patients with COVID-19 - impact of hospital-acquired superinfections [\[548\]](#)
- 2020 - Clinical characteristics of 945 sarcoidosis patients with COVID-19 [\[549\]](#)
- 2020 - Clinical characteristics of 916 ambulatory patients with COVID-19 [\[550\]](#)
- 2021 - Clinical characteristics and outcomes among 915 patients hospitalized with COVID-19 - impact of prior vaccination [\[551\]](#)

- 2020 - Clinical characteristics of 900 patients hospitalized with COVID-19 [\[552\]](#)
- 2020 - Gastrointestinal manifestations among 878 patients hospitalized with COVID-19, in an Intensive Care Unit [\[553\]](#)
- 2020 - Clinical characteristics of 866 patients with COVID-19 - impact of race and ethnicity [\[554\]](#)
- 2020 - Clinical characteristics and outcomes of 846 ambulatory patients with COVID-19 [\[555\]](#)
- 2020 - Clinical characteristics of 843 cases of COVID-19 - impact of diabetes and pre-diabetes [\[556\]](#)
- 2020 - Clinical characteristics of 842 critically-ill patients with COVID-19 - impact of pneumothorax [\[557\]](#)
- 2020 - Clinical characteristics of 832 patients hospitalized with COVID-19 - risk factors for severe disease or death [\[558\]](#)
- 2020 - Clinical characteristics of 832 diabetic patients with COVID-19 - risk factors for severity [\[559\]](#)
- 2020 - Clinical characteristics of 831 patients hospitalized with COVID-19 - impact of comorbid conditions and patient race [\[560\]](#)
- 2020 - Clinical and epidemiological characteristics of 821 patients with COVID-19 [\[561\]](#)
- 2020 - Clinical characteristics of 817 elderly patients with COVID-19 - impact of delirium [\[562\]](#)
- 2020 - Clinical characteristics and outcomes of 802 patients hospitalized with COVID-19 [\[563\]](#)
- 2020 - Clinical characteristics of 786 cases of COVID-19 diagnosed in an Emergency Room [\[564\]](#)
- 2020 - Clinical characteristics of 776 patients hospitalized with COVID-19 - impact of gender [\[565\]](#)
- 2020 - Clinical characteristics of 774 patients with COVID-19 - impact of secondary bacterial infections [\[566\]](#)
- 2020 - Clinical characteristics of 761 patients with sickle-cell disease / trait and COVID-19 [\[567\]](#)
- 2020 to 2021 - Clinical characteristics and outcomes among 750 sickle-cell disease patients with COVID-19 [\[568\]](#)
- 2020 to 2021 - Clinical characteristics of 745 patients with COVID-19 - impact of infection by additional respiratory pathogens [\[569\]](#)
- 2020 - Clinical characteristics of 722 patients with COVID-19 [\[570\]](#)
- 2020 - Clinical characteristics of 710 patients with COVID-19 - impact of altered mental status [\[571\]](#)
- 2020 - Clinical characteristics and outcomes of 706 hospitalized cases of COVID-19 - prisoners vs. non-prisoners [\[572\]](#)
- 2020 - Clinical characteristics and complications among 678 hip fracture surgery patients with COVID-19 [\[573\]](#)
- 2020 - Clinical characteristics of 582 hospitalized cases of COVID-19 - comparison with influenza patients [\[574\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 565 patients hospitalized with COVID-19 [\[575\]](#)
- 2020 - Clinical characteristics of 562 asthma patients with COVID-19 [\[576\]](#)
- 2020 - Clinical characteristics of 545 gastrointestinal endoscopy patients with COVID-19 [\[577\]](#)
- 2020 - Clinical characteristics and outcomes among 543 COVID-19 patients with intellectual and developmental disabilities [\[578\]](#)
- 2020 - Clinical characteristics of 542 patients with COVID-19 - impact of bacterial co-infection [\[579\]](#)
- 2020 - Clinical characteristics of 531 patients with COVID-19 - factors associated with hospitalization [\[580\]](#)
- 2020 - Clinical characteristics of 531 patients with COVID-19 - comparison of hospitalized vs. non-hospitalized cases [\[581\]](#)
- 2020 - Clinical characteristics of 531 patients with COVID-19 - impact of co-morbid dementia [\[582\]](#)
- 2020 - Clinical and demographic characteristics of 522 patients with COVID-19 [\[583\]](#)
- 2020 - Clinical characteristics of 513 patients hospitalized with COVID-19 - impact of cytokine storm [\[584\]](#)
- 2020 - Clinical characteristics of 513 patients without co-morbidities hospitalized with COVID-19 [\[585\]](#)
- 2020 - Clinical characteristics of 508 patients hospitalized with COVID-19 - factors associated with prompt recovery [\[586\]](#)
- 2020 - Clinical characteristics of 502 patients hospitalized with COVID-19 - risk factors for mortality [\[587\]](#)
- 2020 - Clinical characteristics and outcomes of 495 critically-ill patients with COVID-19 [\[588\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 487 patients hospitalized with COVID-19 [\[589\]](#)
- 2020 - Clinical characteristics and outcomes of 470 patients hospitalized with COVID-19 [\[590\]](#)
- 2020 - Clinical characteristics and outcomes of 468 critically-ill patients with COVID-19 [\[591\]](#)
- 2020 - Clinical characteristics and outcomes of 466 patients hospitalized with COVID-19 [\[592\]](#)
- 2020 - Clinical characteristics of 463 patients with COVID-19 [\[593\]](#)
- 2020 - Clinical characteristics of 460 patients with COVID-19 - risk factors for hospitalization [\[594\]](#)
- 2020 - Clinical characteristics and outcomes of 449 pre-operative patients hospitalized with COVID-19 [\[595\]](#)
- 2020 - Clinical characteristics of 440 veterans hospitalized with COVID-19 - impact of smoking [\[596\]](#)
- 2020 - Clinical characteristics of 430 patients with COVID-19 - impact of onychomycosis [\[597\]](#)
- 2020 to 2021 - Clinical characteristics and outcomes among 422 cystic fibrosis patients with COVID-19 [\[598\]](#)
- 2020 - Clinical characteristics of 408 patients hospitalized with COVID-19 [\[599\]](#)
- 2020 - Clinical characteristics of 396 patients with severe COVID-19 - impact of pulmonary aspergillosis [\[76\]](#)
- 2020 - Clinical characteristics of 395 patients hospitalized with COVID-19 - impact of comorbidities [\[601\]](#)
- 2020 - Clinical characteristics of 393 cases (40 fatal) of COVID-19 treated at two hospitals in New York City [\[602\]](#)

- 2020 - Clinical characteristics of 375 patients hospitalized with COVID-19 - impact of secondary bloodstream infections [\[603\]](#)
- 2020 - Clinical characteristics of 371 patients hospitalized with COVID-19 [\[604\]](#)
- 2020 - Clinical characteristics of 370 patients hospitalized with COVID-19 - impact of gender [\[605\]](#)
- 2020 - Clinical characteristics of 355 patients with COVID-19 - impact of coronary artery disease [\[606\]](#)
- 2020 - Clinical characteristics of 355 patients with COVID-19 - impact of diabetes [\[607\]](#)
- 2020 - Clinical characteristics of 350 non-ICU hospitalized patients with COVID-19 [\[608\]](#)
- 2020 - Gastrointestinal manifestations among 344 patients hospitalized with COVID-19 [\[609\]](#)
- 2020 - Clinical characteristics of 343 patients with COVID-19 - impact of asthma [\[610\]](#)
- 2020 - Clinical characteristics of 343 fatal cases of COVID-19 [\[611\]](#)
- 2020 - Clinical and imaging characteristics of 338 patients with COVID-19 [\[612\]](#)
- 2020 - Clinical characteristics and risk factors for critical illness and mortality among 337 patients with COVID-19 [\[613\]](#)
- 2020 - Clinical characteristics and prognostic factors among 330 Emergency Department patients with COVID-19 [\[614\]](#)
- 2020 - Clinical characteristics of 326 patients with COVID-19 - impact of race [\[615\]](#)
- 2020 - Clinical characteristics of 321 patients with COVID-19 - impact of C-reactive protein and albumin [\[616\]](#)
- 2020 - Clinical characteristics of 316 patients with COVID-19 [\[617\]](#)
- 2020 - Clinical characteristics and risk factors for mortality of 313 patients with COVID-19 [\[618\]](#)
- 2020 - Clinical characteristics of 310 patients who were found to have COVID-19 following elective surgery [\[619\]](#)
- 2021 (publication year) - Clinical characteristics of 306 patients with COVID-19 - impact of respiratory viral co-infection [\[620\]](#)
- 2020 - Clinical characteristics of 305 adult patients hospitalized with COVID-19 [\[621\]](#)
- 2020 to 2021 - Clinical characteristics of 303 non-hospitalized patients following recovery from acute COVID-19 [\[622\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 300 patients with COVID-19 treated in Intensive Care Units [\[623\]](#)
- 2020 - Clinical characteristics of 296 cases of COVID-19 - impact of disease-related eruptions [\[624\]](#)
- 2020 - Clinical characteristics of 290 cases of COVID-19 - impact of BMI [\[625\]](#)
- 2020 - Clinical characteristics of 288 Intensive Care Unit patients with COVID-19 - impact of race [\[626\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 284 patients with COVID-19 [\[627\]](#)
- 2020 - Clinical characteristics of 278 cases of COVID-19, including 97 with gastrointestinal symptoms [\[628\]](#)
- 2020 - Clinical characteristics of 275 cases of COVID-19 - impact of atopic disease [\[629\]](#)
- 2020 - Clinical and demographic characteristics of 272 patients hospitalized with COVID-19 [\[630\]](#)
- 2020 - Clinical characteristics of 257 cases of COVID-19 - impact of demographic factors and co-morbid conditions [\[631\]](#)
- 2020 - Clinical characteristics vs. viral RNA shedding among 251 patients with COVID-19 [\[632\]](#)
- 2020 - Clinical characteristics of 251 cases of COVID-19 in patients with pre-existing hypothyroidism [\[633\]](#)
- 2020 - Clinical characteristics and outcomes of 249 patients with COVID-19 - impact of race [\[634\]](#)
- 2020 - Clinical and socioeconomic characteristics of 247 patients hospitalized with COVID-19 [\[635\]](#)
- 2020 - Clinical characteristics of 245 patients with COVID-19 - criteria for admission to Intensive Care [\[636\]](#)
- 2020 - Clinical characteristics of 244 patients hospitalized with COVID-19 - impact of secondary pulmonary infections [\[637\]](#)
- 2020 - Clinical characteristics of 242 patients hospitalized with COVID-19 [\[638\]](#)
- 2020 - Clinical characteristics of 242 patients with COVID-19 - impact of bacterial co-infection [\[639\]](#)
- 2020 to 2021 - Clinical characteristics of 240 patients hospitalized with COVID-19 - impact of rhabdomyolysis [\[640\]](#)
- 2020 - Clinical characteristics of 239 patients hospitalized with COVID-19 - analysis of cytokine profiles [\[641\]](#)
- 2020 - Clinical characteristics and outcomes among 238 psychiatric patients hospitalized with COVID-19 [\[642\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 235 critically-ill patients with COVID-19 [\[643\]](#)
- 2020 - Clinical characteristics of 235 Intensive Care Unit patients with COVID-19 - impact of rhabdomyolysis [\[644\]](#)
- 2020 - Clinical characteristics and risk factors among 235 minority population patients with COVID-19 [\[645\]](#)
- 2020 - Timing of intubation and mortality among 231 ICU patients with COVID-19 [\[646\]](#)
- 2020 - Clinical characteristics of 225 health-care workers with COVID-19 infection [\[647\]](#)
- 2020 - Clinical characteristics of 224 patients with COVID-19 - impact of interleukin levels [\[648\]](#)
- 2020 - Clinical characteristics of 220 asthmatic patients with COVID-19 [\[649\]](#)
- 2020 - Clinical characteristics of 219 active Army Service members with COVID-19 [\[650\]](#)
- 2020 - Clinical characteristics of 218 Intensive Care Unit patients with of COVID-19 - impact of gastrointestinal injury [\[651\]](#)
- 2020 - Clinical characteristics and predictors of mortality among 217 patients hospitalized with COVID-19 [\[652\]](#)
- 2020 - Clinical characteristics of 217 patients with COVID-19 - impact of old age [\[653\]](#)

- 2020 - Clinical characteristics of 217 patients hospitalized with COVID-19 [\[654\]](#)
- 2020 - Clinical characteristics of 210 patients with diabetic ketoacidosis and COVID-19 [\[262\]](#)
- 2020 - Clinical characteristics and outcomes of 209 cases of COVID-19 - impact of antibody response [\[656\]](#)
- 2020 - Clinical characteristics of 207 cases of COVID-19, including 71 with gastrointestinal symptoms [\[657\]](#)
- 2020 - Clinical characteristics of 205 patients hospitalized with COVID-19 - impact of viral load [\[658\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 200 minority patients hospitalized with COVID-19 [\[659\]](#)
- 2020 - Clinical characteristics of 199 homeless persons hospitalized with COVID-19 [\[660\]](#)
- 2020 - Clinical characteristics of 184 patients hospitalized with COVID-19 [\[661\]](#)
- 2020 - Clinical characteristics of 180 patients with mild COVID-19 - prognostic indicators of subsequent hospitalization [\[662\]](#)
- 2020 - Clinical characteristics of 180 diabetic patients with COVID-19 [\[663\]](#)
- 2020 - Clinical characteristics of 179 patients with COVID-19 - impact of secondary bacterial pneumonia [\[664\]](#)
- 2020 - Clinical characteristics and outcomes of 174 cases of COVID-19 - impact of pneumomediastinum [\[665\]](#)
- 2020 - Clinical characteristics of 168 patients hospitalized with COVID-19 [\[666\]](#)
- 2020 - Clinical characteristics of 167 cases of COVID-19 treated at a long-term care facility [\[667\]](#)
- 2020 - Clinical characteristics of 166 patients hospitalized with COVID-19 - impact of sickle cell trait [\[668\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 163 patients hospitalized with COVID-19 [\[669\]](#)
- 2020 - Clinical characteristics of 161 COVID-19 patients following discharge from hospital [\[670\]](#)
- 2020 - Clinical characteristics of 161 patients with COVID-19 hyperinflammatory syndrome [\[671\]](#)
- 2020 - Clinical characteristics of 158 patients with COVID-19 [\[672\]](#)
- 2020 - Clinical characteristics of 158 African American patients with COVID-19 admitted to an Intensive Care Unit [\[673\]](#)
- 2020 - Clinical characteristics of 157 outpatients with COVID-19 [\[674\]](#)
- 2020 - Clinical characteristics of 156 patients hospitalized with severe COVID-19 - assessment of need for ICU care [\[675\]](#)
- 2020 - Clinical characteristics of 154 patients hospitalized with severe COVID-19 [\[676\]](#)
- 2020 - Clinical and imaging characteristics of 154 patients with COVID-19 [\[677\]](#)
- 2020 - Clinical characteristics of 150 cases of COVID-19, including 31 with gastrointestinal symptoms [\[678\]](#)
- 2020 - Clinical and neuroimaging characteristics of 150 patients with COVID-19 [\[679\]](#)
- 2020 - Clinical characteristics of 148 patients hospitalized with severe COVID-19 [\[680\]](#)
- 2020 - Clinical characteristics of 147 cases of COVID-19 - impact of diabetes [\[681\]](#)
- 2020 - Gastrointestinal manifestations among 147 patients with COVID-19 during hospitalization and follow-up [\[682\]](#)
- 2020 - Clinical characteristics of 145 student athletes recovering from COVID-19 [\[683\]](#)
- 2020 - Clinical characteristics of 143 cases of COVID-19 in patients with rheumatic and musculoskeletal disease [\[684\]](#)
- 2020 - Clinical characteristics of 140 patients hospitalized with COVID-19 [\[685\]](#)
- 2020 - Clinical characteristics of 140 patients hospitalized with COVID-19 complicated by rhabdomyolysis [\[686\]](#)
- 2020 - Clinical characteristics and outcomes of 137 critically-ill patients hospitalized with COVID-19 [\[687\]](#)
- 2020 - Clinical characteristics of 132 Intensive Care Unit patients with COVID-19 [\[688\]](#)
- 2020 - Clinical characteristics on admission and outcomes of 131 patients hospitalized with COVID-19 [\[689\]](#)
- 2020 - Clinical characteristics of 129 cases (23 fatal) of COVID-19 treated at a long-term care facility [\[690\]](#)
- 2020 - Clinical characteristics and outcomes among 128 critically-ill patients with COVID-19 [\[691\]](#)
- 2020 - Clinical characteristics and occurrence of prolonged symptoms among 127 outpatients with COVID-19 [\[692\]](#)
- 2020 - Clinical characteristics of 126 COVID-19 patients following discharge from hospital - six-month follow-up [\[693\]](#)
- 2020 - Clinical characteristics of 126 COVID-19 patients following discharge from hospital - six-month follow-up [\[694\]](#)
- 2020 - Clinical characteristics of 122 patients with COVID-19 - impact of electrographic seizures [\[695\]](#)
- 2020 - Clinical characteristics of 118 outpatients with COVID-19 [\[696\]](#)
- 2020 - Clinical characteristics and risk factors for mortality among 117 patients with COVID-19 [\[697\]](#)
- 2020 - Clinical characteristics and outcomes of 116 COVID-19 patients treated in a provisional intensive care unit [\[698\]](#)
- 2020 - Clinical characteristics and outcomes of 114 patients who underwent surgery following recovery from COVID-19 [\[699\]](#)
- 2020 - Clinical characteristics of 113 patients with COVID-19 - impact of acute coronary syndrome [\[700\]](#)
- 2020 - Clinical characteristics of 111 patients hospitalized with COVID-19 - impact of inflammatory biomarkers [\[701\]](#)
- 2020 - Clinical characteristics of 111 COVID-19 patients - follow up at three months [\[702\]](#)
- 2020 - Clinical characteristics outcomes among 106 outpatients with COVID-19 [\[703\]](#)
- 2020 - Clinical and imaging characteristics of 105 patients with COVID-19 [\[704\]](#)
- 2020 - Clinical characteristics and mortality among 103 cases of COVID-19 - impact of hyperthermia [\[705\]](#)

- 2020 - Clinical characteristics outcomes among 101 patients with COVID-19 in a skilled nursing facility [\[706\]](#)
- 2020 - Clinical characteristics and outcomes of 101 patients hospitalized with COVID-19 [\[707\]](#)
- 2020 - Demographic and clinical characteristics, and outcomes of 100 adults hospitalized with COVID-19 [\[708\]](#)
- 2020 - Clinical characteristics of 100 cases of COVID-19 presenting to an emergency room [\[709\]](#)
- 2020 - Clinical characteristics and outcome of 100 multiple myeloma patients hospitalized with COVID-19 [\[710\]](#)
- 2020 - Clinical characteristics of 100 COVID-19 patients - follow-up assessment [\[711\]](#)
- 2020 - Clinical characteristics of 99 COVID-19 patients following discharge from hospital [\[712\]](#)
- 2020 - Clinical and laboratory characteristics of 99 Intensive Care Unit patients with COVID-19 who were subsequently downgraded to a hospital floor [\[713\]](#)
- 2020 - Clinical characteristics and outcome of 95 patients with COVID-19 [\[714\]](#)
- 2020 - Clinical characteristics and outcome of 93 patients hospitalized with COVID-19 - impact of vitamin D status [\[715\]](#)
- 2020 to 2021 - Clinical, sociodemographic, and epidemiologic characteristics and mortality among 91 patients with COVID-19 / tuberculosis coinfection [\[716\]](#)
- 2020 - Clinical characteristics and outcomes of 86 prisoners hospitalized with COVID-19 [\[717\]](#)
- 2020 - Clinical characteristics of 86 patients with immune-mediated inflammatory disease and COVID-19 [\[718\]](#)
- 2020 - Clinical characteristics of 85 patients with COVID-19 - impact of diabetes [\[719\]](#)
- 2020 - Clinical characteristics and outcomes of 85 patients with COVID-19 - impact of RNA-emia [\[720\]](#)
- 2020 - Clinical characteristics of 83 patients with COVID-19 and stroke [\[721\]](#)
- 2020 - Clinical characteristics of 83 inflammatory bowel disease patients with COVID-19 [\[722\]](#)
- 2020 - Clinical characteristics of 80 asthma patients with COVID-19 [\[723\]](#)
- 2020 - Clinical characteristics of 80 patients with COVID-19 - long-term impact on pulmonary function [\[724\]](#)
- 2020 - Clinical characteristics of 77 sarcoidosis patients with COVID-19 [\[725\]](#)
- 2020 - Clinical characteristics of 72 patients with COVID-19 and pneumothorax [\[726\]](#)
- 2020 - Clinical characteristics of 74 asymptomatic and presymptomatic cases of COVID-19 [\[727\]](#)
- 2020 - Clinical characteristics of 73 patients with potential SARS-CoV-2 reinfection [\[728\]](#)
- 2020 - Clinical characteristics of 73 elderly patients with COVID-19 [\[729\]](#)
- 2020 - Clinical characteristics of 72 patients with COVID-19 treated in a low disease-volume setting [\[730\]](#)
- 2020 - Clinical characteristics of 70 cases of COVID-19 in patients with rheumatic disease [\[731\]](#)
- 2020 - Clinical characteristics and outcomes among 66 sickle-cell disease patients with COVID-19 [\[732\]](#)
- 2020 - Clinical characteristics of 65 patients with COVID-19 - impact of hypoalbuminemia and abnormalities in hepatobiliary markers [\[733\]](#)
- 2020 - Clinical characteristics of 65 Intensive Care Unit patients with COVID-19 - comparison with a control group of Influenza patients [\[734\]](#)
- 2020 - Clinical characteristics of 64 respiratory illness patients with vs. without COVID-19 [\[735\]](#)
- 2020 - Demographic characteristics of 63 patients with COVID-19 - impact on outcome [\[736\]](#)
- 2020 - Clinical and imaging characteristics of 62 patients with COVID-19 - impact of pulmonary embolism [\[737\]](#)
- 2020 - Clinical characteristics of 61 COVID-19 patients following recovery from acute illness [\[738\]](#)
- 2020 - Clinical characteristics of 60 patients with COVID-19 - impact of inflammatory markers [\[739\]](#)
- 2020 - Clinical characteristics of 59 COVID-19 patients following discharge from an Intensive Care Unit [\[740\]](#)
- 2020 - Clinical characteristics and outcome of 58 multiple myeloma patients hospitalized with COVID-19 [\[741\]](#)
- 2020 - Clinical characteristics and outcome of 58 multiple myeloma patients hospitalized with COVID-19 [\[742\]](#)
- 2020 - Clinical characteristics and outcomes of 58 Intensive Care Unit patients with COVID-19 [\[743\]](#)
- 2020 - Clinical characteristics and outcome of 57 rheumatic disease patients hospitalized with COVID-19 [\[744\]](#)
- 2020 to 2021 - Clinical characteristics and outcomes among 57 inflammatory bowel disease patients with COVID-19 [\[745\]](#)
- 2020 - Clinical characteristics of 57 Intensive Care Unit patients with COVID-19 - impact of hypothermia [\[746\]](#)
- 2020 - Clinical characteristics of 52 cases of COVID-19 in patients with rheumatic disease [\[747\]](#)
- 2020 - Clinical characteristics of 52 patients with COVID-19 - impact of cytokine response. [\[748\]](#)
- 2020 - Clinical characteristics of 50 health-care workers with COVID-19 [\[749\]](#)
- 2020 - Clinical characteristics of 49 diabetic patients with COVID-19 managed as outpatients [\[750\]](#)
- 2020 to 2021 - Clinical characteristics and outcomes among 48 COVID-19 patients with proven or possible pulmonary aspergillosis. [\[80\]](#)
- 2020 - Clinical characteristics of 45 patients with COVID-19 and large-vessel occlusion [\[752\]](#)
- 2020 - Clinical characteristics of 43 patients with COVID-19 [\[753\]](#)
- 2020 - Clinical characteristics of 43 patients with COVID-19 and diabetic ketoacidosis [\[754\]](#)

- 2020 - Clinical characteristics of 41 cases of COVID-19 with gastrointestinal bleeding [\[755\]](#)
- 2020 - Clinical characteristics and prognostic factors among 40 sickle cell disease patients with COVID-19 [\[756\]](#)
- 2020 - Clinical characteristics of 40 patients hospitalized with COVID-19 - impact of circulating fibrinogen concentration [\[757\]](#)
- 2020 - Clinical characteristics of 39 inflammatory bowel disease patients with COVID-19 [\[758\]](#)
- 2020 - Clinical characteristics and outcomes of 39 COVID-19 patients who underwent surgery [\[759\]](#)
- 2020 - Clinical characteristics of COVID-19 in 36 patients with movement disorders [\[760\]](#)
- 2020 - Perioperative morbidity and mortality among 36 surgical patients with COVID-19 [\[761\]](#)
- 2020 - Clinical characteristics of 33 patients with COVID-19 who had undergone prior bariatric surgery [\[762\]](#)
- 2020 - Clinical characteristics of 32 patients with COVID-19 who underwent extracorporeal membrane oxygenation (ECMO) therapy [\[763\]](#)
- 2020 - Clinical characteristics of 32 Intensive Care Unit patients with COVID-19 [\[764\]](#)
- 2020 - Clinical characteristics of 30 patients with COVID-19 [\[765\]](#)
- 2020 - Perioperative outcomes of 29 surgical patients with COVID-19 [\[766\]](#)
- 2020 - Clinical characteristics and outcomes of 27 COVID-19 patients with ARDS - comparison with ARDS due to other etiologies [\[767\]](#)
- 2020 - Clinical characteristics of 27 mechanically-ventilated patients with COVID-19 [\[768\]](#)
- 2020 - Clinical characteristics of 24 critically-ill patients with COVID-19 treated among nine hospitals [\[769\]](#)
- 2020 - Clinical characteristics of 24 sickle-cell disease patients with COVID-19 [\[770\]](#)
- 2020 - Clinical characteristics of 23 patients with COVID-19 - analysis of inflammatory cytokines [\[771\]](#)
- 2020 to 2021 - Clinicopathological characteristics of 22 patients with COVID-19-associated ischemic enterocolitis [\[772\]](#)
- 2020 - Clinical characteristics of 21 critically-ill patients with COVID-19 [\[773\]](#)
- 2020 - Clinical characteristics of 21 patients with COVID-19 complicated by *Clostridioides difficile* infection. [\[774\]](#)
- 2020 - Clinical characteristics of 20 patients with COVID-19 [\[775\]](#)
- 2020 to 2021 - Clinical characteristics of 20 patients with COVID-19 complicated by bowel ischemia [\[776\]](#)
- 2020 - Intestinal biopsy findings in 19 patients hospitalized with COVID-19 [\[777\]](#)
- 2020 - Clinical characteristics of 19 patients who were readmitted following successful treatment for COVID-19 [\[778\]](#)
- 2020 - Clinical characteristics of 17 hip fracture patients with COVID-19 [\[779\]](#)
- 2020 - Clinical characteristics of 17 cases of COVID-19 associated with acute pancreatitis [\[780\]](#)
- 2021 (publication year) - Clinical characteristics of 17 patients with COVID-19 and common variable immunodeficiency [\[781\]](#)
- 2020 - Clinical characteristics of 16 patients with COVID-19 and acute ischemic stroke [\[782\]](#)
- 2020 - Clinical characteristics of 16 patients with COVID-19 and primary immune deficiency diseases [\[783\]](#)
- 2020 - Dermatological characteristics of 15 patients with COVID-19 [\[784\]](#)
- 2020 - Clinical characteristics of 15 adults hospitalized with COVID-19 and Multisystem Inflammatory Syndrome [\[785\]](#)
- 2020 - Clinical characteristics outcomes among 14 severely ill patients with COVID-19 at a Military Treatment Facility [\[786\]](#)
- 2020 - Clinical characteristics of 13 patients with COVID-19 and acute ischemic stroke [\[787\]](#)
- 2020 - Clinical characteristics of 13 orthopedic trauma surgery patients with COVID-19 [\[788\]](#)
- 2020 - Clinical and virological characteristics of the first 12 patients with COVID-19 in the United States [\[789\]](#)
- 2020 - Clinical characteristics of 12 patients with Down syndrome and COVID-19 [\[790\]](#)
- 2020 - Clinical characteristics of 11 adults with multisystem inflammatory syndrome related to COVID-19 - in the United States and United Kingdom [\[791\]](#)
- 2020 - Clinical characteristics and outcomes of 11 patients with COVID-19 associated with immune thrombocytopenia [\[792\]](#)
- 2020 to 2021 - Clinical characteristics of 11 Gaucher disease patients with COVID-19 [\[793\]](#)
- 2020 - Clinical characteristics of 10 hip fracture patients with COVID-19 [\[794\]](#)
- 2020 - Clinical characteristics of 10 cases of COVID-19 treated with requiring extracorporeal life support. (ECMO) [\[795\]](#)
- 2020 - Clinical characteristics of 9 patients with COVID-19 and *Clostridioides difficile* infection [\[796\]](#)
- 2021 (publication year) - Clinical characteristics of 9 COVID-19 patients with post-acute sequelae at follow-up [\[797\]](#)
- 2020 - Clinical characteristics of 7 patients with COVID-19-associated leukoencephalopathy [\[798\]](#)
- 2020 - Clinical characteristics of 6 patients with COVID-19 following bariatric surgery [\[799\]](#)
- 2020 - Clinical characteristics of 6 cases of COVID-19 - impact of anti-neutrophil cytoplasmic antibody-associated vasculitis [\[800\]](#)
- 2020 - Clinical characteristics of 6 patients with COVID-19 and stroke [\[801\]](#)

- 2020 - Clinical characteristics of 6 patients with antibody-associated vasculitis and COVID-19 [\[800\]](#)
- 2020 - Clinical characteristics of COVID-19 in 5 patients with inflammatory bowel disease [\[278\]](#)
- 2020 - Clinical characteristics of 5 patients with COVID-19 and diabetic ketoacidosis [\[804\]](#)
- 2021 (publication year) - Clinical characteristics of 5 patients with COVID-19 and influenza co-infection [\[805\]](#)
- 2020 - Clinical characteristics of COVID-19 in 5 patients with aplastic anemia [\[806\]](#)
- 2020 - Clinical characteristics of COVID-19 in 5 patients with sickle cell disease [\[807\]](#)
- 2020 - Clinical characteristics of COVID-19 in 5 patients with sickle cell disease [\[808\]](#)
- 2020 - Clinical characteristics of COVID-19 in 4 patients with sickle cell disease [\[809\]](#)
- 2021 (publication year) - Clinical characteristics of COVID-19 in 4 patients with late-onset Pompe disease [\[810\]](#)

Pregnant women

- 2020 - Clinical characteristics of 409,462 women or reproductive age with COVID-19 - comparison of pregnant vs. non-pregnant subjects [\[811\]](#)
- 2020 to 2021 - Characteristics and outcomes among 18,715 pregnant women with COVID-19 [\[812\]](#)
- 2020 to 2021 - Clinical characteristics and risk factors among 7,590 pregnant women with COVID-19 [\[813\]](#)
- 2020 - Clinical characteristics and outcomes of 7,432 pregnant women with COVID-19 [\[814\]](#)
- 2020 - Clinical characteristics and outcomes of 6,550 pregnant women with COVID-19 [\[815\]](#)
- 2020 - Clinical characteristics and outcomes of 6,380 pregnant women with COVID-19 [\[816\]](#)
- 2020 - Clinical characteristics and outcomes of 5,252 pregnant women with COVID-19 [\[817\]](#)
- 2020 - Clinical characteristics and outcomes of 1,609 pregnant women with COVID-19 [\[818\]](#)
- 2020 - Clinical characteristics and outcomes of 1,219 pregnant women with COVID-19 [\[819\]](#)
- 2020 to 2021 - Clinical characteristics and risk factors among 1,098 pregnant women with COVID-19 [\[820\]](#)
- 2020 - Clinical characteristics of 598 pregnant women hospitalized with COVID-19 [\[821\]](#)
- 2020 - Clinical characteristics of 498 pregnant women with COVID-19 - impact of absolute lymphocyte count and neutrophil to lymphocyte ratio [\[822\]](#)
- 2020 - Clinical characteristics of 427 pregnant women with COVID-19 - changes in presentation over time [\[823\]](#)
- 2020 - Clinical characteristics of 262 women with COVID-19 - pregnant vs. non-pregnant [\[824\]](#)
- 2020 - Clinical characteristics and outcomes of 252 pregnant women with COVID-19 [\[825\]](#)
- 2020 - Clinical characteristics of 241 pregnant women with COVID-19 [\[826\]](#)
- 2020 - Clinical characteristics and outcomes of 240 pregnant women with COVID-19 [\[827\]](#)
- 2020 - Clinical characteristics and prognostic factors among 233 pregnant women with COVID-19 [\[828\]](#)
- 2020 - Clinical characteristics and outcomes of 218 pregnant women with asymptomatic COVID-19 [\[829\]](#)
- 2020 - Biomarkers among 175 pregnant women with COVID-19 - symptomatic vs. asymptomatic patients [\[830\]](#)
- 2020 - Clinical characteristics of 158 pregnant women with COVID-19 [\[831\]](#)
- 2020 - Clinical characteristics and outcomes of 142 pregnant women with COVID-19 [\[832\]](#)
- 2020 - Clinical characteristics and comorbidities among 141 pregnant or post-partum women with COVID-19 [\[833\]](#)
- 2020 - Clinical characteristics of 125 pregnant women with COVID-19 [\[834\]](#)
- 2020 - Imaging characteristics of 106 pregnant women with COVID-19 [\[835\]](#)
- 2020 - Clinical characteristics of 105 pregnant women hospitalized with COVID-19 [\[836\]](#)
- 2020 - Clinical and demographic characteristics of 93 pregnant women with COVID-19 [\[837\]](#)
- 2020 - Clinical characteristics of 92 pregnant women with COVID-19 [\[838\]](#)
- 2020 - Clinical characteristics of 92 pregnant women with COVID-19 [\[839\]](#)
- 2020 - Clinical characteristics of 91 pregnant women with COVID-19 [\[840\]](#)
- 2020 - Clinical characteristics and outcomes of 85 pregnant women with COVID-19 [\[841\]](#)
- 2020 - Clinical characteristics of 83 pregnant women with COVID-19 - impact of hypertensive disorders of pregnancy [\[842\]](#)
- 2020 - Clinical characteristics of 79 pregnant women with COVID-19 at time of delivery [\[843\]](#)
- 2020 - Clinical characteristics and outcomes of 75 pregnant women with COVID-19 [\[844\]](#)
- 2020 - Clinical characteristics of 70 pregnant women with COVID-19 [\[845\]](#)
- 2020 - Placental pathology in 65 pregnant women with COVID-19 [\[846\]](#)
- 2020 - Clinical characteristics of 64 pregnant women with severe or critical COVID-19 [\[847\]](#)
- 2020 - Histopathological evaluation of placentas from 61 women with COVID-19 [\[848\]](#)
- 2020 - Histopathological evaluation of placentas from 50 women with COVID-19 [\[849\]](#)
- 2020 - Histopathological evaluation of placentas from 50 women with COVID-19 [\[850\]](#)
- 2020 - Clinical characteristics and risk factors for progression to severe disease among 50 pregnant women with

COVID-19 [\[851\]](#)

- 2020 - Clinical characteristics of 46 pregnant women with COVID-19 [\[852\]](#)
- 2020 - Clinical characteristics of 43 pregnant women with COVID-19 [\[853\]](#)
- 2020 - Clinical characteristics of 43 pregnant women with COVID-19 - impact of cesarean birth [\[854\]](#)
- 2020 - Clinical characteristics of 40 pregnant women with COVID-19 [\[855\]](#)
- 2020 - Clinical characteristics and prognosis among 38 pregnant women with COVID-19 [\[856\]](#)
- 2020 - Clinical characteristics of 34 pregnant women with suspected or confirmed COVID-19 [\[857\]](#)
- 2020 - Clinical characteristics of 34 pregnant women with COVID-19 and their neonates [\[858\]](#)
- 2020 - Clinical characteristics and outcomes of 32 critically-ill pregnant women with COVID-19 [\[859\]](#)
- 2020 - Clinical characteristics of 31 pregnant women with COVID-19 - impact of myocardial injury [\[860\]](#)
- 2020 - Clinical characteristics of 29 pregnant women with COVID-19 [\[861\]](#)
- 2020 - Clinical characteristics of 23 pregnant women with COVID-19 [\[246\]](#)
- 2020 - Clinical characteristics of 16 pregnant women with COVID-19 [\[863\]](#)
- 2020 - Clinical characteristics of 16 pregnant women with COVID-19 - analysis of placental pathology [\[864\]](#)
- 2020 to 2021 - Clinical characteristics of 15 fatal cases of COVID-19 among pregnant women [\[865\]](#)
- 2020 - Clinical characteristics and outcomes of 9 pregnant women with COVID-19 [\[866\]](#)

Pediatric patients

- 2020 - Clinical characteristics and outcomes among 12,306 pediatric patients with COVID-19 [\[867\]](#)
- 2020 - Gastrointestinal manifestations among 6,639 pediatric patients with COVID-19, [\[868\]](#)
- 2020 to 2021 - Clinical and demographic characteristics 2,818 children with COVID-19 and multisystem inflammatory syndrome [\[869\]](#)
- 2020 to 2021 - Clinical characteristics and risk factors for severe disease among 2,293 children with COVID-19 [\[870\]](#)
- 2020 - Clinical characteristics of 1,695 children or adolescents with COVID-19 - neurological involvement and impact of multisystem inflammatory syndrome [\[871\]](#)
- 2021 (publication year) - Risk for hospitalization in 1,252 children with COVID-19 - impact of co-morbid asthma [\[872\]](#)
- 2020 - Clinical characteristics of 1,215 children with COVID-19 [\[873\]](#)
- 2020 - Clinical characteristics of 1,116 children with COVID-19 - impact of multisystem inflammatory syndrome [\[874\]](#)
- 2020 - Clinical characteristics and prognostic factors of 1,080 children with COVID-19 and multisystem inflammatory syndrome [\[62\]](#)
- 2020 - Clinical characteristics of 1,000 children with COVID-19 [\[876\]](#)
- 2020 to 2021 - Clinical characteristics and outcomes among 915 children and adolescents hospitalized with COVID-19 [\[877\]](#)
- 2020 - Clinical characteristics of 627 children with COVID-19 [\[878\]](#)
- 2020 - Clinical characteristics of 531 children with COVID-19 [\[879\]](#)
- 2020 - Clinical characteristics and risk factors for severe disease among 454 pediatric patients with COVID-19 [\[880\]](#)
- 2020 - Clinical characteristics of 424 pediatric patients with COVID-19 [\[881\]](#)
- 2020 - Clinical characteristics of 424 pediatric patients with COVID-19 [\[882\]](#)
- 2020 to 2021 - Clinical characteristics of 394 Pediatric Intensive Care patients with COVID-19 [\[883\]](#)
- 2021 (publication year) - Clinical characteristics of 319 children with COVID-19 - risk factors for hospitalization [\[884\]](#)
- 2020 - Clinical characteristics of 293 children with COVID-19 [\[885\]](#)
- 2020 - Clinical characteristics and prognostic features among 281 pediatric patients hospitalized with COVID-19 [\[886\]](#)
- 2020 - Clinical characteristics of 266 diabetic children with COVID-19 [\[887\]](#)
- 2020 - Clinical characteristics of 255 neonates born to mothers with COVID-19 [\[888\]](#)
- 2020 - Clinical characteristics and complications among 232 infants hospitalized with COVID-19 [\[889\]](#)
- 2020 - Clinical and epidemiological characteristics of 200 fatal cases of COVID-19 [\[890\]](#)
- 2020 - Clinical characteristics of 186 children with COVID-19 and multisystem inflammatory syndrome [\[60\]](#)
- 2020 - Clinical characteristics of 177 children and young adults COVID-19 [\[892\]](#)
- 2020 - Clinical characteristics of 152 children with COVID-19 - impact of acute kidney injury and multisystem inflammatory syndrome [\[893\]](#)
- 2020 - Clinical characteristics of 133 children with COVID-19 - impact of asthma [\[894\]](#)
- 2020 - Clinical characteristics of 106 critically-ill children with COVID-19 - impact of acute kidney injury [\[895\]](#)
- 2020 to 2021 - Clinical characteristics of 103 children with COVID-19 - impact of SARS-CoV-2 RNAemia [\[896\]](#)
- 2020 - Clinical characteristics of 98 pediatric oncology patients with COVID-19 [\[897\]](#)

- 2021 (publication year) - Imaging characteristics of 95 children with COVID-19 - comparison with influenza [\[898\]](#)
- 2020 - Clinical characteristics of 95 children with COVID-19 and multisystem inflammatory syndrome [\[899\]](#)
- 2020 - Clinical characteristics of 92 children with COVID-19 and multisystem inflammatory syndrome - impact of acute kidney injury [\[900\]](#)
- 2020 - Clinical characteristics of 83 infants with COVID-19 and multisystem inflammatory syndrome [\[901\]](#)
- 2020 - Clinical characteristics and prognostic factors among 82 pediatric patients with COVID-19 [\[902\]](#)
- 2020 - Clinical characteristics of 81 pediatric patients with COVID-19 [\[903\]](#)
- 2020 - Clinical characteristics of 78 pediatric patients with COVID-19 [\[904\]](#)
- 2020 - Clinical characteristics of 77 pediatric patients with COVID-19 [\[905\]](#)
- 2020 - Clinical characteristics of 70 children with COVID-19 [\[906\]](#)
- 2020 - Clinical characteristics of 67 children with COVID-19 [\[907\]](#)
- 2020 - Surgical outcomes among 66 preoperative children with COVID-19 [\[908\]](#)
- 2020 - Clinical characteristics of 64 children with COVID-19 [\[909\]](#)
- 2020 - Clinical characteristics of 57 children with COVID-19 [\[910\]](#)
- 2020 - Imaging characteristics of 55 children with COVID-19 [\[911\]](#)
- 2020 to 2021 - Clinical characteristics of 55 children with rheumatic diseases and COVID-19 [\[912\]](#)
- 2020 - Clinical characteristics of 54 children with COVID-19 and multisystem inflammatory syndrome [\[913\]](#)
- 2020 - Clinical characteristics of 54 children with COVID-19 and multisystem inflammatory syndrome - impact of echocardiographic indicators [\[914\]](#)
- 2020 - Clinical characteristics of 53 infants with COVID-19 - impact of serious bacterial infections [\[915\]](#)
- 2020 - Clinical and epidemiological characteristics of 50 children with COVID-19 [\[916\]](#)
- 2020 - Clinical characteristics of 50 children with COVID-19 - impact of thrombotic microangiopathy [\[917\]](#)
- 2020 - Clinical characteristics of 48 children with COVID-19 in the United States and Canada [\[918\]](#)
- 2020 - Imaging characteristics of 47 children with COVID-19 and multisystem inflammatory syndrome [\[919\]](#)
- 2020 - Oral manifestations of 47 children with COVID-19 and multisystem inflammatory syndrome [\[920\]](#)
- 2020 - Clinical characteristics of 42 children and young adults with COVID-19 and co-morbid heart disease [\[921\]](#)
- 2020 - Coagulation profiles of 40 children with COVID-19 and multisystem inflammatory syndrome [\[922\]](#)
- 2020 - Clinical characteristics of 36 children with COVID-19 - association with electrocardiographic abnormalities [\[923\]](#)
- 2020 - Clinical characteristics of 33 children with COVID-19 and multisystem inflammatory syndrome [\[924\]](#)
- 2020 - Clinical characteristics of 33 children with COVID-19 and multisystem inflammatory syndrome [\[925\]](#)
- 2020 - Clinical characteristics of 33 children with COVID-19 and multisystem inflammatory syndrome [\[926\]](#)
- 2020 - Cardiac findings in 33 children with COVID-19 and multisystem inflammatory syndrome [\[927\]](#)
- 2020 - Clinical characteristics of 32 children with COVID-19 and multisystem inflammatory syndrome [\[928\]](#)
- 2020 - Echocardiographic findings in 28 children with COVID-19 and multisystem inflammatory syndrome [\[929\]](#)
- 2020 to 2021 - Clinical characteristics of 26 children with COVID-19 and multisystem inflammatory syndrome [\[930\]](#)
- 2020 - Clinical characteristics of 25 children with COVID-19 and multisystem inflammatory syndrome [\[931\]](#)
- 2020 - Clinical characteristics of 24 children with COVID-19 [\[932\]](#)
- 2020 - Imaging characteristics of 24 children with COVID-19 [\[933\]](#)
- 2020 - Clinical characteristics of 19 children with COVID-19 [\[934\]](#)
- 2020 - Inflammatory biomarkers in 19 children with COVID-19-associated multisystem inflammatory syndrome - comparison with cases of Kawasaki disease and macrophage activation syndrome [\[935\]](#)
- 2020 - Clinical characteristics of 18 infants with COVID-19 [\[936\]](#)
- 2020 - Clinical characteristics of 17 children with COVID-19 and multisystem inflammatory syndrome [\[937\]](#)
- 2020 - Clinical characteristics of 17 children with COVID-19 and multisystem inflammatory syndrome [\[938\]](#)
- 2020 - Imaging characteristics of 16 children with COVID-19 and multisystem inflammatory syndrome [\[939\]](#)
- 2020 - Clinical characteristics of 15 children with COVID-19 and multisystem inflammatory syndrome [\[940\]](#)
- 2020 - Imaging characteristics of 11 children with COVID-19 and multisystem inflammatory syndrome [\[941\]](#)
- 2020 - Clinical characteristics of 8 infants with COVID-19 [\[942\]](#)
- 2020 - Clinical characteristics of 6 children with COVID-19 and multisystem inflammatory syndrome [\[943\]](#)
- 2020 - Clinical characteristics of 6 children with COVID-19 and multisystem inflammatory syndrome [\[944\]](#)
- 2020 - Clinical and epidemiological features of 5 infants with COVID-19 [\[945\]](#)
- 2020 - Clinical characteristics of 4 children with COVID-19 and multisystem inflammatory syndrome [\[946\]](#)
- 2020 - Clinical characteristics of 3 neonates with COVID-19 [\[947\]](#)

Kidney disease

- 2020 - Clinical characteristics of 9,657 cases of COVID-19 - impact of acute kidney injury [\[948\]](#)
- 2020 - Clinical characteristics of 7,624 cases of COVID-19 - impact of chronic kidney disease on mortality [\[949\]](#)
- 2020 - Clinical characteristics of 5,216 veterans hospitalized with COVID-19 - impact of acute kidney injury [\[950\]](#)
- 2020 - Clinical characteristics of 4,732 cases of COVID-19 - impact of acute kidney injury [\[951\]](#)
- 2020 - Clinical characteristics of 4,378 patients hospitalized with COVID-19 - impact co-morbid chronic kidney disease [\[952\]](#)
- 2020 - Clinical characteristics of 4,264 cases of COVID-19 - impact of pre-existing kidney disease [\[953\]](#)
- 2020 - Clinical characteristics of 4,232 patients with COVID-19 - impact of HIV infection and acute kidney injury [\[954\]](#)
- 2020 - Clinical characteristics of 3,993 cases of COVID-19 - impact of acute kidney injury [\[955\]](#)
- 2020 - Clinical characteristics of 3,099 cases of COVID-19 - impact of acute kidney injury [\[956\]](#)
- 2020 - Clinical characteristics of 2,600 cases of COVID-19 - impact of acute kidney injury [\[957\]](#)
- 2020 - Clinical characteristics of 1,993 cases of COVID-19 associated with acute kidney injury [\[958\]](#)
- 2020 - Clinical characteristics of 1,406 cases of COVID-19 associated with acute kidney injury [\[959\]](#)
- 2020 - Clinical characteristics of 1,324 patients hospitalized with COVID-19 - impact of acute kidney injury [\[960\]](#)
- 2020 - Clinical characteristics and acute kidney injury among 1,091 patients with COVID-19 - comparison with a cohort of influenza patients [\[961\]](#)
- 2020 - Clinical characteristics of 1,049 cases of COVID-19 - impact of viral load on acute kidney injury [\[962\]](#)
- 2020 - Clinical characteristics of 759 cases of COVID-19 - impact of co-morbid end-stage kidney disease [\[963\]](#)
- 2020 - Clinical characteristics of 469 cases of COVID-19 - impact of acute kidney injury [\[964\]](#)
- 2020 - Clinical characteristics of 438 hemodialysis patients with COVID-19 [\[219\]](#)
- 2020 - Clinical characteristics of 419 patients with end-stage kidney disease and COVID-19 [\[966\]](#)
- 2020 - Clinical characteristics of 419 patients with end-stage kidney disease and COVID-19 [\[967\]](#)
- 2020 - Clinical characteristics of 362 cases of COVID-19 - impact of end-stage renal disease [\[968\]](#)
- 2020 - Clinical characteristics of 283 patients with COVID-19 - impact of acute kidney injury [\[969\]](#)
- 2020 - Clinical characteristics of 267 patients with COVID-19 - impact of acute kidney injury and patient race [\[970\]](#)
- 2020 - Clinical characteristics of 254 cases of COVID-19 - impact of race and acute kidney injury [\[971\]](#)
- 2020 - Clinical characteristics of 210 cases of COVID-19 in patients with chronic kidney disease [\[972\]](#)
- 2020 - Clinical characteristics of 206 cases of COVID-19 - impact of acute kidney injury [\[973\]](#)
- 2020 - Assessment of 182 patients with COVID-19 and acute kidney injury following hospital discharge [\[974\]](#)
- 2020 - Clinical characteristics of 122 dialysis patients hospitalized with COVID-19 [\[975\]](#)
- 2020 - Clinical characteristics of 115 patients with COVID-19 and acute renal failure [\[976\]](#)
- 2020 - Clinical characteristics of 106 critically-ill children with COVID-19 - impact of acute kidney injury [\[895\]](#)
- 2020 - Clinical characteristics of 92 children with COVID-19 and multisystem inflammatory syndrome - impact of acute kidney injury [\[900\]](#)
- 2020 - Clinical characteristics and outcomes among 64 hemodialysis patients with COVID-19 [\[979\]](#)
- 2020 - Clinical characteristics of 10 cases of COVID-19 associated with acute kidney injury [\[980\]](#)

Heart disease

- 2020 - Clinical characteristics and outcomes of 8,383 heart failure patients hospitalized with COVID-19 [\[981\]](#)
- 2020 - Clinical characteristics of 6,439 cases of COVID-19 - impact of prior heart failure [\[982\]](#)
- 2020 - Clinical characteristics and outcomes of 6,148 heart failure patients hospitalized with COVID-19 [\[983\]](#)
- 2020 - Clinical characteristics and outcomes of 4,695 patients hospitalized with COVID-19 - impact of myocardial injury [\[984\]](#)
- 2020 - Clinical characteristics and outcomes of 3,970 patients hospitalized with COVID-19 - impact of atrial fibrillation [\[985\]](#)
- 2020 - Clinical characteristics of 2,736 patients with COVID-19 - impact of myocardial injury [\[986\]](#)
- 2020 - Clinical characteristics of 2,716 patients hospitalized with COVID-19 - impact of troponin levels [\[987\]](#)
- 2020 - Clinical characteristics of 1,736 patients with COVID-19 - impact of myocardial injury [\[988\]](#)
- 2020 - Clinical characteristics and outcomes of 1,533 patients hospitalized with COVID-19 - impact of acute myocardial infarction [\[989\]](#)
- 2020 - Clinical characteristics of 1,498 patients with COVID-19 - impact of myocardial injury [\[990\]](#)
- 2020 - Clinical characteristics of 1,258 cases of COVID-19 - impact of electrocardiographic findings [\[991\]](#)
- 2020 - Clinical characteristics of 1,053 patients with COVID-19 - impact of bradycardia [\[992\]](#)
- 2020 - Clinical characteristics of 1,029 cases of COVID-19 - impact of atrial arrhythmias [\[993\]](#)

- 2020 - Clinical characteristics of 1,020 patients with COVID-19 - impact of myocardial injury [\[994\]](#)
- 2020 - Clinical characteristics of 979 patients with COVID-19 and co-morbid heart failure [\[995\]](#)
- 2020 - Clinical characteristics of 887 patients with COVID-19 - impact of electrocardiographic findings and troponin levels [\[996\]](#)
- 2020 - Clinical characteristics of 773 patients with COVID-19 - electrocardiographic findings [\[997\]](#)
- 2021 (publication year) - Clinical characteristics of 772 patients with COVID-19 - impact of cardiac troponin levels [\[998\]](#)
- 2020 - Clinical characteristics of 756 patients with COVID-19 - electrocardiographic findings [\[999\]](#)
- 2020 - Clinical characteristics of 700 patients hospitalized with COVID-19 - impact of cardiac arrhythmias [\[1000\]](#)
- 2020 - Clinical characteristics of 700 patients hospitalized with COVID-19 - impact of cardiovascular events [\[1001\]](#)
- 2020 - Clinical characteristics of 586 patients with COVID-19 - impact of cardiovascular comorbidities [\[1002\]](#)
- 2020 - Clinical characteristics of 535 patients hospitalized with COVID-19 - impact of myocardial infarction [\[1003\]](#)
- 2020 - Clinical characteristics of 483 patients hospitalized with COVID-19 - impact of myocardial injury [\[1004\]](#)
- 2020 - Clinical characteristics of 447 COVID-19 patients following discharge from hospital - impact of thromboembolic events [\[1005\]](#)
- 2020 - Clinical characteristics of 367 patients with COVID-19 - impact of myocardial injury [\[1006\]](#)
- 2020 - Clinical characteristics of 310 cases of COVID-19 with atrial arrhythmias - impact of patient race [\[1007\]](#)
- 2020 - Clinical characteristics of 305 cases of COVID-19 - impact of myocardial injury [\[1008\]](#)
- 2020 - Clinical characteristics of 288 cases of COVID-19 - impact of cardiac involvement [\[1009\]](#)
- 2021 (publication year) - Clinical characteristics of 280 patients with COVID-19 - impact of cardiovascular comorbidities [\[1010\]](#)
- 2020 - Clinical characteristics of 279 patients with COVID-19 - impact of prolonged QTc [\[1011\]](#)
- 2020 - Clinical characteristics of 268 patients hospitalized with COVID-19 - impact of myocardial injury [\[1012\]](#)
- 2020 to 2021 - Clinical characteristics of 211 patients hospitalized with COVID-19 and co-morbid heart failure [\[1013\]](#)
- 2020 - Clinical characteristics of 200 patients with COVID-19 - impact of atrial arrhythmia [\[1014\]](#)
- 2020 - Electrocardiographic characteristics of 186 patients with COVID-19 - impact on mortality [\[1015\]](#)
- 2020 - Clinical characteristics of 182 patients with COVID-19 - impact of elevated cardiac troponin [\[1016\]](#)
- 2020 - Clinical characteristics of 181 patients with COVID-19 - impact of cardiac injury [\[1017\]](#)
- 2020 - Clinical characteristics of 179 cases of COVID-19 - impact of cardiac abnormalities [\[1018\]](#)
- 2020 - Clinical characteristics and outcomes of 173 patients hospitalized with COVID-19 - impact of arrhythmias and conduction disturbances [\[1019\]](#)
- 2020 - Clinical characteristics and outcomes of 171 Intensive Care patients with COVID-19 - impact of atrial fibrillation [\[1020\]](#)
- 2020 - Electrocardiographic characteristics of 145 patients with COVID-19 - [\[1021\]](#)
- 2020 - Clinical characteristics of 143 patients with COVID-19 - impact of reduced cardiac function [\[1022\]](#)
- 2020 - Clinical characteristics of 143 patients with COVID-19 - impact of cardiac arrhythmias [\[1023\]](#)
- 2020 - Cardiovascular complications among 142 patients with COVID-19 - impact of diabetes [\[1024\]](#)
- 2020 - Left ventricular function in 96 patients with COVID-19 [\[1025\]](#)
- 2020 - Clinical characteristics of 55 cases of COVID-19 complicated by in-hospital cardiac arrest [\[1026\]](#)
- 2021 (publication year) - Autopsy findings in 50 cases of COVID-19 - cardiac pathology [\[1027\]](#)
- 2020 - Autopsy findings in 41 cases of COVID-19 - cardiac pathology [\[1028\]](#)
- 2020 - Clinical characteristics of 181 patients with COVID-19 and severe cardiac complications [\[1029\]](#)
- 2020 - Clinical characteristics of 42 children and young adults with COVID-19 and co-morbid heart disease [\[921\]](#)
- 2020 - Clinical characteristics of 36 children with COVID-19 - association with electrocardiographic abnormalities [\[923\]](#)
- 2020 - Cardiac findings in 33 children with COVID-19 and multisystem inflammatory syndrome [\[927\]](#)
- 2020 - Clinical characteristics of 31 pregnant women with COVID-19 - impact of myocardial injury [\[860\]](#)
- 2020 - Echocardiographic findings in 28 children with COVID-19 and multisystem inflammatory syndrome [\[929\]](#)
- 2020 - Clinical characteristics of 18 cases of COVID-19 associated with ST-segment elevation [\[1035\]](#)
- 2020 - Autopsy findings in 17 cases of COVID-19 - impact of acute kidney injury [\[1036\]](#)
- 2020 - Autopsy findings in 13 cases of COVID-19 - impact of cardiac injury [\[1037\]](#)
- 2021 (publication year) - Clinical characteristics of 6 patients with COVID-19 and inflammation-related bradycardia [\[1038\]](#)

Liver disease

- 2020 to 2021 - Clinical characteristics of 837 patients with COVID-19 and co-morbid chronic liver disease [\[1039\]](#)
- 2020 - Clinical characteristics of 3,352 patients hospitalized with COVID-19 - impact of hepatic dysfunction [\[1040\]](#)

- 2020 - Clinical characteristics of 2,856 patients hospitalized with COVID-19 - impact of hepatic dysfunction [\[1041\]](#)
- 2020 - Clinical characteristics of 2,273 cases of COVID-19 associated with acute liver injury [\[1042\]](#)
- 2020 - Clinical characteristics of 1,935 patients hospitalized with COVID-19 - impact of liver injury [\[1043\]](#)
- 2020 - Clinical characteristics of 1,827 cases of COVID-19 - impact of abnormal liver function tests [\[1044\]](#)
- 2020 - Clinical characteristics of 1,059 cases of COVID-19 - assessment of gastrointestinal and hepatic findings [\[540\]](#)
- 2020 - Clinical characteristics and outcomes among 867 patients with chronic liver disease and COVID-19 [\[1046\]](#)
- 2020 - Clinical characteristics and outcomes among 820 patients with chronic liver disease and COVID-19 [\[24\]](#)
- 2020 - Clinical characteristics of 639 patients hospitalized with COVID-19 - impact of liver injury [\[1048\]](#)
- 2020 - Clinical characteristics of 624 patients with COVID-19 and acute liver failure [\[1049\]](#)
- 2020 - Clinical characteristics of 551 cases of COVID-19 - impact of abnormal liver function tests [\[1050\]](#)
- 2020 - Clinical characteristics of 551 cases of COVID-19 - impact of acute liver injury [\[1051\]](#)
- 2020 - Clinical characteristics of 363 patients with COVID-19 - impact of chronic liver disease [\[1052\]](#)
- 2020 - Clinical characteristics of 342 patients hospitalized with COVID-19 - impact impact of hepatic steatosis [\[1053\]](#)
- 2020 - Clinical characteristics of 305 patients with hepatic cirrhosis and COVID-19 [\[1054\]](#)
- 2020 - Clinical characteristics of 250 cases of COVID-19 in patients with pre-existing liver disease [\[1055\]](#)
- 2020 - Clinical characteristics of 200 cases of COVID-19 - impact of abnormal liver function tests [\[1056\]](#)
- 2020 - Clinical characteristics of 192 cases of COVID-19 in patients with pre-existing liver disease [\[1057\]](#)
- 2020 - Clinical characteristics of 176 cases of COVID-19 - impact of liver injury on cytokine response [\[1058\]](#)
- 2020 - Clinical characteristics of 105 patients hospitalized with COVID-19 - impact of liver injury [\[1059\]](#)
- 2020 - Clinical characteristics of 50 health-care workers with COVID-19 - analysis of liver function [\[1060\]](#)
- 2020 - Clinical characteristics of 37 patients with hepatic cirrhosis and COVID-19 [\[1061\]](#)
- 2020 - Autopsy findings in the livers of 17 cases of COVID-19 [\[1062\]](#)
- 2020 - Clinical characteristics of 12 patients with COVID-19 and cholangiopathy [\[1063\]](#)
- 2020 - Clinical characteristics of 3 patients with alcoholic cirrhosis and COVID-19 [\[1064\]](#)

Thrombosis and embolism

- 2020 to 2021 - Clinical characteristics and outcomes among 11,537 cases of COVID-19 - impact of thrombotic events [\[1065\]](#)
- 2020 - Clinical characteristics of 10,871 cases of COVID-19 - impact of venous thromboembolism [\[1066\]](#)
- 2020 - Clinical characteristics of 9,407 cases of COVID-19 - impact of venous thromboembolism [\[1067\]](#)
- 2020 - Clinical characteristics of 6,513 cases of COVID-19 - impact of venous thromboembolism [\[1068\]](#)
- 2020 - Risk for thromboembolism in 6,319 patients hospitalized with COVID-19 - impact of patient ethnicity [\[1069\]](#)
- 2020 - Clinical characteristics of 4,461 cases of COVID-19 - impact of venous thromboembolism [\[1070\]](#)
- 2020 - Clinical characteristics of 1,114 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1071\]](#)
- 2020 - Clinical characteristics of 609 cases of COVID-19 - impact of obesity on development of venous thromboembolism [\[1072\]](#)
- 2020 - Clinical characteristics of 533 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1073\]](#)
- 2021 (publication year) - Clinical characteristics of 451 patients hospitalized with COVID-19 - impact of acute deep venous thrombosis [\[1074\]](#)
- 2020 - Clinical characteristics of 443 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1075\]](#)
- 2020 - Clinical characteristics of 424 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1076\]](#)
- 2020 - Clinical characteristics of 413 patients hospitalized with COVID-19 - impact of pulmonary embolism [\[1077\]](#)
- 2020 - Clinical characteristics of 400 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1078\]](#)
- 2020 - Clinical characteristics of 355 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1079\]](#)
- 2020 - Clinical characteristics of 349 patients hospitalized with COVID-19 - impact of thrombotic events [\[1080\]](#)
- 2020 - Clinical characteristics of 240 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1081\]](#)
- 2020 - Clinical characteristics of 218 cancer patients with COVID-19 - impact of thrombosis [\[1082\]](#)
- 2020 - Clinical characteristics of 210 patients hospitalized with COVID-19 - impact of venous thromboembolism [\[1083\]](#)
- 2020 - Clinical characteristics of 163 patients with COVID-19 - impact of post-discharge thrombosis [\[1084\]](#)
- 2020 - Clinical characteristics of 109 patients hospitalized with COVID-19 - impact of thromboembolism [\[1085\]](#)
- 2020 - Clinical characteristics of 107 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1086\]](#)
- 2020 - Clinical characteristics of 90 cancer patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1087\]](#)
- 2020 - Clinical characteristics of 71 patients with COVID-19 - impact of deep venous thrombosis [\[1088\]](#)

- 2020 - Clinical characteristics of 71 patients with COVID-19 - impact of deep venous thrombosis [\[1089\]](#)
- 2020 - Clinical and virological characteristics of 71 cancer patients with COVID-19 [\[1090\]](#)
- 2020 - Characteristics of 49 patients with COVID-19 and acute arterial thromboembolism [\[1091\]](#)
- 2020 - Clinical characteristics of 45 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1092\]](#)
- 2020 - Clinical characteristics of 45 patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1093\]](#)
- 2020 - Clinical characteristics of 21 patients with COVID-19 associated with acute thrombotic manifestations [\[1094\]](#)
- 2020 - Clinical characteristics of 3 patients with COVID-19 and pulmonary embolism [\[1095\]](#)

Neurological manifestations

- 2020 - Clinical characteristics of 4,491 patients with COVID-19 - neurological manifestations [\[1096\]](#)
- 2020 - Clinical characteristics of 3,203 patients hospitalized with COVID-19 - impact of neurological findings [\[1097\]](#)
- 2020 - Clinical characteristics and risk for mortality among 1,053 patients with COVID-19 - impact of neurological findings at admission [\[1098\]](#)
- 2020 - Clinical characteristics of 581 patients with COVID-19 and neurological involvement [\[1099\]](#)
- 2020 - Clinical characteristics of 577 patients with COVID-19 - impact of co-morbid chronic obstructive lung disease and emphysema [\[1100\]](#)
- 2020 - Clinical characteristics of 574 patients with COVID-19 - impact of neurological findings [\[1101\]](#)
- 2020 - Clinical characteristics of 509 patients with COVID-19 - neurological manifestations [\[1102\]](#)
- 2020 - Clinical characteristics of 404 patients with COVID-19 - neurological manifestations [\[1103\]](#)
- 2020 - Electroencephalographic characteristics of 197 patients with COVID-19 and neurological findings [\[1104\]](#)
- 2020 - Clinical characteristics of 96 patients with COVID-19 - impact of co-morbid chronic obstructive lung disease [\[1105\]](#)
- 2020 - Clinical characteristics of 91 patients with demyelinating diseases and COVID-19 [\[1106\]](#)
- 2020 - Clinical characteristics of 90 patients with COVID-19 - association of neurological manifestations with Native American ethnicity [\[1107\]](#)
- 2020 - Clinical characteristics of 74 patients with COVID-19 - impact of neurological findings [\[1108\]](#)
- 2020 - Clinical characteristics of 56 patients with COVID-19 and neurological manifestations [\[1109\]](#)
- 2020 - Clinical characteristics of 50 patients with COVID-19 - neurological manifestations [\[1110\]](#)
- 2020 - Clinical characteristics of 46 patients with COVID-19 and co-morbid Parkinson's disease [\[1111\]](#)
- 2020 - Clinical characteristics of 33 patients with COVID-19 - neurological manifestations [\[1112\]](#)
- 2020 - Clinical characteristics of 26 patients with COVID-19 and neurovascular complications [\[1113\]](#)
- 2020 - Clinical characteristics of 25 patients with COVID-19 and co-morbid Parkinson's disease [\[1114\]](#)
- 2020 - CSF characteristics 18 patients with COVID-19 and neurological manifestations [\[1115\]](#)
- 2020 - Clinical characteristics of 16 patients with COVID-19 - neurological and neuroimaging manifestations [\[1116\]](#)
- 2021 (publication year) - Clinical characteristics of 14 patients with COVID-19 and neurological manifestations [\[1117\]](#)
- 2021 (publication year) - Clinical characteristics of 13 vaccinated multiple sclerosis patients with COVID-19 [\[1118\]](#)
- 2021 (publication year) - Clinical characteristics of 12 patients with COVID-19 and disorders of consciousness [\[1119\]](#)

Transplant recipients

- 2020 - Clinical characteristics of 2,307 solid organ transplant recipients with COVID-19 [\[1120\]](#)
- 2020 - Clinical characteristics and outcomes among 1,925 solid organ transplant recipients with COVID-19 [\[1121\]](#)
- 2020 - Clinical characteristics of 1,051 solid organ transplant recipients with COVID-19 - lung vs. non-lung recipients [\[1122\]](#)
- 2020 - Clinical characteristics of 482 solid organ transplant recipients with COVID-19 [\[1123\]](#)
- 2020 - Clinical characteristics of 318 hematopoietic cell transplant recipients with COVID-19 [\[1124\]](#)
- 2020 - Clinical characteristics of 294 liver transplant recipients with COVID-19 [\[1125\]](#)
- 2020 - Clinical characteristics of 136 patients with COVID-19, wait-listed or following kidney transplant [\[1126\]](#)
- 2020 - Clinical characteristics of 132 kidney transplant recipients with COVID-19 [\[1127\]](#)
- 2020 - Clinical characteristics and outcomes among 128 solid organ transplant recipients with COVID-19 [\[1128\]](#)
- 2020 - Clinical characteristics of 126 liver transplant recipients with COVID-19 [\[1129\]](#)
- 2020 - Clinical characteristics of 117 solid organ transplant recipients with COVID-19 [\[1130\]](#)
- 2020 - Clinical characteristics of 98 solid organ transplant recipients with COVID-19 [\[1131\]](#)
- 2020 - Clinical characteristics of 90 solid organ transplant recipients with COVID-19 [\[1132\]](#)
- 2020 - Clinical characteristics of 82 solid organ transplant recipients with COVID-19 [\[1133\]](#)
- 2020 - Clinical characteristics of 77 hematopoietic cell transplant recipients with COVID-19 [\[1134\]](#)
- 2020 to 2021 - Clinical characteristics of 66 previously vaccinated solid organ transplant recipients with COVID-19 [\[1135\]](#)

- 2020 to 2021 - Clinical characteristics and outcomes among 54 lung transplant recipients with COVID-19 [\[1136\]](#)
- 2020 - Clinical characteristics of 45 solid organ transplant recipients with COVID-19 [\[1137\]](#)
- 2020 - Clinical characteristics of 44 kidney transplant recipients with COVID-19 [\[1138\]](#)
- 2020 to 2021 - Clinical characteristics at follow-up of 44 lung transplant recipients following recovery from COVID-19 [\[1139\]](#)
- 2020 - Clinical characteristics of 41 kidney transplant recipients with COVID-19 [\[1140\]](#)
- 2020 - Clinical characteristics of 41 kidney transplant recipients with COVID-19 [\[1141\]](#)
- 2020 - Clinical characteristics of 38 kidney transplant-recipients with COVID-19 [\[1142\]](#)
- 2020 - Clinical characteristics of 38 kidney transplant-recipients with COVID-19 [\[1143\]](#)
- 2020 - Clinical characteristics of 32 lung transplant recipients with COVID-19 [\[1144\]](#)
- 2020 - Clinical characteristics of 28 heart transplant recipients with COVID-19 [\[1145\]](#)
- 2020 to 2021 - Clinical characteristics and mortality among 28 heart transplant recipients with COVID-19 [\[1146\]](#)
- 2020 - Clinical characteristics of 28 hematopoietic cell transplant recipients with COVID-19 [\[1147\]](#)
- 2020 - Clinical characteristics of 25 kidney transplant recipients with COVID-19 [\[1148\]](#)
- 2020 - Clinical characteristics of 25 lung transplant recipients with COVID-19 [\[1149\]](#)
- 2020 - Clinical characteristics and outcomes among 23 kidney transplant-recipients with COVID-19 [\[1150\]](#)
- 2020 - Clinical characteristics of 22 heart transplant recipients with COVID-19 [\[1151\]](#)
- 2020 - Clinical characteristics of 22 solid organ transplant recipients with COVID-19 [\[1152\]](#)
- 2020 - Clinical characteristics of 22 solid organ transplant recipients with COVID-19 [\[1153\]](#)
- 2020 - Clinical characteristics of 21 solid organ transplant recipients with COVID-19 [\[1154\]](#)
- 2020 to 2021 - Renal biopsy findings in 18 kidney transplant-recipients with COVID-19 [\[1155\]](#)
- 2020 - Clinical characteristics of 16 solid organ transplant recipients with COVID-19 [\[1156\]](#)
- 2020 - Clinical characteristics of 15 kidney transplant-recipients with COVID-19 [\[1157\]](#)
- 2020 to 2021 - Clinical characteristics and outcomes among 14 lung transplant recipients with breakthrough COVID-19 [\[1158\]](#)
- 2020 - Clinical characteristics of 13 heart transplant-recipients with COVID-19 [\[1159\]](#)
- 2020 - Clinical characteristics of 11 HIV-positive liver and kidney transplant recipients with COVID-19 [\[1160\]](#)
- 2020 - Clinical characteristics of 11 kidney transplant-recipients with COVID-19 [\[1161\]](#)
- 2020 - Clinical characteristics of 10 solid organ transplant recipients with COVID-19 [\[1162\]](#)
- 2020 - Clinical characteristics of 6 solid organ transplant recipients with COVID-19 [\[1163\]](#)
- 2020 - Clinical characteristics of 5 heart transplant recipients with COVID-19 [\[1164\]](#)
- 2020 - Clinical characteristics of 4 kidney transplant recipients with COVID-19 [\[1165\]](#)

Cancer

- 2020 to 2021 - Clinical characteristics and outcomes of 19,929 patients with COVID-19 and comorbid HIV infection and/or cancer [\[1166\]](#)
- 2020 - Clinical characteristics of 6,724 cases of COVID-19 - impact of comorbid cancer [\[1167\]](#)
- 2020 - Clinical characteristics of 5,556 cases of COVID-19 - impact of comorbid cancer [\[1168\]](#)
- 2020 - Clinical characteristics and prognostic factors among 4,966 cancer patients with COVID-19 [\[1169\]](#)
- 2020 - Clinical characteristics and outcomes among 4,641 inpatients with COVID-19 - impact of co-morbid cancer [\[1170\]](#)
- 2020 - Clinical characteristics of 4,627 cases of COVID-19 - impact of comorbid cancer [\[1171\]](#)
- 2020 - Clinical characteristics and outcomes of 3,014 cancer patients hospitalized with COVID-19 - impact of viral load [\[1172\]](#)
- 2020 - Clinical characteristics and prognostic factors among 2,708 cancer patients with COVID-19 [\[1173\]](#)
- 2020 - Clinical characteristics of 2,476 cases of COVID-19 - impact of prior cancer and comorbid cardiovascular disease [\[1174\]](#)
- 2020 - Clinical characteristics and outcomes of 2,052 patients hospitalized with COVID-19, in China and the United States - impact of co-morbid cancer [\[1175\]](#)
- 2020 - Mortality rates among 1,682 cancer patients hospitalized with COVID-19 [\[1176\]](#)
- 2020 - Clinical characteristics and outcomes of 928 cancer patients hospitalized with COVID-19 [\[1177\]](#)
- 2020 - Clinical characteristics of 423 cancer patients with COVID-19 [\[1178\]](#)
- 2020 - Clinical characteristics and outcomes of 374 cancer patients with COVID-19 - impact of acute kidney injury [\[1179\]](#)
- 2020 - Clinical characteristics of 334 cancer patients with COVID-19 [\[1180\]](#)
- 2020 - Clinical characteristics of 312 cancer patients with COVID-19 [\[1181\]](#)

- 2020 - Clinical characteristics and mortality among 266 cancer patients with COVID-19 [\[1182\]](#)
- 2020 - Clinical characteristics and outcomes of 255 cancer patients with COVID-19 [\[1183\]](#)
- 2020 - Clinical characteristics and outcomes of 248 cancer patients with COVID-19 - impact of baseline imaging findings [\[1184\]](#)
- 2020 - Clinical characteristics of 218 cancer patients with COVID-19 - impact of thrombosis [\[1082\]](#)
- 2020 - Clinical characteristics and outcomes of 206 patients hospitalized with COVID-19 - impact of comorbid cancer [\[1186\]](#)
- 2020 - Clinical characteristics and outcomes of 188 patients hospitalized with COVID-19 - impact of comorbid cancer [\[1187\]](#)
- 2020 - Clinical characteristics and outcomes of 183 cancer patients with COVID-19 [\[1188\]](#)
- 2020 - Clinical characteristics of 121 cases of COVID-19 in patients with gynecological cancer [\[1189\]](#)
- 2020 - Clinical characteristics and outcomes of 109 pediatric cancer patients hospitalized with COVID-19 [\[1190\]](#)
- 2020 - Clinical characteristics and outcomes of 107 irradiated cancer patients hospitalized with COVID-19 [\[1191\]](#)
- 2020 - Clinical characteristics of 106 cancer patients with COVID-19 - impact of myelosuppressive chemotherapy [\[1192\]](#)
- 2020 - Clinical characteristics of 102 cases of COVID-19 in patients with lung cancer [\[1193\]](#)
- 2020 - Clinical characteristics of 98 pediatric oncology patients with COVID-19 [\[897\]](#)
- 2020 - Clinical characteristics of 90 cancer patients hospitalized with COVID-19 - impact of thromboembolic phenomena [\[1087\]](#)
- 2020 - Clinical characteristics and outcomes of 89 critically ill cancer patients with COVID-19 [\[1196\]](#)
- 2020 - Clinical characteristics of 86 gynecological cancer patients with COVID-19 - impact of inflammatory markers [\[1197\]](#)
- 2020 - Clinical characteristics and outcome of 85 cancer patients hospitalized with COVID-19 [\[1198\]](#)
- 2020 - Clinical characteristics of 68 cancer patients with COVID-19 [\[1199\]](#)
- 2020 to 2021 - Clinical characteristics and outcome of 62 hematologic cancer patients hospitalized with COVID-19 [\[1200\]](#)
- 2020 - Clinical characteristics of 61 cancer patients with COVID-19 [\[1201\]](#)
- 2020 to 2021 - Clinical characteristics and outcome of 53 patients hospitalized with COVID-19 - impact of comorbid hematologic malignancies. [\[1202\]](#)
- 2020 - Clinical characteristics of 36 cancer patients with COVID-19 [\[1203\]](#)
- 2020 - Clinical characteristics and outcomes of 32 head-and-neck cancer patients hospitalized with COVID-19 [\[1204\]](#)
- 2020 - Clinical characteristics of 28 cancer patients hospitalized with COVID-19 [\[1205\]](#)
- 2020 - Clinical characteristics and outcome of 21 thyroid cancer patients with COVID-19 [\[1206\]](#)
- 2020 - Clinical characteristics of 10 sarcoma patients with COVID-19 [\[1207\]](#)
- 2020 - Clinical characteristics of 3 hematology-oncology patients with COVID-19 {p - 2020 - Clinical characteristics of 218 cancer patients with COVID-19 - impact of thrombosis [\[1082\]](#)

HIV / AIDS

- 2020 - Clinical characteristics of 21,528 patients hospitalized with COVID-19 - impact of co-morbid HIV infection [\[1209\]](#)
- 2020 - Clinical characteristics of 21,528 patients hospitalized with COVID-19 - impact of co-morbid HIV infection [\[1210\]](#)
- 2020 to 2021 - Clinical characteristics and outcomes of 19,929 patients with COVID-19 and comorbid HIV infection and/or cancer [\[1166\]](#)
- 2020 - Clinical characteristics of 4,613 patients with COVID-19 - impact of co-morbid HIV infection [\[1212\]](#)
- 2020 - Clinical characteristics of 4,232 patients with COVID-19 - impact of HIV infection and acute kidney injury [\[954\]](#)
- 2020 - Clinical characteristics and outcomes of COVID-19 in 2,988 HIV-positive patients [\[1214\]](#)
- 2020 - Clinical characteristics and outcomes of COVID-19 in 1,638 HIV-positive patients [\[1215\]](#)
- 2020 - Clinical characteristics of COVID-19 in 404 HIV-positive patients [\[1216\]](#)
- 2020 - Clinical characteristics and outcomes of COVID-19 in 286 HIV-positive patients [\[1217\]](#)
- 2020 - Clinical characteristics of COVID-19 in 122 HIV-positive patients [\[1218\]](#)
- 2020 - Clinical characteristics and outcomes of COVID-19 in 110 HIV-positive patients [\[1219\]](#)
- 2020 - Clinical characteristics of COVID-19 in 72 HIV-positive patients [\[1220\]](#)
- 2020 - Clinical characteristics and outcomes of COVID-19 in 68 HIV-positive patients [\[1221\]](#)
- 2020 - Clinical characteristics of COVID-19 in 30 HIV-positive patients [\[1222\]](#)
- 2020 - Clinical characteristics of COVID-19 in 27 HIV-positive patients [\[1223\]](#)
- 2020 - Clinical characteristics and outcomes of COVID-19 in 23 HIV-positive patients [\[1224\]](#)
- 2020 - Clinical characteristics of COVID-19 in 21 HIV-positive patients [\[1225\]](#)
- 2020 - Clinical characteristics of COVID-19 in 11 HIV-positive liver and kidney transplant recipients [\[1160\]](#)

- 2020 - Clinical characteristics of COVID-19 in 9 HIV-positive patients [\[1227\]](#)
- 2020 - Clinical characteristics of COVID-19 in 6 HIV-positive patients [\[1228\]](#)
- 2020 - Clinical characteristics of COVID-19 in 5 HIV-positive patients [\[1229\]](#)
- 2020 - Clinical characteristics of COVID-19 in 5 HIV-positive patients [\[1230\]](#)

Obesity

- 2020 - Clinical characteristics of 6,916 cases of COVID-19 - impact of obesity [\[1231\]](#)
- 2020 - Clinical characteristics of 3,676 cases of COVID-19 - impact of metabolic syndrome [\[1232\]](#)
- 2020 - Clinical characteristics of 3,533 cases of COVID-19 - impact of obesity and diabetes [\[1233\]](#)
- 2020 - Clinical characteristics of 3,530 cases of COVID-19 - impact of obesity [\[1234\]](#)
- 2020 - Clinical characteristics of 3,406 cases of COVID-19 - impact of obesity [\[1235\]](#)
- 2020 - Clinical characteristics of 1,983 patients hospitalized with COVID-19 - impact of obesity [\[1236\]](#)
- 2020 - Clinical characteristics of 1,919 cases of COVID-19 - impact of obesity [\[1237\]](#)
- 2020 - Clinical characteristics of 1,337 cases of COVID-19 - impact of obesity [\[1238\]](#)
- 2020 - Clinical characteristics of 791 cases of COVID-19 - impact of obesity [\[1239\]](#)
- 2020 - Clinical characteristics of 781 cases of COVID-19 - impact of obesity [\[1240\]](#)
- 2020 - Clinical characteristics of 770 patients with COVID-19 - impact of obesity [\[1241\]](#)
- 2020 - Clinical characteristics of 609 cases of COVID-19 - impact of obesity on development of venous thromboembolism [\[1072\]](#)
- 2020 - Clinical characteristics of 504 cases of COVID-19 - impact of obesity [\[1243\]](#)
- 2020 - Clinical characteristics and outcomes among 425 patients hospitalized with COVID-19 - impact of obesity [\[1244\]](#)
- 2020 - Clinical characteristics and risk for death among 305 patients with COVID-19 - impact of obesity [\[1245\]](#)
- 2020 - Clinical characteristics of 302 cases of COVID-19 - impact of diabetes and obesity [\[1246\]](#)
- 2020 - Clinical characteristics of 277 cases of COVID-19 - impact of obesity [\[1247\]](#)
- 2020 - Clinical characteristics of 238 cases of COVID-19 - impact of obesity [\[1248\]](#)
- 2020 - Clinical characteristics of 210 cases of COVID-19 - impact of obesity [\[1249\]](#)
- 2020 - Clinical characteristics of 200 cases of COVID-19 - impact of obesity [\[1250\]](#)
- 2020 - Clinical characteristics of 176 cases of COVID-19 - impact of Body Mass Index [\[1251\]](#)
- 2020 - Clinical characteristics of 112 cases of COVID-19 - impact of obesity and smoking [\[1252\]](#)
- 2020 - Clinical characteristics of 112 cases of COVID-19 - impact of obesity and smoking [\[1253\]](#)
- 2020 - Clinical characteristics of 103 cases of COVID-19 - impact of obesity [\[1254\]](#)

Imaging characteristics

- 2020 - Imaging characteristics of 579 patients with COVID-19 [\[1255\]](#)
- 2020 - Imaging characteristics of 341 patients with COVID-19 - value of abdominopelvic CT [\[1256\]](#)
- 2020 - Imaging characteristics of 326 patients with COVID-19 - impact of patient race [\[1257\]](#)
- 2020 - Imaging characteristics of 315 patients with COVID-19 [\[1258\]](#)
- 2020 - Imaging characteristics of 308 patients hospitalized with COVID-19 - impact of coagulopathy [\[1259\]](#)
- 2020 - Neuro-imaging characteristics of 278 patients with COVID-19 [\[1260\]](#)
- 2020 - Imaging characteristics of 254 patients with COVID-19 [\[1261\]](#)
- 2020 - Imaging characteristics of 245 patients with COVID-19 [\[1262\]](#)
- 2020 - Imaging characteristics of 200 patients with COVID-19 [\[1263\]](#)
- 2020 - Imaging characteristics of 192 Emergency Department cases of COVID-19 [\[1264\]](#)
- 2020 to 2021 - Imaging characteristics of 160 patients with COVID-19 [\[1265\]](#)
- 2020 - Imaging characteristics of 154 patients with COVID-19 [\[677\]](#)
- 2020 - Imaging characteristics of 151 patients with COVID-19 [\[1267\]](#)
- 2020 - Neuro-imaging characteristics of 151 patients with of COVID-19 [\[1268\]](#)
- 2020 - Encephalographic findings in 111 patients with COVID-19 [\[1269\]](#)
- 2020 - Imaging characteristics of 110 patients with COVID-19 [\[1270\]](#)
- 2020 - Imaging characteristics of 106 pregnant women with COVID-19 [\[835\]](#)
- 2021 (publication year) - Imaging characteristics of 95 children with COVID-19 - comparison with influenza [\[898\]](#)
- 2020 - Imaging characteristics of 93 patients with COVID-19 [\[1273\]](#)
- 2020 - Imaging characteristics of 92 patients with COVID-19 [\[1274\]](#)
- 2020 - Abdominal imaging characteristics of 73 patients with COVID-19 [\[1275\]](#)

- 2020 - Imaging characteristics of 62 patients with COVID-19 [\[1276\]](#)
- 2021 - Imaging characteristics of 60 patients hospitalized with breakthrough COVID-19 [\[1277\]](#)
- 2020 - Echocardiographic findings in 58 patients with COVID-19 [\[1278\]](#)
- 2020 - Echocardiographic findings in 52 patients with COVID-19 [\[1279\]](#)
- 2020 - Imaging characteristics of 45 critically-ill patients with COVID-19 [\[1280\]](#)
- 2020 - Encephalographic findings in 43 patients with COVID-19 [\[1281\]](#)
- 2020 - Abdominal CT findings in 43 patients with COVID-19 [\[1282\]](#)
- 2020 - Encephalographic findings in 37 patients with COVID-19 [\[1283\]](#)
- 2020 - Imaging characteristics of 36 patients with COVID-19 [\[1284\]](#)
- 2020 - Imaging characteristics of 31 cancer patients with COVID-19 [\[1285\]](#)
- 2020 - Imaging characteristics of 24 children with COVID-19 [\[933\]](#)
- 2020 - Lung ultrasound characteristics of 22 patients with COVID-19 [\[1287\]](#)
- 2020 - Neurological and neuroimaging manifestations of 16 patients with COVID-19 [\[1116\]](#)
- 2020 - Imaging characteristics of 11 children with COVID-19 and multisystem inflammatory syndrome [\[941\]](#)
- 2020 - Imaging characteristics of 10 patients with COVID-19 [\[1290\]](#)
- 2020 - Imaging characteristics of 8 patients with COVID-19 [\[1291\]](#)

Laboratory and pathological characteristics

- 2020 - Electrolyte abnormalities in 10,385 patients hospitalized with COVID-19 [\[1292\]](#)
- 2020 - Impact of hyponatremia and hypernatremia in 9,946 hospitalized patients with COVID-19 [\[1293\]](#)
- 2020 - Impact of D-dimer elevation on mortality among 3,418 Intensive Care Unit patients with COVID-19 [\[1294\]](#)
- 2020 - Impact of C-reactive protein (CRP) elevation in 2,601 patients with COVID-19 [\[1295\]](#)
- 2020 - Impact of red-cell distribution width on mortality among 2,562 patients with COVID-19 [\[1296\]](#)
- 2020 - Impact of D-dimer elevation in 2,377 patients hospitalized with COVID-19 [\[1297\]](#)
- 2020 - Impact of of neutrophil-to-lymphocyte ratio in 2,071 Intensive Care Unit patients with COVID-19 [\[1298\]](#)
- 2020 - Impact of hyponatremia in 1,373 patients with COVID-19 [\[1299\]](#)
- 2020 - Inflammatory markers in 1,123 patients hospitalized with COVID-19 [\[1300\]](#)
- 2020 - Impact of D-dimer elevation in 1,065 patients hospitalized with COVID-19 [\[1301\]](#)
- 2020 - Impact of viral load on acute kidney injury in 1049 patients with COVID-19 [\[962\]](#)
- 2020 - Impact of hyperlipasemia among 992 patients hospitalized with COVID-19 [\[1303\]](#)
- 2020 - Impact of blood type in 825 patients hospitalized with COVID-19 [\[1304\]](#)
- 2020 - Inflammatory markers in 781 patients with COVID-19 - impact of patient gender [\[1305\]](#)
- 2020 - Impact of anemia at admission on mortality among 733 patients with COVID-19 [\[1306\]](#)
- 2020 - Impact of hypertriglyceridemia in 600 patients hospitalized with COVID-19 [\[1307\]](#)
- 2020 - Impact of C-reactive protein levels on outcome among 541 patients hospitalized with COVID-19 [\[1308\]](#)
- 2020 - Clinical characteristics of 498 pregnant women with COVID-19 - impact of absolute lymphocyte count and neutrophil to lymphocyte ratio [\[822\]](#)
- 2020 - Impact of hyperglycemia in 495 patients with COVID-19 [\[1310\]](#)
- 2020 - Impact of hyperglycemia in 403 non-diabetic patients with COVID-19 [\[1311\]](#)
- 2020 - Lymphocyte counts in 312 patients hospitalized with COVID-19 [\[1312\]](#)
- 2020 - Impact of procalcitonin levels in 271 Intensive Care Unit patients with COVID-19 [\[1313\]](#)
- 2020 - Impact of CRP elevation in 268 patients with COVID-19 [\[1314\]](#)
- 2020 - Impact of elevated cardiac troponin-I among 257 patients hospitalized with COVID-19 [\[1315\]](#)
- 2020 - Hemogram analysis in 246 cases of COVID-19 [\[1316\]](#)
- 2020 - Impact of hemogram and coagulation parameters in 225 patients with COVID-19 [\[1317\]](#)
- 2020 - Impact of of neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios in 184 COVID-19 patients. [\[1318\]](#)
- 2020 - Impact of viral load on severity and mortality in 178 cases of COVID-19 [\[1319\]](#)
- 2020 - Biomarkers among 175 pregnant women with COVID-19 - symptomatic vs. asymptomatic patients [\[830\]](#)
- 2020 - Hemogram analysis in 155 patients with COVID-19 [\[1321\]](#)
- 2020 - Coagulation and inflammatory parameters in 138 patients with COVID-19 [\[1322\]](#)
- 2020 - Clinical and cardiac characteristics in 133 fatal cases of COVID-19 [\[1323\]](#)
- 2020 - Impact of early-onset hyperglycemia in 133 Intensive Care Unit patients with COVID-19 [\[1324\]](#)
- 2020 - Impact of transaminase levels on mortality rates in 130 patients hospitalized with COVID-19 [\[1325\]](#)

- 2020 - Impact of hypoalbuminemia on hospitalization rates in 100 patients with COVID-19 [\[1326\]](#)
- 2020 - Impact of D-dimer elevation in 100 patients hospitalized with COVID-19 [\[1327\]](#)
- 2020 - Autopsy findings in 100 cases of COVID-19 [\[1328\]](#)
- 2020 - Hemogram analysis in 90 patients with COVID-19 [\[1329\]](#)
- 2020 - Cerebrospinal analysis in 79 patients with COVID-19 [\[1330\]](#)
- 2020 - Impact of C-reactive protein / albumin ratio in 75 patients hospitalized with COVID-19 [\[1331\]](#)
- 2020 - Autopsy findings in 68 cases of COVID-19 (Italy and the United States) - [\[1332\]](#)
- 2020 - Placental pathology in 65 pregnant women with COVID-19 [\[846\]](#)
- 2020 - Analysis of glucose levels in 63 patients with COVID-19 [\[1334\]](#)
- 2020 - Lipid profiles in 50 patients with COVID-19 [\[1335\]](#)
- 2021 (publication year) - Autopsy findings in 50 cases of COVID-19 - cardiac pathology [\[1027\]](#)
- 2020 - Neuropathological findings in 41 fatal cases of COVID-19 [\[1337\]](#)
- 2020 - Impact of thrombotic coagulopathy among 27 children and young adults hospitalized with COVID-19 [\[1338\]](#)
- 2020 - Clinical laboratory findings in 24 patients with COVID-19 [\[1339\]](#)
- 2020 - Bone marrow and peripheral blood findings in 22 patients with COVID-19 [\[1340\]](#)
- 2020 - Autopsy findings in 20 cases of COVID-19 [\[1341\]](#)
- 2020 - Inflammatory biomarkers in 19 children with COVID-19-associated multisystem inflammatory syndrome - comparison with cases of Kawasaki disease and macrophage activation syndrome [\[935\]](#)
- 2020 - CSF characteristics 18 patients with COVID-19 and neurological manifestations [\[1115\]](#)
- 2020 - Impact of G6PD deficiency among 17 patients with COVID-19 [\[1344\]](#)
- 2020 - Renal biopsy findings of 17 patients with COVID-19 [\[1345\]](#)
- 2020 - Renal biopsy findings of 17 patients with COVID-19 [\[1346\]](#)
- 2020 - Autopsy findings in the livers of 17 cases of COVID-19 [\[1062\]](#)
- 2020 - Autopsy findings in 16 cases of COVID-19 - comparison with influenza cases [\[1348\]](#)
- 2020 - Pathological characteristics of 14 fatal cases of COVID-19 [\[1349\]](#)
- 2020 to 2021 - Pulmonary pathology of 11 patients who had recovered from COVID-19 [\[1350\]](#)
- 2020 - Pathological characteristics of 8 fatal cases of COVID-19 [\[1351\]](#)
- 2020 - Hemogram analysis in 12 cases of COVID-19 [\[1352\]](#)

* series do not include experimental diagnostic or treatment protocols

References

1. [N Engl J Med 2020 Jan 31;](#)
2. [ProMED <promedmail.org> archive: 20200131.6937255](#)
3. [MMWR Morb Mortal Wkly Rep 2020 Feb 28;69\(8\):216-219.](#)
4. [Int J Health Plann Manage 2021 Sep 12;](#)
5. [Adv Ther 2020 Oct 12;](#)
6. [Nature 2021 Aug 26;](#)
7. [JAMA 2020 Apr 06;](#)
8. [MMWR Morb Mortal Wkly Rep 2020 Feb 14;69\(6\):166-170.](#)
9. [Proc Natl Acad Sci U S A 2020 Apr 03;](#)
10. [MMWR Morb Mortal Wkly Rep 2020 Mar 06;69\(9\):245-246.](#)
11. [Nature 2020 Mar ;579\(7798\):181-182.](#)
12. [MMWR Morb Mortal Wkly Rep 2020 Apr 17;69\(15\):465-471.](#)
13. [ProMED <promedmail.org> archive: 20200422.7255900](#)
14. [MMWR Morb Mortal Wkly Rep 2020 Jun 19;69\(24\):759-765.](#)
15. [Clin Infect Dis 2020 Jul 08;](#)
16. [Am J Cardiol 2021 Mar 06;](#)
17. [Endocrinol Diabetes Metab 2021 Jul 18::e00291.](#)
18. [Clin Infect Dis 2020 Dec 18;](#)
19. [JAMA Netw Open 2021 Jul 01;4\(7\):e2116901.](#)
20. [Prev Chronic Dis 2021 Jul 01;18:E66.](#)
21. [JAMA Netw Open 2020 Dec 01;3\(12\):e2029058.](#)

22. [JAMA Netw Open 2021 02 01;4\(2\):e2037431.](#)
23. [JAMA Netw Open 2021 Mar 01;4\(3\):e216315.](#)
24. [EClinicalMedicine 2021 Jan ;31:100688.](#)
25. [JAMA Oncol 2021 Oct 28;](#)
26. [PLoS One 2020 ;15\(12\):e0243027.](#)
27. [J Vasc Surg Venous Lymphat Disord 2021 Apr 06;](#)
28. [Clin Infect Dis 2020 Aug 28;](#)
29. [Diagn Microbiol Infect Dis 2021 Jan 20;100\(1\):115312.](#)
30. [J Gen Intern Med 2021 Jan 26;](#)
31. [JAMA Intern Med 2020 Dec 22;](#)
32. [MMWR Morb Mortal Wkly Rep 2020 Jul 17;69\(28\):923-929.](#)
33. [MMWR Morb Mortal Wkly Rep 2020 Oct 23;69\(42\):1517-1521.](#)
34. [MMWR Morb Mortal Wkly Rep 2020 Oct 23;69\(42\):1522-1527.](#)
35. [Obesity \(Silver Spring\) 2020 Dec 18;](#)
36. [Ann Intern Med 2021 Aug 10;](#)
37. [Clin Infect Dis 2021 Apr 28;](#)
38. [MSMR 2020 Dec ;27\(12\):2-8.](#)
39. [Ann Epidemiol 2020 Dec 15;](#)
40. [PLoS One 2021 ;16\(7\):e0246217.](#)
41. [JMIR Public Health Surveill 2020 Dec 14;](#)
42. [MMWR Morb Mortal Wkly Rep 2020 Aug 14;69\(32\):1081-1088.](#)
43. [J Dermatol 2021 Aug 17;](#)
44. [JAMA Netw Open 2021 Apr 01;4\(4\):e215298.](#)
45. [JAMA Netw Open 2021 Jun 01;4\(6\):e2111182.](#)
46. [Surg Obes Relat Dis 2021 Oct 05;](#)
47. [MMWR Morb Mortal Wkly Rep 2020 Mar 27;69\(12\):343-346.](#)
48. [MMWR Morb Mortal Wkly Rep 2020 Apr 03;69\(13\):382-386.](#)
49. [J Am Heart Assoc 2021 Feb 25;:e019259.](#)
50. [MMWR Morb Mortal Wkly Rep 2020 Apr 17;69\(15\):465-471.](#)
51. [MMWR Morb Mortal Wkly Rep 2020 Apr 17;69\(15\):477-481.](#)
52. [JAMA Netw Open 2021 Jan 04;4\(1\):e2033706.](#)
53. [JAMA Netw Open 2020 Sep 01;3\(9\):e2022310.](#)
54. [PLoS Med 2020 Sep ;17\(9\):e1003379.](#)
55. [MMWR Morb Mortal Wkly Rep 2020 Jun 19;69\(24\):759-765.](#)
56. [MMWR Morb Mortal Wkly Rep 2020 Apr 17;69\(15\):458-464.](#)
57. [MMWR Morb Mortal Wkly Rep 2020 Apr 10;69\(14\):422-426.](#)
58. [J Public Health Manag Pract 2020 Apr 10;](#)
59. [MMWR Morb Mortal Wkly Rep 2020 Oct 02;69\(39\):1410-1415.](#)
60. [N Engl J Med 2020 Jun 29;](#)
61. [MMWR Morb Mortal Wkly Rep 2020 Aug 14;69\(32\):1074-1080.](#)
62. [Lancet Child Adolesc Health 2021 Mar 09;](#)
63. [JAMA Netw Open 2021 Jun 01;4\(6\):e2116420.](#)
64. [Clin Infect Dis 2021 Dec 05;](#)
65. [MMWR Morb Mortal Wkly Rep 2020 May 15;69\(19\):603-605.](#)
66. [Am J Obstet Gynecol 2020 Apr 15;](#)
67. [MMWR Morb Mortal Wkly Rep 2020 Sep 25;69\(38\):1364-1368.](#)
68. [JAMA 2020 Nov 10;324\(18\):1819.](#)
69. [Clin Infect Dis 2020 Aug 17;](#)
70. [J Clin Invest 2020 May 28;](#)
71. [Cancer Discov 2020 May 01;](#)
72. [MMWR Morb Mortal Wkly Rep 2020 May 08;69\(18\)](#)
73. [Emerg Infect Dis 2021 Feb 16;27\(4\)](#)
74. [PLoS One 2021 ;16\(4\):e0250853.](#)
75. [Emerg Infect Dis 2021 Mar 11;27\(5\)](#)

76. [Clin Infect Dis 2021 Mar 09;](#)
77. [Mycoses 2020 Dec ;63\(12\):1368-1372.](#)
78. [Clin Infect Dis 2020 Sep 05;](#)
79. [Diagn Microbiol Infect Dis 2021 Apr ;99\(4\):115272.](#)
80. [J Fungi \(Basel\) 2021 Nov 10;7\(11\)](#)
81. [Emerg Infect Dis 2021 Feb 04;27\(4\)](#)
82. [J Investig Med High Impact Case Rep 2020 Jan-Dec;8:2324709620930540.](#)
83. [J Investig Med High Impact Case Rep 2020 Jan-Dec;8:2324709620972244.](#)
84. [Emerg Infect Dis 2021 Mar 23;27\(5\)](#)
85. [MMWR Morb Mortal Wkly Rep 2021 Dec 17;70\(50\):1750-1751.](#)
86. [Clin Infect Dis 2021 Apr 29;](#)
87. [MMWR Morb Mortal Wkly Rep 2020 Oct 02;69\(39\):1416-1418.](#)
88. [Infect Control Hosp Epidemiol 2020 Dec 14.;1-20.](#)
89. [MMWR Morb Mortal Wkly Rep 2020 Oct 09;69\(40\):1457-1459.](#)
90. [N Engl J Med 2020 Apr 24;](#)
91. [N Engl J Med 2020 Jan 31;](#)
92. [ProMED <promedmail.org> archive: 20200123.6910685](#)
93. [ProMED <promedmail.org> archive: 20200121.6903878](#)
94. [ProMED <promedmail.org> archive: 20200206.6959291](#)
95. [ProMED <promedmail.org> archive: 20200210.6976117](#)
96. [ProMED <promedmail.org> archive: 20200213.6984084](#)
97. [ProMED <promedmail.org> archive: 20200219.7005749](#)
98. [ProMED <promedmail.org> archive: 20200222.7013077](#)
99. [ProMED <promedmail.org> archive: 20200224.7022200](#)
100. [ProMED <promedmail.org> archive: 20200226.7026481](#)
101. [ProMED <promedmail.org> archive: 20200226.7029842](#)
102. [ProMED <promedmail.org> archive: 20200228.7032761](#)
103. [ProMED <promedmail.org> archive: 20200228.7035438](#)
104. [ProMED <promedmail.org> archive: 20200229.7037179](#)
105. [ProMED <promedmail.org> archive: 20200301.7039103](#)
106. [ProMED <promedmail.org> archive: 20200303.7042402](#)
107. [ProMED <promedmail.org> archive: 20200305.7051670](#)
108. [ProMED <promedmail.org> archive: 20200309.7066281](#)
109. [ProMED <promedmail.org> archive: 20200310.7070560](#)
110. [ProMED <promedmail.org> archive: 20200314.7088746](#)
111. [ProMED <promedmail.org> archive: 20200316.7096222](#)
112. [ProMED <promedmail.org> archive: 20200320.7116046](#)
113. [ProMED <promedmail.org> archive: 20200211.6979942](#)
114. [ProMED <promedmail.org> archive: 20200327.7149046](#)
115. [ProMED <promedmail.org> archive: 20200404.7182744](#)
116. [ProMED <promedmail.org> archive: 20200417.7235118](#)
117. [ProMED <promedmail.org> archive: 20200425.7267692](#)
118. [ProMED <promedmail.org> archive: 20200506.7306556](#)
119. [ProMED <promedmail.org> archive: 20200527.7385049](#)
120. [ProMED <promedmail.org> archive: 20200611.7458885](#)
121. [ProMED <promedmail.org> archive: 20200807.7653452](#)
122. [ProMED <promedmail.org> archive: 20201205.7994443](#)
123. [ProMED <promedmail.org> archive: 20210130.8149707](#)
124. [ProMED <promedmail.org> archive: 20210615.8450798](#)
125. [ProMED <promedmail.org> archive: 20210914.8668802](#)
126. [MMWR Morb Mortal Wkly Rep 2020 Oct 16;69\(41\):1492-1493.](#)
127. [MMWR Morb Mortal Wkly Rep 2020 Oct 23;69\(42\):1542-1546.](#)
128. [MMWR Morb Mortal Wkly Rep 2020 Oct 30;69\(43\):1600-1604.](#)
129. [MMWR Morb Mortal Wkly Rep 2020 May 01;69\(17\):523-526.](#)

130. [MMWR Morb Mortal Wkly Rep 2021 Jan 29;70\(4\):141-143.](#)
131. [MMWR Morb Mortal Wkly Rep 2021 Jan 29;70\(4\):118-122.](#)
132. [MMWR Morb Mortal Wkly Rep 2020 May 22;69\(20\):632-635.](#)
133. [MMWR Morb Mortal Wkly Rep 2020 May 29;69\(21\):651-655.](#)
134. [ProMED <promedmail.org> archive: 20200307.7060338](#)
135. [Emerg Infect Dis 2021 Feb 16;27\(4\)](#)
136. [MMWR Morb Mortal Wkly Rep 2020 Jul 03;69\(26\):830-835.](#)
137. [MMWR Morb Mortal Wkly Rep 2020 Jun 12;69\(23\):714-721.](#)
138. [JAMA Netw Open 2020 Oct 01;3\(10\):e2022095.](#)
139. [N Engl J Med 2020 Nov 11;](#)
140. [MMWR Morb Mortal Wkly Rep 2020 May 08;69\(18\)](#)
141. [MMWR Morb Mortal Wkly Rep 2020 Jul 10;69\(27\):887-892.](#)
142. [MMWR Morb Mortal Wkly Rep 2020 Aug 07;69\(31\):1015-1019.](#)
143. [Emerg Infect Dis 2021 Dec 02;28\(1\)](#)
144. [ProMED <promedmail.org> archive: 20200709.7557324](#)
145. [MMWR Morb Mortal Wkly Rep 2021 Mar 05;70\(9\):316-320.](#)
146. [MMWR Morb Mortal Wkly Rep 2021 Mar 05;70\(9\):321-325.](#)
147. [Am J Public Health 2021 Apr ;111\(4\):571-573.](#)
148. [Clin Infect Dis 2021 Jul 23;](#)
149. [J Am Geriatr Soc 2021 Mar 19;](#)
150. [Infect Control Hosp Epidemiol 2021 Mar 19::1-27.](#)
151. [MMWR Morb Mortal Wkly Rep 2020 Aug 07;69\(31\):1023-1025.](#)
152. [ProMED <promedmail.org> archive: 20200803.7639012](#)
153. [Clin Infect Dis 2020 Aug 03;](#)
154. [ProMED <promedmail.org> archive: 20200808.7656732](#)
155. [MMWR Morb Mortal Wkly Rep 2020 Nov 13;69\(45\):1671-1674.](#)
156. [MMWR Morb Mortal Wkly Rep 2020 Nov 13;69\(45\):1686-1690.](#)
157. [J Adolesc Health 2020 Aug 11;](#)
158. [MMWR Morb Mortal Wkly Rep 2021 Apr 02;70\(13\):467-472.](#)
159. [Am J Infect Control 2021 Apr 01;](#)
160. [MMWR Morb Mortal Wkly Rep 2020 Nov 27;69\(47\):1771-1776.](#)
161. [MMWR Morb Mortal Wkly Rep 2020 Oct 30;69\(43\):1591-1594.](#)
162. [J Ambul Care Manage 2020 Oct/Dec;43\(4\):294-300.](#)
163. [MMWR Morb Mortal Wkly Rep 2021 Apr 23;70\(16\):589-594.](#)
164. [MMWR Morb Mortal Wkly Rep 2021 Apr 30;70\(17\):617-621.](#)
165. [MMWR Morb Mortal Wkly Rep 2021 Sep 24;70\(38\):1349-1354.](#)
166. [MMWR Morb Mortal Wkly Rep 2021 Oct 08;70\(40\):1425-1426.](#)
167. [Emerg Infect Dis 2021 Nov 18;28\(1\)](#)
168. [J Public Health Manag Pract 2022 Jan-Feb 01;28\(1\):50-59.](#)
169. [ProMED <promedmail.org> archive: 20210216.8193221](#)
170. [MMWR Morb Mortal Wkly Rep 2021 Jul 16;70\(28\):1004-1007.](#)
171. [MMWR Morb Mortal Wkly Rep 2021 Aug 06;70\(31\):1059-1062.](#)
172. [MMWR Morb Mortal Wkly Rep 2021 Sep 03;70\(35\):1195-1200.](#)
173. [MMWR Morb Mortal Wkly Rep 2021 Sep 03;70\(35\):1214-1219.](#)
174. [MMWR Morb Mortal Wkly Rep 2021 Sep 03;70\(35\):1223-1227.](#)
175. [MMWR Morb Mortal Wkly Rep 2021 Apr 30;70\(17\):639-643.](#)
176. [J Food Prot 2021 Jan 18;](#)
177. [Pediatr Res 2021 Oct 30;](#)
178. [Children \(Basel\) 2021 Aug 30;8\(9\)](#)
179. [J Pediatr Orthop 2020 Nov/Dec;40\(10\):e990-e993.](#)
180. [Acta Paediatr 2021 Nov 30;](#)
181. [Pediatr Infect Dis J 2020 Dec 15;Publish Ahead of Print](#)
182. [JAMA Pediatr 2020 Nov 23;](#)
183. [J Neurosurg Anesthesiol 2022 Jan 01;34\(1\):132-135.](#)

184. [Public Health Rep 2021 Mar 05::33354921999385.](#)
185. [MMWR Morb Mortal Wkly Rep 2020 Nov 06;69\(44\):1625-1630.](#)
186. [MMWR Morb Mortal Wkly Rep 2020 Aug 21;69\(33\):1139-1143.](#)
187. [Acta Paediatr 2021 Mar 24;](#)
188. [bioRxiv 2020 Dec 08;](#)
189. [MMWR Morb Mortal Wkly Rep 2021 Apr 23;70\(16\):583-588.](#)
190. [MMWR Morb Mortal Wkly Rep 2020 May 01;69\(17\):521-522.](#)
191. [West J Emerg Med 2020 Aug 17;21\(5\):1048-1053.](#)
192. [Ann Intern Med 2020 Sep 15;](#)
193. [Open Forum Infect Dis 2020 Nov ;7\(11\):ofaa477.](#)
194. [Clin Infect Dis 2020 Sep 08;](#)
195. [bioRxiv 2021 Nov 05;](#)
196. [Nature 2021 Dec 23;](#)
197. [Pediatr Transplant 2021 Apr 03::e14018.](#)
198. [J Heart Lung Transplant 2021 Jun 17;](#)
199. [JCO Clin Cancer Inform 2021 Feb ;5:168-175.](#)
200. [J Natl Cancer Inst 2020 Oct 08;](#)
201. [WMJ 2020 Dec ;119\(4\):286-288.](#)
202. [Cancer Treat Res Commun 2021 Feb 26;27:100346.](#)
203. [Cancer Med 2021 Oct 28;](#)
204. [J Pediatr 2020 Oct 09;](#)
205. [N C Med J 2021 Jan-Feb;82\(1\):85-86.](#)
206. [J Infect Prev 2021 Jan ;22\(1\):7-11.](#)
207. [Infect Control Hosp Epidemiol 2021 Jun 24::1-19.](#)
208. [ProMED <promedmail.org> archive: 20200404.7182653](#)
209. [Clin Infect Dis 2020 Aug 19;](#)
210. [MMWR Morb Mortal Wkly Rep 2020 Apr 10;69\(14\):419-421.](#)
211. [Am J Infect Control 2021 Jan 08;](#)
212. [Hosp Pract \(1995\) 2021 Mar 01;](#)
213. [Surgery 2020 Aug 14;](#)
214. [J Am Coll Emerg Physicians Open 2021 Feb ;2\(1\):e12321.](#)
215. [Pediatr Surg Int 2021 Mar 14;](#)
216. [Ann Epidemiol 2021 Dec 15;](#)
217. [Emerg Infect Dis 2021 Feb 02;27\(4\)](#)
218. [Open Forum Infect Dis 2021 Sep ;8\(9\):ofab407.](#)
219. [Am J Kidney Dis 2021 Jan 16;](#)
220. [Am J Infect Control 2021 May ;49\(5\):542-546.](#)
221. [Am Surg 2021 Apr 13::31348211011090.](#)
222. [Emerg Infect Dis 2020 Nov 30;27\(1\)](#)
223. [BMC Infect Dis 2020 Nov 16;20\(1\):853.](#)
224. [Infect Control Hosp Epidemiol 2021 Jan 28::1-23.](#)
225. [J Clin Invest 2020 Nov 19;](#)
226. [Infect Control Hosp Epidemiol 2020 Nov 20::1-7.](#)
227. [MMWR Morb Mortal Wkly Rep 2020 Oct 30;69\(43\):1605-1610.](#)
228. [MMWR Morb Mortal Wkly Rep 2021 Mar 05;70\(9\):308-311.](#)
229. [Res Sq 2020 Aug 19;](#)
230. [J Occup Environ Med 2020 Dec 11;](#)
231. [Open Forum Infect Dis 2020 Dec ;7\(12\):ofaa534.](#)
232. [Clin Infect Dis 2020 Jun 16;](#)
233. [Proc \(Bayl Univ Med Cent\) 2021 Mar 30;34\(4\):437-441.](#)
234. [Front Med \(Lausanne\) 2021 ;8:749732.](#)
235. [Emerg Infect Dis 2020 Jul 02;26\(10\)](#)
236. [PLoS One 2021 ;16\(1\):e0245586.](#)
237. [J Community Hosp Intern Med Perspect 2021 Jan 26;11\(1\):36-38.](#)

238. [Emerg Infect Dis 2022 Jan ;28\(1\):9-19.](#)
239. [Am J Public Health 2021 Feb 18::e1-e4.](#)
240. [MMWR Morb Mortal Wkly Rep 2020 Jul 24;69\(29\):960-964.](#)
241. [MMWR Morb Mortal Wkly Rep 2021 May 14;70\(19\):707-711.](#)
242. [Front Public Health 2021 ;9:695442.](#)
243. [medRxiv 2020 Apr 14;](#)
244. [PLoS Med 2020 Sep ;17\(9\):e1003379.](#)
245. [Cureus 2020 Sep 29;12\(9\):e10707.](#)
246. [J Community Health 2020 Oct 31;](#)
247. [Am J Obstet Gynecol 2020 Apr 26;](#)
248. [Am J Obstet Gynecol MFM 2020 Jul 02::100169.](#)
249. [AJP Rep 2020 Oct ;10\(4\):e413-e416.](#)
250. [Am J Obstet Gynecol MFM 2020 Sep 11::100226.](#)
251. [PLoS One 2020 ;15\(12\):e0238409.](#)
252. [Am J Obstet Gynecol MFM 2021 Mar 20::100361.](#)
253. [Public Health 2021 Jan 16;192:30-32.](#)
254. [medRxiv 2020 Nov 01;](#)
255. [J Med Microbiol 2021 Sep ;70\(9\)](#)
256. [Psychiatry Res 2021 Feb 02;298:113776.](#)
257. [Community Ment Health J 2021 Mar 26;](#)
258. [JAMA Netw Open 2021 Nov 01;4\(11\):e2134969.](#)
259. [Psychiatry Res 2021 Feb 23;298:113833.](#)
260. [Clin Infect Dis 2020 Aug 16;](#)
261. [Clin Infect Dis 2020 May 08;](#)
262. [JAMA Netw Open 2021 Mar 01;4\(3\):e211091.](#)
263. [Prehosp Disaster Med 2021 Jan 05::1-13.](#)
264. [J Public Health \(Oxf\) 2020 Dec 24;](#)
265. [MMWR Morb Mortal Wkly Rep 2020 Aug 11;69\(32\):1095-1099.](#)
266. [Public Health Rep 2021 Feb 16::33354921990370.](#)
267. [J Am Dent Assoc 2021 Jan 19;](#)
268. [J Am Med Dir Assoc 2020 Oct ;21\(10\):1378-1383.e1.](#)
269. [MMWR Morb Mortal Wkly Rep 2020 Apr 10;69\(14\):416-418.](#)
270. [MMWR Morb Mortal Wkly Rep 2020 Nov 20;69\(46\):1743-1747.](#)
271. [Clin Orthop Relat Res 2021 Mar 12;](#)
272. [J Am Acad Orthop Surg 2021 Feb 04;](#)
273. [Global Spine J 2021 Dec 06::21925682211057489.](#)
274. [PLoS One 2021 ;16\(7\):e0254994.](#)
275. [J Acquir Immune Defic Syndr 2020 Oct 08;](#)
276. [Open Forum Infect Dis 2021 Jul ;8\(7\):ofab053.](#)
277. [HIV Res Clin Pract 2020 Nov 19::1-10.](#)
278. [Gastroenterology 2020 May 06;](#)
279. [Emerg Infect Dis 2021 Mar 03;27\(5\)](#)
280. [medRxiv 2020 May 28;](#)
281. [PLoS One 2021 ;16\(11\):e0259823.](#)
282. [J Pediatric Infect Dis Soc 2020 Oct 13;](#)
283. [Acta Paediatr 2021 Nov 30;](#)
284. [Pediatr Infect Dis J 2021 Jul 01;40\(7\):e272-e274.](#)
285. [MMWR Morb Mortal Wkly Rep 2021 Mar 05;70\(9\):312-315.](#)
286. [BMJ Paediatr Open 2021 ;5\(1\):e001259.](#)
287. [Emerg Microbes Infect 2021 Aug 10::1-20.](#)
288. [Emerg Infect Dis 2021 Feb ;27\(2\):669-672.](#)
289. [medRxiv 2020 Nov 13;](#)
290. [Vector Borne Zoonotic Dis 2021 Dec 10;](#)
291. [ProMED <promedmail.org> archive: 20211230.8700589](#)

292. [Clin Transplant 2021 Apr 27::e14329.](#)
293. [Pediatr Transplant 2021 Apr 03::e14018.](#)
294. [JCO Oncol Pract 2021 Jun 16::OP2100113.](#)
295. [Pediatr Blood Cancer 2020 Dec 23::e28857.](#)
296. [medRxiv 2021 Jan 16;](#)
297. [medRxiv 2021 Aug 11;](#)
298. [JAMA Netw Open 2021 Feb 01;4\(2\):e2035234.](#)
299. [mSphere 2021 Aug 04::e0045021.](#)
300. [J Racial Ethn Health Disparities 2020 Nov 23;](#)
301. [J Am Pharm Assoc \(2003\) 2021 Jan 21;](#)
302. [Ann Epidemiol 2021 Dec 15;](#)
303. [medRxiv 2021 Jan 31;](#)
304. [Sci Rep 2021 Feb 04;11\(1\):3081.](#)
305. [JAMA Netw Open 2021 Mar 01;4\(3\):e211552.](#)
306. [Am J Med 2020 Oct 29;](#)
307. [Open Forum Infect Dis 2021 Aug ;8\(8\):ofab379.](#)
308. [J Infect Dis 2021 Jun 04;](#)
309. [PLoS One 2021 ;16\(5\):e0252235.](#)
310. [Open Forum Infect Dis 2021 Sep ;8\(9\):ofab407.](#)
311. [PLoS One 2021 ;16\(4\):e0249466.](#)
312. [Kidney Med 2021 Feb 05;](#)
313. [Nat Rev Nephrol 2020 Nov 23;](#)
314. [J Am Soc Nephrol 2021 Jul 02;](#)
315. [JAMA Netw Open 2021 Jul 01;4\(7\):e2116572.](#)
316. [Int J Infect Dis 2021 Mar 12;](#)
317. [J Med Virol 2021 Jul 21;](#)
318. [J Patient Cent Res Rev 2021 ;8\(2\):146-150.](#)
319. [Pathog Glob Health 2021 Mar 17::1-4.](#)
320. [Am J Clin Pathol 2020 Sep 11;](#)
321. [Am J Infect Control 2021 Sep ;49\(9\):1158-1161.](#)
322. [Infect Control Hosp Epidemiol 2020 Sep 23::1-25.](#)
323. [Ann Emerg Med 2021 May ;77\(5\):556-557.](#)
324. [Fla Public Health Rev 2021 Feb 25;18\(1\):1-10.](#)
325. [Sci Rep 2021 Sep 14;11\(1\):18285.](#)
326. [Emerg Infect Dis 2020 Nov 30;27\(1\)](#)
327. [Front Med \(Lausanne\) 2020 ;7:471.](#)
328. [Sci Rep 2021 May 06;11\(1\):9694.](#)
329. [Mayo Clin Proc 2021 May ;96\(5\):1165-1174.](#)
330. [BMJ Open 2021 Nov 03;11\(11\):e053158.](#)
331. [Infect Control Hosp Epidemiol 2020 Oct 26::1-9.](#)
332. [Infect Control Hosp Epidemiol 2021 Feb 09::1-20.](#)
333. [Infect Control Hosp Epidemiol 2020 Aug 03::1-7.](#)
334. [Clin Infect Dis 2020 Nov 05;](#)
335. [Hosp Pediatr 2020 Dec 23;](#)
336. [Emerg Infect Dis 2021 Mar ;27\(3\):823-834.](#)
337. [BMJ Open 2021 Feb 12;11\(2\):e043584.](#)
338. [Infect Dis Rep 2021 Oct 21;13\(4\):910-916.](#)
339. [Ann Emerg Med 2020 Dec 17;](#)
340. [J Clin Invest 2020 Nov 19;](#)
341. [MMWR Morb Mortal Wkly Rep 2020 Sep 04;69\(35\):1221-1226.](#)
342. [Ann Intern Med 2021 Jan 29;](#)
343. [Infect Control Hosp Epidemiol 2020 Nov 20::1-7.](#)
344. [Lancet Reg Health Am 2021 Jul 29::100030.](#)
345. [Clin Infect Dis 2020 Jul 06;](#)

346. [J Hosp Med 2021 May ;16\(5\):282-289.](#)
347. [Infect Control Hosp Epidemiol 2021 Dec 02::1-24.](#)
348. [JAMA Netw Open 2021 Mar 01;4\(3\):e211283.](#)
349. [Open Forum Infect Dis 2021 Jan ;8\(1\):ofaa582.](#)
350. [Perioper Med \(Lond\) 2021 Mar 02;10\(1\):7.](#)
351. [Infect Control Hosp Epidemiol 2020 Dec 09::1-27.](#)
352. [J Hosp Infect 2021 Apr 27;](#)
353. [Br J Surg 2021 Jun 21;](#)
354. [Am J Infect Control 2020 Dec 31;](#)
355. [R I Med J \(2013\) 2021 Jun 01;104\(5\):20-23.](#)
356. [JAMA 2020 Aug 06;](#)
357. [Infect Control Hosp Epidemiol 2020 Dec 14::1-8.](#)
358. [J Gen Intern Med 2021 Jan 19;](#)
359. [PLoS One 2020 ;15\(11\):e0240006.](#)
360. [Infect Control Hosp Epidemiol 2020 Dec 15::1-17.](#)
361. [Open Forum Infect Dis 2020 Dec ;7\(12\):ofaa534.](#)
362. [J Occup Environ Med 2021 Aug 18;](#)
363. [Proc \(Bayl Univ Med Cent\) 2021 Mar 30;34\(4\):437-441.](#)
364. [PLoS One 2021 ;16\(6\):e0243676.](#)
365. [medRxiv 2020 Oct 27;](#)
366. [Front Med \(Lausanne\) 2021 ;8:749732.](#)
367. [Virulence 2021 Dec ;12\(1\):1597-1609.](#)
368. [Prehosp Emerg Care 2021 Apr 05::1-10.](#)
369. [Occup Environ Med 2021 Aug 25;](#)
370. [Am J Med Sci 2021 Oct 01;](#)
371. [Clin Biochem 2021 Feb 01;](#)
372. [medRxiv 2021 Feb 19;](#)
373. [J Am Osteopath Assoc 2021 02 01;121\(2\):199-210.](#)
374. [medRxiv 2020 May 25;](#)
375. [medRxiv 2021 Mar 09;](#)
376. [J Infect Dis 2021 May 24;](#)
377. [Nat Commun 2020 Sep 17;11\(1\):4698.](#)
378. [Vet Sci 2020 Aug 05;7\(3\)](#)
379. [mSphere 2021 02 03;6\(1\)](#)
380. [Int J Epidemiol 2021 Feb 22;](#)
381. [Am J Public Health 2022 Jan ;112\(1\):38-42.](#)
382. [J Infect Dis 2021 Apr 29;](#)
383. [medRxiv 2020 Jul 21;](#)
384. [J Racial Ethn Health Disparities 2021 Nov 08;](#)
385. [mBio 2020 Sep 29;11\(5\)](#)
386. [Public Health Rep 2021 Nov 09::333549211055137.](#)
387. [JAMA Intern Med 2020 Jul 21;](#)
388. [PLoS One 2021 ;16\(11\):e0260286.](#)
389. [Am J Public Health 2021 Feb 18::e1-e4.](#)
390. [Emerg Infect Dis 2020 Nov 10;27\(1\)](#)
391. [MMWR Morb Mortal Wkly Rep 2020 Jul 24;69\(29\):965-970.](#)
392. [MMWR Morb Mortal Wkly Rep 2020 Jul 24;69\(29\):960-964.](#)
393. [Pathogens 2021 Jun 06;10\(6\)](#)
394. [J Infect Dis 2021 Apr 09;](#)
395. [JAMA Intern Med 2020 Nov 24;](#)
396. [J Infect Dis 2020 Sep 09;](#)
397. [JAMA Netw Open 2021 03 01;4\(3\):e212816.](#)
398. [Sci Immunol 2020 Jul 29;5\(49\)](#)
399. [Am J Perinatol 2021 Nov 10;](#)

400. [Clin Epidemiol Glob Health 2021 Nov 17::100901.](#)
401. [Clin Infect Dis 2020 Nov 30;](#)
402. [PLoS One 2021 ;16\(4\):e0250319.](#)
403. [JAMA 2021 Sep 02;](#)
404. [Transfus Med Rev 2021 Jul 30;](#)
405. [BMC Infect Dis 2021 Aug 25;21\(1\):871.](#)
406. [PLoS One 2021 ;16\(7\):e0254667.](#)
407. [Emerg Infect Dis 2021 Jan 25;27\(3\)](#)
408. [Emerg Infect Dis 2020 Sep 21;26\(12\)](#)
409. [J Occup Environ Med 2020 Sep 18;](#)
410. [Open Forum Infect Dis 2021 Feb ;8\(2\):ofab015.](#)
411. [Open Forum Infect Dis 2021 Jan ;8\(1\):ofaa611.](#)
412. [J Occup Environ Med 2021 Nov 01;63\(11\):e807-e812.](#)
413. [J Prim Care Community Health 2020 Jan-Dec;11:2150132720971390.](#)
414. [Clin Infect Dis 2021 Jan 30;](#)
415. [J Occup Environ Med 2020 Dec 03;](#)
416. [Prehosp Disaster Med 2021 Jan 05::1-13.](#)
417. [J Adolesc Health 2020 Oct 14;](#)
418. [Lancet HIV 2021 Apr 29;](#)
419. [EClinicalMedicine 2021 Mar ;33:100770.](#)
420. [Rheumatology \(Oxford\) 2021 Oct 02;](#)
421. [bioRxiv 2020 Dec 08;](#)
422. [MMWR Morb Mortal Wkly Rep 2020 Jun 12;69\(23\):710-713.](#)
423. [ProMED <promedmail.org> archive: 20200406.7191352](#)
424. [ProMED <promedmail.org> archive: 20200422.7256272](#)
425. [ProMED <promedmail.org> archive: 20200423.7259119](#)
426. [bioRxiv 2020 Dec 08;](#)
427. [J Am Vet Med Assoc 2021 Nov 01;259\(9\):1032-1039.](#)
428. [ProMED <promedmail.org> archive: 20200703.7535112](#)
429. [ProMED <promedmail.org> archive: 20200805.7648734](#)
430. [ProMED <promedmail.org> archive: 20200813.7672505](#)
431. [ProMED <promedmail.org> archive: 20211102.8699412](#)
432. [mBio 2020 Oct 13;11\(5\)](#)
433. [J Zoo Wildl Med 2021 Jan ;51\(4\):733-744.](#)
434. [ProMED <promedmail.org> archive: 20201104.7915683](#)
435. [ProMED <promedmail.org> archive: 20201214.8017000](#)
436. [ProMED <promedmail.org> archive: 20201223.8042405](#)
437. [PLoS Pathog 2021 Nov ;17\(11\):e1009952.](#)
438. [ProMED <promedmail.org> archive: 20200818.7692815](#)
439. [ProMED <promedmail.org> archive: 20201009.7847704](#)
440. [Emerg Infect Dis 2021 Mar ;27\(3\):988-990.](#)
441. [ProMED <promedmail.org> archive: 20201213.8015608](#)
442. [ProMED <promedmail.org> archive: 20211115.8699676](#)
443. [ProMED <promedmail.org> archive: 20210726.8545843](#)
444. [ProMED <promedmail.org> archive: 20210802.8563564](#)
445. [ProMED <promedmail.org> archive: 20211013.8699020](#)
446. [ProMED <promedmail.org> archive: 20210112.8095510](#)
447. [ProMED <promedmail.org> archive: 20210216.8195382](#)
448. [ProMED <promedmail.org> archive: 20210913.8665151](#)
449. [ProMED <promedmail.org> archive: 20211026.8699258](#)
450. [ProMED <promedmail.org> archive: 20211227.8700517](#)
451. [Emerg Infect Dis 2021 Dec ;27\(12\):3171-3173.](#)
452. [ProMED <promedmail.org> archive: 20211018.8699125](#)
453. [Proc Natl Acad Sci U S A 2021 Nov 23;118\(47\)](#)

454. [bioRxiv 2021 Nov 05;](#)
455. [ProMED <promedmail.org> archive: 20211230.8700589](#)
456. [Transbound Emerg Dis 2021 May 06;](#)
457. [ProMED <promedmail.org> archive: 20210420.8317717](#)
458. [PLoS One 2021 ;16\(7\):e0254809.](#)
459. [Influenza Other Respir Viruses 2021 Aug 25;](#)
460. [Lancet HIV 2021 Oct 13;](#)
461. [Brain Behav Immun Health 2020 Sep 01::100136.](#)
462. [Int J Cardiol Cardiovasc Risk Prev 2021 Nov 09::200117.](#)
463. [Obesity \(Silver Spring\) 2020 Oct 31;](#)
464. [J Med Virol 2020 Dec 15;](#)
465. [Mayo Clin Proc 2021 Oct ;96\(10\):2508-2510.](#)
466. [Mayo Clin Proc 2021 Jul 05;](#)
467. [Acad Emerg Med 2020 Aug 06;](#)
468. [Lancet Rheumatol 2020 Dec 24;](#)
469. [Stroke 2021 Feb 04::STROKEAHA120031786.](#)
470. [PLoS One 2021 ;16\(3\):e0243291.](#)
471. [Circulation 2020 Nov 17;](#)
472. [JAMA Psychiatry 2021 Jan 27;](#)
473. [PLoS One 2021 ;16\(7\):e0253660.](#)
474. [SN Compr Clin Med 2020 Aug 09::1-4.](#)
475. [Am J Emerg Med 2020 Nov 07;](#)
476. [J Gen Intern Med 2020 Jun 30;](#)
477. [Med Care 2021 Aug 02;](#)
478. [JAMA 2020 Apr 22;](#)
479. [Clin Infect Dis 2020 Sep 18;](#)
480. [JAMA Intern Med 2021 Jan 04;](#)
481. [Ann Allergy Asthma Immunol 2021 Feb 26;](#)
482. [medRxiv 2021 Apr 07;](#)
483. [Open Forum Infect Dis 2021 Aug ;8\(8\):ofab370.](#)
484. [BMC Geriatr 2021 Oct 14:21\(1\):554.](#)
485. [medRxiv 2021 Feb 05;](#)
486. [Chron Respir Dis 2021 Jan-Dec;18:1479973120986806.](#)
487. [J Diabetes 2021 Jan 23;](#)
488. [Medicine \(Baltimore\) 2021 Dec 17;100\(50\):e28302.](#)
489. [medRxiv 2020 Dec 16;](#)
490. [Hypertension 2020 Dec 16;](#)
491. [Am J Respir Crit Care Med 2021 Apr 23;](#)
492. [Chest 2020 Aug 28;](#)
493. [J Racial Ethn Health Disparities 2021 Sep 10;](#)
494. [BMJ 2020 12 15;371:m4677.](#)
495. [Br J Sports Med 2021 Nov 01;](#)
496. [Stroke 2020 Aug 10::STROKEAHA120030685.](#)
497. [Clin Gastroenterol Hepatol 2021 Jul 01;](#)
498. [JAMA 2020 Aug 13;](#)
499. [PLoS One 2020 ;15\(12\):e0241956.](#)
500. [Clin Gastroenterol Hepatol 2020 Sep 29;](#)
501. [Open Forum Infect Dis 2021 Sep ;8\(9\):ofab448.](#)
502. [JAMA Netw Open 2020 Oct 01;3\(10\):e2023934.](#)
503. [Clin Infect Dis 2020 Jul 16;](#)
504. [Arthritis Rheumatol 2020 Dec 10;](#)
505. [Diabetes Metab 2021 Jul 28::101267.](#)
506. [JAMA Intern Med 2020 Jul 15;](#)
507. [medRxiv 2021 Feb 19;](#)

508. [medRxiv 2020 Apr 23;](#)
509. [J Stroke Cerebrovasc Dis 2020 Dec 09;30\(2\):105535.](#)
510. [Clin Gastroenterol Hepatol 2020 Sep 30;](#)
511. [Respir Res 2021 Feb 05;22\(1\):37.](#)
512. [PLoS One 2021 ;16\(7\):e0255544.](#)
513. [Viruses 2021 05 05;13\(5\)](#)
514. [Cureus 2021 Oct ;13\(10\):e18851.](#)
515. [J Community Health 2021 Jan 07;](#)
516. [JAMA Netw Open 2020 09 01;3\(9\):e2022058.](#)
517. [Ann Thorac Surg 2021 Sep 02;](#)
518. [Int J Infect Dis 2020 Nov 15;](#)
519. [Am J Epidemiol 2020 Dec 22;](#)
520. [Crit Care Med 2021 Apr 02;](#)
521. [Am J Crit Care 2021 Oct 28::e1-e12.](#)
522. [J Clin Hypertens \(Greenwich\) 2020 Nov 21;](#)
523. [Ann Intern Med 2020 Nov 24;](#)
524. [Am J Emerg Med 2021 Sep 28;51:1-5.](#)
525. [Sci Rep 2021 Dec 03;11\(1\):23414.](#)
526. [J Gen Intern Med 2021 Jun 07;](#)
527. [Open Forum Infect Dis 2020 Oct ;7\(10\):ofaa436.](#)
528. [Am J Med 2021 Nov 15;](#)
529. [J Intern Med 2020 Jun 04;](#)
530. [JAMA 2020 Apr 24;](#)
531. [J Allergy Clin Immunol 2020 Aug 06;](#)
532. [Open Forum Infect Dis 2020 Jul ;7\(7\):ofaa271.](#)
533. [R I Med J \(2013\) 2021 Jun 01;104\(5\):24-29.](#)
534. [Clin Exp Gastroenterol 2021 ;14:405-411.](#)
535. [BMJ Open Respir Res 2020 Oct ;7\(1\)](#)
536. [J Prim Care Community Health 2021 Jan-Dec;12:21501327211010991.](#)
537. [Lancet 2020 May 19;](#)
538. [Lancet 2020 May 19;](#)
539. [Diabetes Care 2020 Aug 07;](#)
540. [Gastroenterology 2020 May 07;](#)
541. [EClinicalMedicine 2021 Mar ;33:100765.](#)
542. [Open Forum Infect Dis 2021 Jan ;8\(1\):ofaa578.](#)
543. [BMJ 2020 May 29;369:m1996.](#)
544. [medRxiv 2020 Apr 22;](#)
545. [J Am Coll Emerg Physicians Open 2021 Aug ;2\(4\):e12453.](#)
546. [medRxiv 2020 Dec 11;](#)
547. [Epidemiol Infect 2020 Oct 13::1-20.](#)
548. [Infect Control Hosp Epidemiol 2021 Apr 13::1-15.](#)
549. [Respir Med 2021 Jul 22;187:106538.](#)
550. [Open Forum Infect Dis 2021 Jan ;8\(1\):ofaa576.](#)
551. [Trop Med Infect Dis 2021 Sep 26;6\(4\)](#)
552. [Arch Med Sci Atheroscler Dis 2020 ;5:e306-e312.](#)
553. [Gastroenterology 2020 Nov 11;](#)
554. [PLoS One 2020 ;15\(12\):e0244270.](#)
555. [J Prim Care Community Health 2021 Jan-Dec;12:21501327211017016.](#)
556. [Int J Endocrinol 2021 ;2021:5516192.](#)
557. [Respir Med 2021 May 13;184:106464.](#)
558. [Hum Vaccin Immunother 2020 Oct 20::1-4.](#)
559. [Endocr Pract 2021 Jun 05;](#)
560. [J Racial Ethn Health Disparities 2021 Jan 07;](#)
561. [Int J Gen Med 2021 ;14:1555-1563.](#)

562. [JAMA Netw Open 2020 Nov 02;3\(11\):e2029540.](#)
563. [Crit Care Explor 2021 May ;3\(5\):e0416.](#)
564. [J Am Coll Emerg Physicians Open 2020 May 22;](#)
565. [Biol Sex Differ 2021 Feb 05;12\(1\):20.](#)
566. [Ann Am Thorac Soc 2021 Apr 06;](#)
567. [Blood Adv 2021 Apr 13;5\(7\):1915-1921.](#)
568. [Blood Adv 2021 Jul 13;5\(13\):2717-2724.](#)
569. [Microbiol Spectr 2021 Oct 20::e0083121.](#)
570. [Sci Rep 2021 Feb 23;11\(1\):4389.](#)
571. [Ir J Med Sci 2021 Feb 10;](#)
572. [Sci Rep 2021 03 22;11\(1\):6488.](#)
573. [J Am Acad Orthop Surg Glob Res Rev 2021 Oct 15;5\(10\)](#)
574. [J Gen Intern Med 2021 Mar 18;](#)
575. [J Intensive Care Med 2021 Mar 24::8850666211001799.](#)
576. [J Asthma 2021 Mar 02::1-14.](#)
577. [Dig Dis Sci 2020 Sep 15;](#)
578. [JAMA Netw Open 2021 Jun 01;4\(6\):e2112862.](#)
579. [J Med Virol 2021 Jan 15;](#)
580. [MMWR Morb Mortal Wkly Rep 2020 Jun 26;69\(25\):790-794.](#)
581. [Emerg Infect Dis 2021;27\(4\):1164-1168.](#)
582. [J Alzheimers Dis 2021 Mar 13;](#)
583. [Ann Med 2020 Jul 03::1-17.](#)
584. [Ann Rheum Dis 2020 Sep 25;](#)
585. [Clin Infect Dis 2020 Dec 03;](#)
586. [Int J Clin Pract 2021 Sep 06::e14818.](#)
587. [Infect Control Hosp Epidemiol 2021 Jan 11::1-33.](#)
588. [Acute Crit Care 2020 Oct 12;](#)
589. [Ann Med Surg \(Lond\) 2020 Dec ;60:308-313.](#)
590. [J Gen Intern Med 2021 Feb 24;](#)
591. [Ann Intern Med 2021 Jan 19;](#)
592. [PLoS One 2021 ;16\(4\):e0250400.](#)
593. [JAMA Netw Open 2020 Jun 01;3\(6\):e2012270.](#)
594. [J Immigr Minor Health 2021 Mar 26;](#)
595. [Am J Surg 2020 Dec 28;](#)
596. [Addict Behav 2020 Oct 07;113:106692.](#)
597. [Arch Dermatol Res 2021 Nov 12;](#)
598. [Respir Med 2021 Sep 08;188:106606.](#)
599. [J Med Virol 2020 Jul 16;](#)
600. [Clin Infect Dis 2021 Mar 09;](#)
601. [PLoS One 2020 ;15\(12\):e0243343.](#)
602. [N Engl J Med 2020 Apr 17;](#)
603. [Clin Infect Dis 2020 Nov 20;](#)
604. [Cureus 2020 Aug 18;12\(8\):e9836.](#)
605. [Cureus 2020 Aug 21;12\(8\):e9912.](#)
606. [Coron Artery Dis 2020 Jul 23;](#)
607. [Acta Diabetol 2020 Aug 17;](#)
608. [J Hosp Med 2020 Oct 21;](#)
609. [Indian J Gastroenterol 2021 Sep 27;](#)
610. [Ann Allergy Asthma Immunol 2021 Feb 24;](#)
611. [J Racial Ethn Health Disparities 2021 Aug 09;](#)
612. [Radiology 2020 May 14::201754.](#)
613. [PLoS One 2020 ;15\(11\):e0242760.](#)
614. [J Am Coll Emerg Physicians Open 2021 Feb ;2\(1\):e12350.](#)
615. [Ann Epidemiol 2021 Mar 15;](#)

616. [Clin Med \(Lond\) 2020 Sep ;20\(5\):463-467.](#)
617. [medRxiv 2020 May 06;](#)
618. [Mayo Clin Proc Innov Qual Outcomes 2020 Nov 05;](#)
619. [Am J Surg 2021 Apr 14;](#)
620. [J Antimicrob Chemother 2021 Sep 23;76\(Supplement 3\):iii12-iii19.](#)
621. [MMWR Morb Mortal Wkly Rep 2020 May 08;69\(18\):545-550.](#)
622. [PLoS One 2021 ;16\(8\):e0254347.](#)
623. [J Intensive Care Med 2020 Oct ;35\(10\):963-970.](#)
624. [J Am Acad Dermatol 2020 Dec 24;](#)
625. [Cureus 2020 Oct 26;12\(10\):e11183.](#)
626. [J Racial Ethn Health Disparities 2021 Jan 19;](#)
627. [J Med Virol 2021 Feb 17;](#)
628. [Gastroenterology 2020 Apr 12;](#)
629. [World Allergy Organ J 2021 Feb ;14\(2\):100508.](#)
630. [Open Forum Infect Dis 2021 Oct ;8\(10\):ofab132.](#)
631. [BMC Infect Dis 2021 Jan 09;21\(1\):40.](#)
632. [J Clin Virol 2020 Aug 05;130:104577.](#)
633. [Front Endocrinol \(Lausanne\) 2020 ;11:565.](#)
634. [Open Forum Infect Dis 2020 Sep ;7\(9\):ofaa339.](#)
635. [EClinicalMedicine 2020 Aug 19;:100504.](#)
636. [Respir Med 2020 Oct 27;174:106203.](#)
637. [Am J Med Sci 2021 Apr 21;](#)
638. [J Med Virol 2020 Jul 03;](#)
639. [J Med Virol 2020 Aug 18;](#)
640. [Cureus 2021 Nov ;13\(11\):e19802.](#)
641. [J Clin Immunol 2021 Jan 18;](#)
642. [Prim Care Companion CNS Disord 2021 Sep 09;23\(5\)](#)
643. [J Trauma Acute Care Surg 2021 May 01;90\(5\):880-890.](#)
644. [J Surg Res 2021 Apr 06;266:35-43.](#)
645. [Cureus 2021 Jan 02;13\(1\):e12431.](#)
646. [Crit Care Med 2020 Aug 14;](#)
647. [Acad Emerg Med 2020 May 12;](#)
648. [J Med Virol 2020 Jul 28;](#)
649. [J Allergy Clin Immunol 2020 Jun 15;](#)
650. [MSMR 2020 May ;27\(5\):50-54.](#)
651. [J Gastrointest Surg 2021 Apr 27;](#)
652. [J Med Virol 2020 Dec 22;](#)
653. [Eur Geriatr Med 2020 Jul 18;](#)
654. [Cureus 2021 Apr 05;13\(4\):e14308.](#)
655. [JAMA Netw Open 2021 Mar 01;4\(3\):e211091.](#)
656. [medRxiv 2020 Dec 22;](#)
657. [Am J Gastroenterol 2020 Jul ;115\(7\):1129-1132.](#)
658. [Am J Pathol 2020 Jul 07;](#)
659. [J Racial Ethn Health Disparities 2021 Feb 04;](#)
660. [J Infect Dis 2021 May 16;](#)
661. [J Med Internet Res 2020 Jun 14;](#)
662. [J Clin Med 2021 Apr 08;10\(8\)](#)
663. [J Clin Endocrinol Metab 2021 Jan 07;](#)
664. [Am J Respir Crit Care Med 2021 Aug 19;](#)
665. [J Intensive Care Med 2021 Sep 13;:8850666211040417.](#)
666. [WMJ 2020 Sep ;119\(3\):198-201.](#)
667. [N Engl J Med 2020 Mar 27;](#)
668. [Blood Adv 2021 Sep 28;5\(18\):3690-3693.](#)
669. [WMJ 2021 Jul ;120\(2\):94-99.](#)

670. [J Gen Intern Med 2021 Jan 14;](#)
671. [Lancet Rheumatol 2020 Sep 29;](#)
672. [South Med J 2021 May ;114\(5\):305-310.](#)
673. [Obesity \(Silver Spring\) 2020 Aug 04;](#)
674. [Influenza Other Respir Viruses 2021 Jan 06;](#)
675. [South Med J 2020 Dec ;113\(12\):618-622.](#)
676. [S D Med 2020 Jul ;73\(7\):312-317.](#)
677. [Eur J Radiol Open 2021 ;8:100322.](#)
678. [Dig Dis 2020 Jun 29;](#)
679. [AJNR Am J Neuroradiol 2020 Sep 10;](#)
680. [HSS J 2020 Aug 18;;1-7.](#)
681. [Obes Med 2020 Dec 30::100316.](#)
682. [Neurogastroenterol Motil 2021 Sep 01::e14251.](#)
683. [JAMA Cardiol 2021 Jan 14;](#)
684. [Ann Rheum Dis 2020 Nov 30;](#)
685. [Am J Infect Control 2020 Jul 08;](#)
686. [Cureus 2021 Jan 07;13\(1\):e12552.](#)
687. [Crit Care Explor 2020 Aug ;2\(8\):e0188.](#)
688. [J Community Hosp Intern Med Perspect 2021 Jan 26;11\(1\):27-32.](#)
689. [Infect Dis Clin Pract \(Baltim Md\) 2021 Sep ;29\(5\):e332-e333.](#)
690. [MMWR Morb Mortal Wkly Rep 2020 Mar 27;69\(12\):339-342.](#)
691. [Respir Care 2021 Jan 14;](#)
692. [Open Forum Infect Dis 2021 Mar ;8\(3\):ofab060.](#)
693. [J Gen Intern Med 2021 Aug 05;](#)
694. [J Intensive Care Med 2021 Dec 17::8850666211062582.](#)
695. [Front Neurol 2021 ;12:614719.](#)
696. [Open Forum Infect Dis 2021 Feb ;8\(2\):ofab007.](#)
697. [PLoS One 2020 ;15\(8\):e0237558.](#)
698. [J Crit Care 2020 Dec 19;62:172-175.](#)
699. [Ann Surg Oncol 2021 Jun 26;](#)
700. [Am Heart J 2020 May 23;226:147-151.](#)
701. [Cell Rep Med 2020 Oct 29::100144.](#)
702. [J Clin Med 2021 Jul 29;10\(15\)](#)
703. [SN Compr Clin Med 2021 Jan 14::1-8.](#)
704. [J Intensive Care Med 2021 Mar ;36\(3\):334-342.](#)
705. [J Intensive Care Med 2020 Dec 15::885066620979622.](#)
706. [J Am Med Dir Assoc 2021 Jan 28;](#)
707. [J Investig Med 2021 Sep 13;](#)
708. [South Med J 2021 03 ;114\(3\):144-149.](#)
709. [Acad Emerg Med 2020 Apr 28;](#)
710. [medRxiv 2020 Jun 11;](#)
711. [Mayo Clin Proc 2021 07 ;96\(7\):1782-1791.](#)
712. [J Gen Intern Med 2021 Feb 02;](#)
713. [J Clin Med Res 2021 Nov ;13\(10-11\):487-496.](#)
714. [WMJ 2020 Dec ;119\(4\):248-252.](#)
715. [Endocr Res 2020 Dec 30::1-8.](#)
716. [JAMA Netw Open 2021 12 01;4\(12\):e2136853.](#)
717. [Clin Nephrol 2021 Nov 15;](#)
718. [N Engl J Med 2020 Apr 29;](#)
719. [Diabetes Res Clin Pract 2020 Apr 30::108185.](#)
720. [Clin Infect Dis 2020 Sep 23;](#)
721. [J Stroke Cerebrovasc Dis 2020 Sep 11::105314.](#)
722. [Inflamm Bowel Dis 2020 Jun 24;](#)
723. [J Allergy Clin Immunol Pract 2020 Oct 22;](#)

724. [EClinicalMedicine 2021 Aug 13::101079.](#)
725. [Sarcoidosis Vasc Diffuse Lung Dis 2021 ;38\(2\):e2021029.](#)
726. [Cureus 2020 Nov 28;12\(11\):e11749.](#)
727. [Eur Radiol 2020 Nov 04;](#)
728. [Clin Infect Dis 2021 Feb 18;](#)
729. [Cardiol Rev 2020 Nov 04;](#)
730. [Emerg Infect Dis 2020 May 14;26\(8\)](#)
731. [Clin Rheumatol 2021 Jan 09;](#)
732. [Blood Adv 2021 Jan 12;5\(1\):207-215.](#)
733. [Sci Rep 2021 May 13;11\(1\):10308.](#)
734. [Ann Am Thorac Soc 2020 Nov 13;](#)
735. [EClinicalMedicine 2020 Aug 26::100518.](#)
736. [J Prim Care Community Health 2020 Jan-Dec;11:2150132720970717.](#)
737. [Radiol Cardiothorac Imaging 2020 Aug ;2\(4\):e200308.](#)
738. [medRxiv 2021 Feb 06;](#)
739. [Cureus 2020 Sep 05;12\(9\):e10257.](#)
740. [Chest 2020 Aug 21;](#)
741. [medRxiv 2020 Jun 05;](#)
742. [J Hematol Oncol 2020 Jul 14;13\(1\):94.](#)
743. [Cureus 2021 Jul ;13\(7\):e16552.](#)
744. [Lancet Rheumatol 2021 May 28;](#)
745. [Am J Gastroenterol 2021 Dec 01;116\(Suppl 1\):S6.](#)
746. [Cureus 2021 Apr 16;13\(4\):e14526.](#)
747. [Ann Rheum Dis 2020 May 26;](#)
748. [Clin Chem Lab Med 2020 Nov 25;](#)
749. [JAMA 2020 Apr 17;](#)
750. [Diabetes Res Clin Pract 2020 May 21::108229.](#)
751. [J Fungi \(Basel\) 2021 Nov 10;7\(11\)](#)
752. [Stroke 2020 Jul 31::STROKEAHA120030397.](#)
753. [Diagnosis \(Berl\) 2020 May 26;7\(2\):91-96.](#)
754. [Cureus 2021 Jan 30;13\(1\):e13000.](#)
755. [Am J Gastroenterol 2020 Aug 13;](#)
756. [Blood Cells Mol Dis 2021 Nov 17;92:102627.](#)
757. [Semin Thromb Hemost 2020 Sep 03;](#)
758. [Inflamm Bowel Dis 2020 Oct 22;](#)
759. [J Surg Res 2020 Nov 23;261:113-122.](#)
760. [Geriatrics \(Basel\) 2020 Sep 18;5\(3\)](#)
761. [Ann Surg 2020 Oct 14;](#)
762. [Surg Obes Relat Dis 2020 Nov 23;](#)
763. [ASAIO J 2020 Apr 17;](#)
764. [J Community Hosp Intern Med Perspect 2020 Oct 29;10\(6\):491-500.](#)
765. [J Emerg Trauma Shock 2020 Apr-Jun;13\(2\):131-134.](#)
766. [Surg Open Sci 2021 May 03;](#)
767. [Ann Am Thorac Soc 2021 Feb 05;](#)
768. [J Clin Anesth 2020 Aug 17;67:110029.](#)
769. [N Engl J Med 2020 Mar 30;](#)
770. [Hemoglobin 2020 Jul 28::1-6.](#)
771. [J Leukoc Biol 2020 Sep 15;](#)
772. [Histopathology 2021 Jul 22;](#)
773. [JAMA 2020 Mar 19;](#)
774. [Infect Drug Resist 2021 ;14:1645-1648.](#)
775. [Rural Remote Health 2021 07 ;21\(3\):6464.](#)
776. [Am Surg 2021 Nov 12::31348211038571.](#)
777. [Gastroenterology 2021 Mar 03;](#)

778. [Int J Clin Pract 2020 Sep 07::e13700.](#)
779. [J Orthop Trauma 2020 May 27;](#)
780. [Eur J Gastroenterol Hepatol 2021 May 01;33\(5\):695-700.](#)
781. [J Clin Immunol 2021 Oct 20;](#)
782. [Front Neurol 2020 ;11:1004.](#)
783. [J Allergy Clin Immunol Pract 2020 Oct 08;](#)
784. [J Am Acad Dermatol 2020 Oct 14;](#)
785. [JAMA Netw Open 2021 May 03;4\(5\):e2110323.](#)
786. [Mil Med 2021 Feb 12;](#)
787. [Front Neurol 2020 ;11:910.](#)
788. [OTA Int 2021 Jun ;4\(2\):e129.](#)
789. [Nat Med 2020 Apr 23;](#)
790. [Genet Med 2020 Oct 16;](#)
791. [MMWR Morb Mortal Wkly Rep 2020 Oct 09;69\(40\):1450-1456.](#)
792. [Transfusion 2021 Mar 16;](#)
793. [Mol Genet Metab 2021 Aug 13;](#)
794. [J Orthop Trauma 2020 May 27;](#)
795. [J Card Surg 2020 Apr 25;](#)
796. [Emerg Infect Dis 2020 May 22;26\(9\)](#)
797. [Ann Neurol 2021 Dec 24;](#)
798. [AJNR Am J Neuroradiol 2021 Jan 07;](#)
799. [Surg Endosc 2021 Jan 25;](#)
800. [Kidney Int Rep 2020 Dec 29;](#)
801. [Arch Med Sci Atheroscler Dis 2020 ;5:e263-e270.](#)
802. [Kidney Int Rep 2020 Dec 29;](#)
803. [Gastroenterology 2020 May 06;](#)
804. [AAACE Clin Case Rep 2020 Dec 28;](#)
805. [Cureus 2021 Aug ;13\(8\):e17597.](#)
806. [Br J Haematol 2021 Apr 29;](#)
807. [J Med Virol 2021 Jan 21;](#)
808. [Am J Case Rep 2021 May 04;22:e931758.](#)
809. [Br J Haematol 2020 Apr 21;](#)
810. [Muscle Nerve 2021 Dec 24;](#)
811. [MMWR Morb Mortal Wkly Rep 2020 Nov 06;69\(44\):1641-1647.](#)
812. [JAMA Netw Open 2021 Aug 02;4\(8\):e2120456.](#)
813. [Clin Infect Dis 2021 May 22;](#)
814. [Obstet Gynecol 2021 Aug 09;](#)
815. [Clin Infect Dis 2021 May 12;](#)
816. [JAMA Intern Med 2021 Jan 15;](#)
817. [MMWR Morb Mortal Wkly Rep 2020 Nov 06;69\(44\):1635-1640.](#)
818. [BMC Pregnancy Childbirth 2021 Apr 16;21\(1\):305.](#)
819. [Obstet Gynecol 2021 Feb 08;](#)
820. [Clin Infect Dis 2021 Aug 19;](#)
821. [MMWR Morb Mortal Wkly Rep 2020 Sep 25;69\(38\):1347-1354.](#)
822. [Am J Perinatol 2021 Jul 16;](#)
823. [Am J Perinatol 2021 Dec 16;](#)
824. [Am J Obstet Gynecol MFM 2021 Jan 22::100319.](#)
825. [JAMA Netw Open 2020 Nov 02;3\(11\):e2029256.](#)
826. [Obstet Gynecol 2020 Jun 16;](#)
827. [Am J Obstet Gynecol 2021 Jan 19;](#)
828. [J Matern Fetal Neonatal Med 2021 Sep 01::1-5.](#)
829. [Am J Obstet Gynecol MFM 2021 Aug 07::100454.](#)
830. [Am J Obstet Gynecol MFM 2021 Aug 14::100458.](#)
831. [Obstet Gynecol 2020 May 27;](#)

832. [J Matern Fetal Neonatal Med 2021 Feb 28::1-9.](#)
833. [Am J Obstet Gynecol MFM 2020 Oct 07::100246.](#)
834. [Am J Obstet Gynecol 2020 May 23;](#)
835. [Ultrasound Obstet Gynecol 2021 Apr 01;](#)
836. [MMWR Morb Mortal Wkly Rep 2020 Sep 23;69\(38\):1355-1359.](#)
837. [Paediatr Perinat Epidemiol 2021 Jan ;35\(1\):24-33.](#)
838. [Am J Perinatol 2020 May 21;](#)
839. [Anaesthesiol Intensive Ther 2021 May 19::1-11.](#)
840. [Am J Perinatol 2021 Feb 06;](#)
841. [J Patient Cent Res Rev 2021 ;8\(3\):286-289.](#)
842. [Am J Obstet Gynecol 2021 Mar 03;](#)
843. [Am J Perinatol 2021 Apr 20;](#)
844. [Am J Perinatol 2021 Apr 14;](#)
845. [BJOG 2020 Jul 07;](#)
846. [Arch Pathol Lab Med 2021 Feb 17;](#)
847. [Am J Obstet Gynecol MFM 2020 May 08::100134.](#)
848. [J Matern Fetal Neonatal Med 2021 Sep 20::1-7.](#)
849. [Am J Obstet Gynecol MFM 2020 Aug 15::100211.](#)
850. [Cureus 2021 Jan 06;13\(1\):e12522.](#)
851. [Am J Obstet Gynecol MFM 2021 Apr 02::100365.](#)
852. [Am J Obstet Gynecol 2020 May 18;](#)
853. [Am J Obstet Gynecol MFM 2020 Apr 09::100118.](#)
854. [Am J Perinatol 2021 Nov 14;](#)
855. [J Perinat Med 2020 Nov 03;](#)
856. [Am J Obstet Gynecol 2020 Nov 19;](#)
857. [Clin Infect Dis 2020 May 11;](#)
858. [AJP Rep 2021 Jan ;11\(1\):e15-e20.](#)
859. [Am J Respir Crit Care Med 2020 Oct 07;](#)
860. [Am J Obstet Gynecol 2020 Oct 10;](#)
861. [BMJ 2020 Apr 14;369:m1485.](#)
862. [J Community Health 2020 Oct 31;](#)
863. [J Matern Fetal Neonatal Med 2020 May 20::1-3.](#)
864. [Am J Clin Pathol 2020 May 22;](#)
865. [MMWR Morb Mortal Wkly Rep 2021 Nov 26;70\(47\):1646-1648.](#)
866. [Cureus 2020 Dec 07;12\(12\):e11946.](#)
867. [Sci Rep 2021 May 13;11\(1\):10231.](#)
868. [Gastroenterology 2021 Jan 06;](#)
869. [Open Forum Infect Dis 2021 Aug ;8\(8\):ofab388.](#)
870. [Pediatrics 2021 Dec 22;](#)
871. [JAMA Neurol 2021 Mar 05;](#)
872. [Pediatr Allergy Immunol 2021 Nov 14;](#)
873. [J Pediatric Infect Dis Soc 2020 Dec 10;](#)
874. [JAMA 2021 Feb 24;](#)
875. [Lancet Child Adolesc Health 2021 Mar 09;](#)
876. [BMC Pediatr 2021 Sep 13;21\(1\):403.](#)
877. [MMWR Morb Mortal Wkly Rep 2021 Dec 31;70\(5152\):1766-1772.](#)
878. [Cureus 2020 Sep 12;12\(9\):e10413.](#)
879. [medRxiv 2020 Oct 13;](#)
880. [Pediatr Infect Dis J 2021 Feb 01;](#)
881. [J Pediatric Infect Dis Soc 2020 Jun 19;](#)
882. [medRxiv 2020 Dec 16;](#)
883. [Pediatr Crit Care Med 2021 May 10;](#)
884. [Clin Pediatr \(Phila\) 2021 Nov 18::99228211059883.](#)
885. [Clin Infect Dis 2020 Nov 03;](#)

886. [J Pediatr 2020 Nov 13;](#)
887. [J Diabetes 2021 Apr 14;](#)
888. [JAMA Netw Open 2021 Apr 01;4\(4\):e217523.](#)
889. [Pediatr Infect Dis J 2021 Dec 21;](#)
890. [Transl Med Commun 2020 ;5\(1\):12.](#)
891. [N Engl J Med 2020 Jun 29;](#)
892. [J Pediatr 2020 May 13;](#)
893. [Kidney Int 2021 Mar 03;](#)
894. [Pediatr Pulmonol 2021 Jun 01;](#)
895. [Clin J Am Soc Nephrol 2020 Nov 03;](#)
896. [J Infect Dis 2021 Oct 07;](#)
897. [Pediatr Blood Cancer 2020 Dec 18::e28843.](#)
898. [Pediatr Pulmonol 2021 Sep 06;](#)
899. [N Engl J Med 2020 Jun 29;](#)
900. [Front Pediatr 2021 ;9:692256.](#)
901. [Pediatr Infect Dis J 2021 Apr 16;](#)
902. [Children \(Basel\) 2021 Oct 22;8\(11\)](#)
903. [Hosp Pediatr 2021 Jan ;11\(1\):79-87.](#)
904. [Glob Pediatr Health 2021 ;8:2333794X211022710.](#)
905. [Ann Intensive Care 2020 Dec 19;10\(1\):171.](#)
906. [J Pediatr 2020 Jul 15;](#)
907. [J Pediatr 2020 May 11;](#)
908. [J Pediatr Surg 2021 Jan 27;](#)
909. [J Pediatric Infect Dis Soc 2020 Jun 01;](#)
910. [J Pediatric Infect Dis Soc 2020 Jun 06;](#)
911. [Pediatr Radiol 2020 Sep 18;](#)
912. [Pediatr Rheumatol Online J 2021 Jun 21;19\(1\):94.](#)
913. [Pediatr Crit Care Med 2020 Sep 29;](#)
914. [J Am Soc Echocardiogr 2021 May 03;](#)
915. [Pediatr Emerg Care 2021 Apr 01;37\(4\):232-236.](#)
916. [JAMA Pediatr 2020 06 03::e202430.](#)
917. [Blood Adv 2020 Dec 08;4\(23\):6051-6063.](#)
918. [JAMA Pediatr 2020 May 11;](#)
919. [Pediatr Radiol 2021 Jan 12;](#)
920. [J Am Dent Assoc 2021 Mar ;152\(3\):202-208.](#)
921. [Cardiol Young 2021 Sep 30::1-7.](#)
922. [J Thromb Haemost 2021 Apr 19;](#)
923. [Heart Rhythm 2020 Jul 01;](#)
924. [J Pediatr 2020 Jun 14;](#)
925. [J Pediatr 2020 Jun 14;](#)
926. [Eur J Pediatr 2021 Jan 16;](#)
927. [Clin Pediatr \(Phila\) 2020 Sep 25::9922820961771.](#)
928. [Am J Emerg Med 2021 Oct 11;51:69-75.](#)
929. [J Clin Invest 2020 Jul 23;](#)
930. [Pediatr Rheumatol Online J 2021 Dec 16;19\(1\):172.](#)
931. [JAMA Dermatol 2020 Dec 09;](#)
932. [Pediatr Crit Care Med 2020 Jul 02;](#)
933. [Clin Imaging 2021 Mar 30;75:165-170.](#)
934. [Pediatr Radiol 2020 Jul 29;](#)
935. [Lancet Rheumatol 2021 Jun 08;](#)
936. [J Pediatr 2020 Jun 18;](#)
937. [JAMA 2020 Jun 08;](#)
938. [Pediatr Emerg Care 2021 Mar 01;37\(3\):179-184.](#)
939. [AJR Am J Roentgenol 2020 Jul 29;](#)

940. [J Med Virol 2020 Jun 25;](#)
941. [Pediatr Radiol 2021 Jan 06;](#)
942. [Clin Pediatr \(Phila\) 2021 May ;60\(4-5\):247-251.](#)
943. [J Pediatric Infect Dis Soc 2020 May 28;](#)
944. [Glob Pediatr Health 2021 ;8:2333794X21996613.](#)
945. [Arch Pediatr 2020 Aug 06;](#)
946. [Pediatr Emerg Care 2020 Aug 18;](#)
947. [Neonatology 2020 Jun 04::1-5.](#)
948. [Am J Kidney Dis 2020 Sep 19;](#)
949. [World J Urol 2021 Jan 22;](#)
950. [Clin J Am Soc Nephrol 2020 Nov 16;](#)
951. [Kidney Int Rep 2021 Feb 04;](#)
952. [Kidney360 2021 Jan 28;2\(1\):63-70.](#)
953. [Am J Kidney Dis 2020 Sep 19;](#)
954. [J Acquir Immune Defic Syndr 2021 Aug 15;87\(5\):1167-1172.](#)
955. [J Am Soc Nephrol 2020 Sep 03;](#)
956. [J Am Soc Nephrol 2020 Oct 16;](#)
957. [Am J Kidney Dis 2021 Jan 07;](#)
958. [Kidney Int 2020 May 13;](#)
959. [medRxiv 2020 May 08;](#)
960. [Front Med \(Lausanne\) 2021 ;8:647023.](#)
961. [Kidney Int Rep 2021 Jul 15;](#)
962. [PLoS One 2021 ;16\(2\):e0247366.](#)
963. [PLoS One 2021 ;16\(6\):e0252679.](#)
964. [Am J Nephrol 2020 Oct 02::1-11.](#)
965. [Am J Kidney Dis 2021 Jan 16;](#)
966. [Am J Nephrol 2020 Jul 30::1-5.](#)
967. [Kidney Int 2020 Aug 15;](#)
968. [Cureus 2020 Sep 11;12\(9\):e10373.](#)
969. [Medicines \(Basel\) 2021 Jan 07;8\(1\)](#)
970. [Rev Cardiovasc Med 2021 Dec 22;22\(4\):1667-1675.](#)
971. [Clin Nephrol 2021 Oct 12;](#)
972. [Int Urol Nephrol 2020 May 26;](#)
973. [Ann Surg 2020 10 ;272\(4\):e280-e281.](#)
974. [JAMA Netw Open 2021 03 01;4\(3\):e211095.](#)
975. [Clin J Am Soc Nephrol 2020 Oct 30;](#)
976. [PLoS One 2020 ;15\(12\):e0244131.](#)
977. [Clin J Am Soc Nephrol 2020 Nov 03;](#)
978. [Front Pediatr 2021 ;9:692256.](#)
979. [Am J Nephrol 2021 Apr 07::1-9.](#)
980. [J Am Soc Nephrol 2020 Jul 13;](#)
981. [JACC Heart Fail 2021 Jan ;9\(1\):65-73.](#)
982. [J Am Coll Cardiol 2020 Oct 26;](#)
983. [ESC Heart Fail 2021 Mar 16;](#)
984. [Eur Heart J Qual Care Clin Outcomes 2021 Aug 30;](#)
985. [JACC Clin Electrophysiol 2021 Feb 24;](#)
986. [J Am Coll Cardiol 2020 Jun 05;](#)
987. [Cardiovasc Revasc Med 2021 Mar 05;](#)
988. [medRxiv 2020 Apr 24;](#)
989. [Am J Cardiol 2020 Dec 29;](#)
990. [Circulation 2020 Nov 05;](#)
991. [Mayo Clin Proc 2020 Oct ;95\(10\):2099-2109.](#)
992. [Clin Cardiol 2021 May 08;](#)
993. [Am J Cardiol 2021 Feb 19;](#)

994. [Am J Cardiol 2020 Jul 24;](#)
995. [Circ Heart Fail 2021 Sep 14;:CIRCHEARTFAILURE121008354.](#)
996. [J Am Heart Assoc 2020 Nov 10;:e018476.](#)
997. [JAMA Netw Open 2021 Apr 01;4\(4\):e216842.](#)
998. [Cardiovasc Pathol 2021 Aug 03;:107374.](#)
999. [J Card Fail 2020 Jun 13;](#)
1000. [Heart Rhythm 2020 Jun 20;](#)
1001. [J Cardiothorac Vasc Anesth 2021 Mar 27;](#)
1002. [Am J Cardiol 2021 Feb 01;](#)
1003. [Case Rep Cardiol 2021 ;2021:9915650.](#)
1004. [J Am Heart Assoc 2021 Dec 31;:e022010.](#)
1005. [Res Pract Thromb Haemost 2021 Feb ;5\(2\):292-295.](#)
1006. [Clin Chem 2021 Apr 16;](#)
1007. [Pacing Clin Electrophysiol 2021 Mar 20;](#)
1008. [J Am Coll Cardiol 2020 Nov 03;76\(18\):2043-2055.](#)
1009. [Crit Care Explor 2020 Dec ;2\(12\):e0288.](#)
1010. [Expert Rev Cardiovasc Ther 2021 Aug 19;](#)
1011. [BMC Cardiovasc Disord 2021 Mar 30;21\(1\):158.](#)
1012. [BMC Cardiovasc Disord 2021 Dec 31;21\(1\):626.](#)
1013. [Open Heart 2021 06 ;8\(1\)](#)
1014. [Pacing Clin Electrophysiol 2021 Mar 18;](#)
1015. [Ann Noninvasive Electrocardiol 2021 Mar 19;:e12833.](#)
1016. [J Appl Lab Med 2020 Jun 02;](#)
1017. [Heart Lung Circ 2020 Nov 23;](#)
1018. [Mayo Clin Proc 2021 Jan 19;](#)
1019. [Am J Cardiol 2022 Jan 01;162:111-115.](#)
1020. [Heart Lung Circ 2021 Mar 06;](#)
1021. [Indian Pacing Electrophysiol J 2021 Feb 28;](#)
1022. [Clin Cardiol 2020 Oct 14;](#)
1023. [PLoS One 2020 ;15\(12\):e0244533.](#)
1024. [Endocrinol Diabetes Metab 2020 Dec 25;:e00218.](#)
1025. [Int J Cardiol Heart Vasc 2021 Mar 24;:100770.](#)
1026. [Resusc Plus 2020 Dec ;4:100054.](#)
1027. [Cardiovasc Pathol 2021 Jul 14;:107370.](#)
1028. [Mod Pathol 2021 Mar 17;](#)
1029. [R I Med J \(2013\) 2021 Jun 01;104\(5\):8-13.](#)
1030. [Cardiol Young 2021 Sep 30;:1-7.](#)
1031. [Heart Rhythm 2020 Jul 01;](#)
1032. [Clin Pediatr \(Phila\) 2020 Sep 25;:9922820961771.](#)
1033. [Am J Obstet Gynecol 2020 Oct 10;](#)
1034. [J Clin Invest 2020 Jul 23;](#)
1035. [N Engl J Med 2020 Apr 17;](#)
1036. [Mayo Clin Proc 2021 Jul 15;](#)
1037. [Ann Clin Lab Sci 2021 Mar ;51\(2\):156-162.](#)
1038. [Case Rep Cardiol 2021 ;2021:9986955.](#)
1039. [medRxiv 2021 Jun 07;](#)
1040. [HepatoL Commun 2021 Mar ;5\(3\):424-433.](#)
1041. [Eur J Gastroenterol Hepatol 2021 Feb 05;](#)
1042. [Hepatology 2020 May 30;](#)
1043. [Dig Dis Sci 2021 May 04;](#)
1044. [Hepatology 2020 Jul 29;](#)
1045. [Gastroenterology 2020 May 07;](#)
1046. [Clin Gastroenterol Hepatol 2020 Sep 17;](#)
1047. [EClinicalMedicine 2021 Jan ;31:100688.](#)

1048. [J Clin Transl Hepatol 2020 Dec 28;8\(4\):476-478.](#)
1049. [BMJ Open Gastroenterol 2021 Nov :8\(1\)](#)
1050. [Eur J Gastroenterol Hepatol 2020 Dec 22;Publish Ahead of Print](#)
1051. [J Clin Transl Hepatol 2021 Aug 28;9\(4\):551-558.](#)
1052. [Liver Int 2020 Jun 25;](#)
1053. [Dig Dis Sci 2020 Sep 27;](#)
1054. [Hepatology 2020 Nov 21;](#)
1055. [Gastroenterology 2020 May 03;](#)
1056. [Ann Gastroenterol 2021 :34\(2\):224-228.](#)
1057. [Hepatol Int 2021 Apr 07;](#)
1058. [Hepatol Commun 2020 Oct 16;](#)
1059. [Clin Gastroenterol Hepatol 2021 May 15;](#)
1060. [Hepatology 2020 May 16;](#)
1061. [Gut 2020 Jul 13;](#)
1062. [Hum Pathol 2020 Dec 08;](#)
1063. [Am J Gastroenterol 2021 May 17;](#)
1064. [J Clin Transl Hepatol 2020 Dec 28;8\(4\):463-466.](#)
1065. [Am J Cardiol 2021 Aug 28;](#)
1066. [J Thromb Thrombolysis 2021 Mar 05;](#)
1067. [Thromb Haemost 2021 Jan 20;](#)
1068. [Blood Adv 2020 Nov 10;4\(21\):5373-5377.](#)
1069. [Chest 2021 Jul 19;](#)
1070. [Am Heart J 2021 Mar 18;](#)
1071. [J Am Coll Cardiol 2020 Nov 03;76\(18\):2060-2072.](#)
1072. [Obes Res Clin Pract 2021 Jul 16;](#)
1073. [JAMA 2020 Jul 20;](#)
1074. [Medicine \(Baltimore\) 2021 Sep 24;100\(38\):e27216.](#)
1075. [J Vasc Surg Venous Lymphat Disord 2020 Oct 08;](#)
1076. [J Vasc Surg 2020 Aug 27;](#)
1077. [Radiology 2021 Jul 13::210777.](#)
1078. [Blood 2020 Jun 03;](#)
1079. [Clin Respir J 2021 Apr 17;](#)
1080. [Cureus 2021 Oct :13\(10\):e18601.](#)
1081. [Crit Care Med 2020 May 27;](#)
1082. [medRxiv 2020 Sep 18;](#)
1083. [Chest 2020 Jul 22;](#)
1084. [Blood 2020 Aug 07;](#)
1085. [Radiol Cardiothorac Imaging 2020 Aug :2\(4\):e200289.](#)
1086. [J Intensive Care Med 2020 Oct 06::885066620964392.](#)
1087. [Acta Haematol 2021 Oct 19::1-8.](#)
1088. [J Vasc Surg Venous Lymphat Disord 2020 Oct 22;](#)
1089. [J Vasc Surg Venous Lymphat Disord 2020 Oct 22;](#)
1090. [Open Forum Infect Dis 2021 Jun :8\(6\):ofab193.](#)
1091. [Ann Vasc Surg 2020 Aug 28;](#)
1092. [Crit Care Med 2020 Jun 26;](#)
1093. [J Thromb Haemost 2020 Jul 21;](#)
1094. [J Vasc Surg 2020 Aug 31;](#)
1095. [Am J Med Sci 2021 Feb 10;](#)
1096. [Neurology 2020 Oct 05;](#)
1097. [Neurocrit Care 2021 Jun 28;](#)
1098. [CNS Neurosci Ther 2021 Jun 16;](#)
1099. [Neurology 2020 Dec 18;](#)
1100. [Chronic Obstr Pulm Dis 2021 Mar 26;](#)
1101. [Front Neurol 2020 :11:585944.](#)

1102. [Ann Clin Transl Neurol 2020 Oct 05;](#)
1103. [J Neurol 2020 Aug 06;](#)
1104. [Ann Neurol 2021 Mar 11;](#)
1105. [Respir Med 2021 Dec 09;191:106714.](#)
1106. [Neurol Neuroimmunol Neuroinflamm 2021 09 ;8\(5\)](#)
1107. [J Stroke Cerebrovasc Dis 2020 Aug 24;29\(12\):105260.](#)
1108. [Neurol Clin Pract 2021 Apr ;11\(2\):e83-e91.](#)
1109. [Acta Neurol Scand 2021 Feb 09;](#)
1110. [J Neurol Sci 2020 Jun 03:415:116969.](#)
1111. [J Neurol 2021 Sep 04;](#)
1112. [Front Neurol 2020 ;11:805.](#)
1113. [Neurosurg Open 2020 Sep ;1\(3\):okaa008.](#)
1114. [Mov Disord Clin Pract 2021 Jul 30;](#)
1115. [J Neurol Sci 2021 May 31:427:117517.](#)
1116. [Brain Behav Immun Health 2021 Mar 03::100238.](#)
1117. [J Neurol Sci 2021 Dec 23:434:120118.](#)
1118. [Mult Scler J Exp Transl Clin 2021 Oct ;7\(4\):20552173211057110.](#)
1119. [Neurology 2021 Dec 03;](#)
1120. [Transplantation 2021 Feb 05;](#)
1121. [Transplant Direct 2021 Nov ;7\(11\):e775.](#)
1122. [Am J Transplant 2021 May 19;](#)
1123. [Clin Infect Dis 2020 Aug 07;](#)
1124. [Lancet Haematol 2021 Jan 19;](#)
1125. [Gastroenterology 2021 Jan 16;](#)
1126. [Am J Transplant 2020 Oct 12;](#)
1127. [Kidney Int 2020 Oct 15;](#)
1128. [Clin Transplant 2021 Jan 06::e14216.](#)
1129. [Gastroenterology 2020 Sep 30;](#)
1130. [Transpl Infect Dis 2021 May 16::e13637.](#)
1131. [Am J Transplant 2020 Aug 26;](#)
1132. [Am J Transplant 2020 Apr 24;](#)
1133. [Am J Transplant 2020 Dec 16;](#)
1134. [J Clin Invest 2020 Sep 08;](#)
1135. [Transpl Infect Dis 2021 Dec 14;](#)
1136. [Clin Transplant 2021 Nov 18::e14540.](#)
1137. [Am J Transplant 2020 Dec 07;](#)
1138. [Transpl Infect Dis 2020 Jun 23::e13383.](#)
1139. [Transpl Infect Dis 2021 Oct 04;](#)
1140. [Clin J Am Soc Nephrol 2020 May 18;](#)
1141. [Transplant Proc 2020 Sep 10;](#)
1142. [Transplantation 2020 Oct 21;](#)
1143. [Clin Transplant 2021 Jan 09::e14221.](#)
1144. [Am J Transplant 2020 Aug 09;](#)
1145. [JAMA Cardiol 2020 May 13;](#)
1146. [Clin Transplant 2021 Jul 28;](#)
1147. [Transpl Infect Dis 2021 Apr 25::e13625.](#)
1148. [Clin Transplant 2020 Nov 28::e14169.](#)
1149. [J Heart Lung Transplant 2021 May 18;](#)
1150. [Ochsner J 2021 ;21\(4\):329-334.](#)
1151. [J Heart Lung Transplant 2020 Sep ;39\(9\):894-903.](#)
1152. [Transplant Direct 2020 Dec ;6\(12\):e633.](#)
1153. [J Intensive Care Med 2020 Oct 09::885066620965163.](#)
1154. [Transplantation 2020 Jun 01;](#)
1155. [Am J Transplant 2021 Aug 17;](#)

1156. [Transplantation 2021 Jan 01;105\(1\):e6-e8.](#)
1157. [J Am Soc Nephrol 2020 Apr 21;](#)
1158. [Transpl Infect Dis 2021 Dec 30;](#)
1159. [J Card Fail 2020 May 14;](#)
1160. [Transplantation 2020 Nov 04;](#)
1161. [Transplant Proc 2021 Jan 13;](#)
1162. [Am J Transplant 2020 Jun 01;](#)
1163. [Transplant Proc 2020 Sep 03;](#)
1164. [Transpl Infect Dis 2020 Jun 24::e13382.](#)
1165. [Pediatr Transplant 2021 Jan 27::e13972.](#)
1166. [medRxiv 2021 Jul 28;](#)
1167. [Cancer Rep \(Hoboken\) 2021 Aug 19::e1413.](#)
1168. [JNCI Cancer Spectr 2021 Feb ;5\(1\):pkaa085.](#)
1169. [Ann Oncol 2021 Mar 18;](#)
1170. [J Cancer Biol 2021 ;2\(1\):25-32.](#)
1171. [Oncologist 2020 Nov 18;](#)
1172. [Cancer Cell 2020 Sep 15;](#)
1173. [Future Oncol 2021 Nov 02;](#)
1174. [J Natl Compr Canc Netw 2020 Nov 03::1-10.](#)
1175. [Oncoimmunology 2021 Jan 04;10\(1\):1854424.](#)
1176. [Clin Transplant 2021 Sep 24::e14492.](#)
1177. [Lancet 2020 May 28;](#)
1178. [medRxiv 2020 May 08;](#)
1179. [Asian Pac J Cancer Prev 2021 Feb 01;22\(2\):517-522.](#)
1180. [Ann Oncol 2020 Apr 21;](#)
1181. [Cancer 2020 Oct 28;](#)
1182. [Int J Radiat Oncol Biol Phys 2021 Nov 01;111\(3S\):e504.](#)
1183. [Cancer Invest 2021 Oct 28::1-9.](#)
1184. [Eur Radiol 2021 Oct 30;](#)
1185. [medRxiv 2020 Sep 18;](#)
1186. [Future Oncol 2021 Jul 15;](#)
1187. [Cancer Control 2020 Jan-Dec;27\(1\):1073274820960457.](#)
1188. [Oncologist 2021 Apr 15;](#)
1189. [Cancer 2020 Jul 30;](#)
1190. [Pediatr Hematol Oncol 2021 May 25::1-14.](#)
1191. [Adv Radiat Oncol 2020 Jul-Aug;5\(4\):707-710.](#)
1192. [Front Med \(Lausanne\) 2021 ;8:604221.](#)
1193. [Ann Oncol 2020 Jun 16;](#)
1194. [Pediatr Blood Cancer 2020 Dec 18::e28843.](#)
1195. [Acta Haematol 2021 Oct 19::1-8.](#)
1196. [Crit Care Explor 2021 Sep ;3\(9\):e0535.](#)
1197. [Gynecol Oncol 2020 Sep 25;](#)
1198. [Cancers \(Basel\) 2020 Aug 22;12\(9\)](#)
1199. [Cancer Treat Res Commun 2021 Jun 10;28:100418.](#)
1200. [Front Oncol 2021 ;11:740320.](#)
1201. [Emerg Radiol 2021 Sep 07;](#)
1202. [Leuk Res 2021 Apr 24;106:106582.](#)
1203. [J Clin Gastroenterol 2020 Oct 27;](#)
1204. [Oral Oncol 2020 Nov 06;112:105087.](#)
1205. [Ann Palliat Med 2020 Nov 18;](#)
1206. [Endocr Pract 2021 Jan 04;](#)
1207. [Cancer Invest 2021 Mar 15::1-11.](#)
1208. [medRxiv 2020 Sep 18;](#)
1209. [medRxiv 2021 Apr 07;](#)

1210. [AIDS 2021 Nov 08;](#)
1211. [medRxiv 2021 Jul 28;](#)
1212. [J Acquir Immune Defic Syndr 2021 Feb 01;86\(2\):224-230.](#)
1213. [J Acquir Immune Defic Syndr 2021 Aug 15;87\(5\):1167-1172.](#)
1214. [JAMA Netw Open 2021 Feb 01;4\(2\):e2037069.](#)
1215. [Open Forum Infect Dis 2021 Jul ;8\(7\):ofab272.](#)
1216. [AIDS 2020 Aug 10;](#)
1217. [Clin Infect Dis 2020 Sep 09;](#)
1218. [Clin Infect Dis 2020 Oct 23;](#)
1219. [AIDS Patient Care STDS 2021 Nov 15;](#)
1220. [J Infect Dis 2020 Jun 30;](#)
1221. [Open Forum Infect Dis 2021 Feb ;8\(2\):ofab029.](#)
1222. [Open Forum Infect Dis 2020 Aug ;7\(8\):ofaa327.](#)
1223. [J Int AIDS Soc 2020 Jul ;23\(7\):e25573.](#)
1224. [J Med Virol 2020 Sep 19;](#)
1225. [J Acquir Immune Defic Syndr 2020 Jun 12;](#)
1226. [Transplantation 2020 Nov 04;](#)
1227. [J Med Virol 2020 May 28;](#)
1228. [J Med Virol 2020 Nov 17;](#)
1229. [J Med Virol 2020 Jul 29;](#)
1230. [AIDS Patient Care STDS 2020 May 29;](#)
1231. [Ann Intern Med 2020 Aug 12;](#)
1232. [Metab Syndr Relat Disord 2022 Jan 06;](#)
1233. [Obesity \(Silver Spring\) 2021 Mar 11;](#)
1234. [Eur J Clin Microbiol Infect Dis 2021 May 06;](#)
1235. [Obesity \(Silver Spring\) 2020 May 23;](#)
1236. [Obes Res Clin Pract 2021 Feb 25;](#)
1237. [PLoS One 2021 ;16\(8\):e0255811.](#)
1238. [BMJ Open Respir Res 2021 Aug ;8\(1\)](#)
1239. [PLoS One 2020 ;15\(12\):e0243888.](#)
1240. [Obes Res Clin Pract 2020 Dec 23;](#)
1241. [Obesity \(Silver Spring\) 2020 May 29;](#)
1242. [Obes Res Clin Pract 2021 Jul 16;](#)
1243. [Int J Obes \(Lond\) 2020 Jul 25;](#)
1244. [J Diabetes Complications 2021 Sep 28::108054.](#)
1245. [Crit Care Med 2020 Nov ;48\(11\):e1097-e1101.](#)
1246. [BMJ Open 2021 Jan 31;11\(1\):e044526.](#)
1247. [Obesity \(Silver Spring\) 2021 Feb 02;](#)
1248. [Obesity \(Silver Spring\) 2020 Jun 26;](#)
1249. [West J Emerg Med 2020 Jun 15;21\(4\):752-755.](#)
1250. [Metabolism 2020 May 15::154262.](#)
1251. [J Clin Med Res 2021 Apr ;13\(4\):230-236.](#)
1252. [medRxiv 2020 Aug 14;](#)
1253. [PLoS One 2020 ;15\(12\):e0238552.](#)
1254. [Obesity \(Silver Spring\) 2020 Apr 30;](#)
1255. [J Am Coll Emerg Physicians Open 2021 Apr ;2\(2\):e12399.](#)
1256. [Abdom Radiol \(NY\) 2020 Oct 12;](#)
1257. [Radiology 2020 Jul 16::202602.](#)
1258. [Radiol Cardiothorac Imaging 2020 Aug ;2\(4\):e200322.](#)
1259. [AJR Am J Roentgenol 2020 Jul 29;](#)
1260. [AJNR Am J Neuroradiol 2020 Aug 20;](#)
1261. [Radiol Cardiothorac Imaging 2020 Oct ;2\(5\):e200337.](#)
1262. [Am Heart J Plus 2021 Nov ;11:100052.](#)
1263. [Radiol Cardiothorac Imaging 2020 Oct ;2\(5\):e200280.](#)

1264. [Emerg Radiol 2020 May 25;](#)
1265. [J Ultrasound Med 2021 Sep 01;](#)
1266. [Eur J Radiol Open 2021 ;8:100322.](#)
1267. [Eur Radiol 2020 May 28;](#)
1268. [J Neuroradiol 2020 Jun 27;](#)
1269. [Epilepsia 2020 Sep 02;](#)
1270. [J Emerg Med 2021 Feb 04;](#)
1271. [Ultrasound Obstet Gynecol 2021 Apr 01;](#)
1272. [Pediatr Pulmonol 2021 Sep 06;](#)
1273. [AJNR Am J Neuroradiol 2021 Feb 04;](#)
1274. [J Comput Assist Tomogr 2020 Aug 24;](#)
1275. [Abdom Radiol \(NY\) 2021 Jan 04;](#)
1276. [Clin Imaging 2020 Nov 05;71:17-23.](#)
1277. [Radiol Cardiothorac Imaging 2021 Dec ;3\(6\):e210248.](#)
1278. [Future Cardiol 2020 Oct 09;](#)
1279. [J Patient Cent Res Rev 2021 ;8\(1\):68-76.](#)
1280. [Abdom Radiol \(NY\) 2021 Jun 11;](#)
1281. [West J Emerg Med 2020 Jun 19;21\(4\):771-778.](#)
1282. [Abdom Radiol \(NY\) 2020 Sep 19;](#)
1283. [medRxiv 2020 Jul 15;](#)
1284. [Proc \(Bayl Univ Med Cent\) 2020 Oct 26;34\(1\):1-4.](#)
1285. [Clin Imaging 2021 Aug 08;80:262-267.](#)
1286. [Clin Imaging 2021 Mar 30;75:165-170.](#)
1287. [J Ultrasound Med 2021 Mar 05;](#)
1288. [Brain Behav Immun Health 2021 Mar 03::100238.](#)
1289. [Pediatr Radiol 2021 Jan 06;](#)
1290. [Am J Trop Med Hyg 2020 Apr 24;](#)
1291. [Curr Probl Diagn Radiol 2020 Apr 11;](#)
1292. [Clin Kidney J 2021 Jun ;14\(6\):1704-1707.](#)
1293. [Nephrol Dial Transplant 2021 Mar 16;](#)
1294. [Crit Care Med 2021 02 12;](#)
1295. [Eur Heart J 2021 Jan 15;](#)
1296. [J Med Virol 2021 Apr 10;](#)
1297. [Arterioscler Thromb Vasc Biol 2020 Aug 25::ATVBAHA120314872.](#)
1298. [Crit Care Explor 2021 May ;3\(5\):e0444.](#)
1299. [Crit Care Med 2020 Aug 18;](#)
1300. [Am J Emerg Med 2020 Nov 24;](#)
1301. [Thromb Res 2020 Aug 20;196:99-105.](#)
1302. [PLoS One 2021 ;16\(2\):e0247366.](#)
1303. [Pancreatology 2021 Mar 04;](#)
1304. [J Clin Med Res 2020 Dec ;12\(12\):809-815.](#)
1305. [PLoS One 2021 ;16\(4\):e0250774.](#)
1306. [Am J Emerg Med 2021 Mar 29;48:140-147.](#)
1307. [J Clin Lipidol 2021 Aug 10;](#)
1308. [J Osteopath Med 2021 Sep 29;](#)
1309. [Am J Perinatol 2021 Jul 16;](#)
1310. [J Diabetes 2020 Nov 20;](#)
1311. [Diabetes Metab 2021 Mar 26::101254.](#)
1312. [Am J Emerg Med 2021 Mar 02;46:16-19.](#)
1313. [Medicina \(Kaunas\) 2021 Oct 07;57\(10\)](#)
1314. [PLoS One 2020 ;15\(11\):e0242400.](#)
1315. [Cardiol Res 2020 Dec ;11\(6\):398-404.](#)
1316. [Elife 2020 Aug 17;9](#)
1317. [Front Physiol 2021 ;12:618929.](#)

1318. [Infez Med 2021 Mar 01;29\(1\):46-53.](#)
1319. [Nat Commun 2020 Oct 30;11\(1\):5493.](#)
1320. [Am J Obstet Gynecol MFM 2021 Aug 14;:100458.](#)
1321. [Am J Clin Pathol 2021 Jun 21;](#)
1322. [J Vasc Surg Venous Lymphat Disord 2020 Nov 11;](#)
1323. [J Cardiovasc Electrophysiol 2020 Oct 06;](#)
1324. [Endocr Pract 2021 Jan 09;](#)
1325. [World J Hepatol 2020 Sep 27;12\(9\):619-627.](#)
1326. [PLoS One 2021 ;16\(4\):e0250906.](#)
1327. [SN Compr Clin Med 2020 Nov 08;:1-7.](#)
1328. [Mod Pathol 2021 Apr 01;](#)
1329. [Am J Clin Pathol 2020 Dec 03;](#)
1330. [Int J Emerg Med 2020 Dec 09;13\(1\):63.](#)
1331. [J Infect Dev Ctries 2021 Aug 31;15\(8\):1086-1093.](#)
1332. [Mod Pathol 2020 Sep 02;](#)
1333. [Arch Pathol Lab Med 2021 Feb 17;](#)
1334. [J Prim Care Community Health 2020 Jan-Dec;11:2150132720958533.](#)
1335. [Diabetes Metab Syndr 2021 Apr 14;15\(3\):863-868.](#)
1336. [Cardiovasc Pathol 2021 Jul 14;:107370.](#)
1337. [Brain 2021 Apr 15;](#)
1338. [Pediatr Blood Cancer 2021 Mar 04;:e28975.](#)
1339. [J Med Virol 2020 Sep 18;](#)
1340. [Am J Clin Pathol 2021 Jan 27;](#)
1341. [Am J Forensic Med Pathol 2021 Jan 07;Publish Ahead of Print](#)
1342. [Lancet Rheumatol 2021 Jun 08;](#)
1343. [J Neurol Sci 2021 May 31;427:117517.](#)
1344. [Ann Hematol 2021 Jan 13;](#)
1345. [J Am Soc Nephrol 2020 Jul 17;](#)
1346. [Am J Kidney Dis 2020 Oct 09;](#)
1347. [Hum Pathol 2020 Dec 08;](#)
1348. [J Pathol Clin Res 2021 May 07;](#)
1349. [Lancet 2020 Jul 16;](#)
1350. [Ann Thorac Surg 2021 Jul 31;](#)
1351. [Emerg Infect Dis 2020 May 21;26\(9\)](#)
1352. [Am J Clin Pathol 2020 08 05;154\(3\):319-329.](#)